

CURRICULUM VITAE

January 21, 2020

NAME: **Mark Alvin Atkinson, Ph.D.**
American Diabetes Association Eminent Scholar
Departments of Pathology, Immunology and Laboratory Medicine /
Pediatrics
College of Medicine
University of Florida
1275 Center Drive, BMS J593
Gainesville, FL 32610-0275
(352) 273-8276
atkinson@ufl.edu

BIRTH: March 27, 1961
Dearborn, Michigan, U.S.A.

EDUCATION: University of Michigan-Dearborn, B.S., Microbiology 1979 -1983
University of Florida, Ph.D., Pathology 1984 - 1988
Hagedorn Research Laboratory, Gentofte, Denmark 1986

ACADEMIC APPOINTMENTS: Post-Doctoral Associate, Department of Pathology, University of Florida 1988 - 1990
Assistant Professor, Department of Pathology, University of Florida 1990 - 1994
Associate Professor / Tenure, Department of Pathology, University of Florida 1994 - 1998
Founder and Director, The Center for Immunology and Transplantation 1998 - 2006
Sebastian Family Professor for Diabetes Research 1998 - 2007
Professor, Department of Pathology, University of Florida 1998 - present
Co-Director, Diabetes Center of Excellence 2000 - 2014
Eminent Scholar, University of Florida 2013 - present
Jeffrey Keene Family Professor 2004 - present
American Diabetes Association Eminent Scholar for Diabetes Research 2007 - present
Director, University of Florida Diabetes Institute 2014 - present

AREAS OF SPECIALIZATION:

Dr. Atkinson is currently the American Diabetes Association Eminent Scholar for Diabetes Research, and the Jeffrey Keene Family Professor at The University of Florida. He also is Director of the new University of Florida Diabetes Institute. The author of over 500 publications, Dr. Atkinson is now in his 35th year of investigation into the field of type 1 diabetes (T1D). Dr. Atkinson has been the recipient of multiple scientific and humanitarian based awards for these efforts, including three awards from the Juvenile Diabetes Research Foundation (JDRF). The first was the Gerold and Gayla Grodsky Award (2001) provided to the outstanding Ph.D. investigating type 1 diabetes. He is a three-time recipient of the Mary Tyler Moore & S. Robert Levine M.D. Award for translational research on type 1 diabetes (2004, 2008, 2015). He was also the recipient of the JDRF's David Rumbough Award for contributions to diabetes research (2005). Dr. Atkinson was also a recipient of the prestigious Eli Lilly Award for Outstanding Scientific Achievement from the American Diabetes Association (ADA; 2004). He also received the Barbara Davis Award for contributions to the field seeking to prevent type 1 diabetes (2016), the Michael Brownlee Award/Joslin Diabetes Center (2018), the George S. Eisenbarth Award (Immunology of Diabetes Society), and is the 2019 recipient of the very prestigious Novo Nordisk Jacobaeus Award. Dr. Atkinson has been active in a leadership service to the T1D community, with active administrative or advisory service to JDRF, ADA, The National Institutes of Health (NIH), The Immunology of Diabetes Society (IDS), and a variety of companies from the pharmaceutical and biotech industry. Dr. Atkinson is a past Chair for Medical Science Research at the JDRF wherein he oversaw professional research review of nearly \$100M in annual funding. He has served on the state, regional, and national Board of Directors for the ADA, as well as past-memberships on their publications, scientific sessions planning, and research review committees. He is an immediate past Associate Editor of the ADA's Journal *Diabetes* and currently serves as Ad hoc Editor in Chief for both *Diabetes* and *Diabetes Care*. He has Chaired two National Expert Panels formed by the NIH giving guidance to diabetes research, as well as congressionally awarded, special funding for T1D. Dr. Atkinson is an internationally recognized authority on multiple aspects pertaining to T1D, with particular interests in disease prediction and prevention, the role for environment in the initiation of the disease, stem cells and pancreatic regeneration, identifying markers of tolerance and immunoregulation, and the identification of biological agents as a means to cure the disease and prevent its complications. Indeed, Expertscape (an organization that tracks scientific citations of researchers) recently noted that Dr. Atkinson was the second most cited authority of over 65,000 investigators in the world in type 1 diabetes. Dr. Atkinson is a founding member of the now 19-year-old, NIH Immune Tolerance Network; amongst only a handful of members whose institutions are located within the Southeastern United States. In terms of clinical trials expertise, he is a member of the NIH TrialNet, as well as a founding member of the Helmsley Trust Consortium on Type 1 Diabetes; both providing guidance to trials aimed at reversing T1D. Dr. Atkinson is the founding Director of the JDRF Network for Pancreatic Organ donors with Diabetes (nPOD) program, a position where he currently oversees the scientific progress of some 240 projects (21 countries) directed at numerous aspects of the disease. This is but one example of many multi-investigator/multi-institutional efforts overseen by Dr. Atkinson, with other examples including but not limited to Directorship of the JDRF Gene Therapy Center at the University of Florida & University of Miami, 22 years of leading an NIH PO1 directed at understanding immune regulation in T1D, and the JDRF Center for Cord Blood Therapies. Beyond this, he served as Steering Committee Chair for the Trans Network Committee for the Human Islet Research Network (HIRN) as well as past Chair for the Consortium on Beta Cell Death and Survival for that effort. His interest in collaboration has driven his participation in a variety of organizations (e.g., the Brehm Coalition, the Helmsley Trust Type 1 Diabetes Centers) and technologies (e.g., nPOD Datashare) are representative examples of that interest. Finally, Dr. Atkinson is active at a global level for causes related to the care and treatment of those in the third world; especially and including persons with T1D. For this cause, he serves as President of Insulin for Life USA and is an Advisor to Life for a Child.

CONTRIBUTION TO DISCIPLINE (PERSONAL STATEMENT):

When I was a first year graduate student at The University of Florida in 1984, my mentor provided words of advice that remain a major part of my academic life. In a conversation regarding what areas would form the best focus for a research career in T1D, he responded, "If you pursue three avenues of investigation and find out their answers, you will make a valuable contribution to type 1 diabetes (sic)". Those recommended efforts were to:

- Determine what causes type 1 diabetes.
- Identify a means to predict, months to years in advance, who will develop the disease.
- Develop a method to cure type 1 diabetes.

Now, some 35 years later, with both a sense of happiness and sadness, I can say that these three avenues remain a major focus of my research efforts. Happiness, in that progress has been made by the research community (with some contributions from my research group and collaborators) towards each goal, but at the same time none have been fully addressed. Indeed, progress towards each goal differs quite dramatically. For example, we and others

goal (a method to prevent or cure the disease), efforts for disease prediction have been somewhat underutilized by the public health care community. That said, we are moving closer (and leading efforts) towards testing agents capable of effectively intervening in the disease, which leaves open the discussion of progress towards the first goal, understanding what causes the disorder. Sadly, of all the goals, this one remains the most elusive. Perhaps in part because of this state of progress, I have expanded my efforts to seeing insulin provided to those in third world areas as, while not a cure, it does represent a life-saving entity.

COMMITTEES:	Medical Science Review Committee, Juvenile Diabetes Foundation	1991 - 2010
	Doctoral Faculty Member, University of Florida	1991 - present
	Graduate Education Committee, Department of Pathology, University of Florida	1991 - 1997
	Ad Hoc Grant Review Panel, United States Veterans Administration	1991 - present
	Vice-Chair, Professional Relations and Standards Committee, University of Florida	1991 - 1992
	Ad Hoc Grant Reviewer, Diabetes Research & Education Center, University of Michigan	1992
	Research Advisory Council, College of Medicine, University of Florida	1992 - 1995
	Public Relations and Communications Committee, Juvenile Diabetes Research Foundation	1993 - 2011
	Reviewer, National Institutes of Health, NIAID & NIDDK, Ad Hoc	1993 - present
	Graduate Program Director, Department of Pathology, University of Florida	1994 - 1997
	Office of Graduate Research and Education Advisory Council, University of Florida	1994 - 1997
	Office of Technology Licensing, Advisory Committee, University of Florida	1994 - 1996
	Medical Sciences Review Committee, Juvenile Diabetes Research Foundation	1994 - 1999
	Executive Committee, American Diabetes Association, Florida	1994 - 1997
	Executive Member, College of Medicine Reorganization Committee, University of Florida	1995 - 1996
	Director, Graduate Program in Immunology & Microbiology, College of Medicine, University of Florida	
	Medical Research Council of Canada, Review Committee	1996 - 1998
	Director, The Center for Immunology and Transplantation, College of Medicine, University of Florida	1996 - 2006
	Graduate Education Advisory Committee, College of Medicine, University of Florida	1996 - 1998

Director, Recruiting & Admissions Committee, Interdisciplinary Graduate Research Program, College of Medicine, University of Florida	1997
Grant Review Committee, American Diabetes Association	1997 - 1999
Co-Chair, Medical Sciences Review Committee (Group 1), Juvenile Diabetes Foundation International	1997 - 1999
Executive Committee, South Coastal Region, American Diabetes Association	1997 - 2000
Research Advisory Board, Juvenile Diabetes Research Foundation	1997 - 2001
T Cell Workshops Committee, Immunology of Diabetes Society (IDS)	1998 - 2004
Executive Board, Immunology of Diabetes Society (IDS)	1998 - 2001
Board of Directors, American Diabetes Association (National)	1999 - 2002
Clinical Affairs Committee, Juvenile Diabetes Research Foundation	1999 - 2001
Publications Committee, American Diabetes Association	2000 - 2002
Scientific Advisory Board, Islet Cell Transplantation Center, Harvard University	1999 - 2000
Professorial Tenure and Promotions Committee, College of Medicine, University of Florida	1999 - 2001
Chair, Immunology and Transplantation Review, Juvenile Diabetes Research Foundation	2000 - 2002
Council on Immunology and Ligand Standardization, NCCLS	2000 - 2003
Scientific Advisory Board, University of Pittsburgh Gene Therapy Center	2002 - 2007
University of Florida / Shands Cancer Center, member	2002 - present
Research Policy Committee, American Diabetes Association	2002 - 2003
Research Executive Committee, Juvenile Diabetes Foundation International	2002 - 2006
Executive Scientific Research Committee, Immune Tolerance Network	2001 - present
Human Stem Cell Research Policy Committee, Juvenile Diabetes Research Foundation	2002 - 2005
Clinical Affairs Advisory Committee, Juvenile Diabetes Research Foundation	2002 - 2005
Expert Member, NIH NIAID Autoimmunity Council	2002 - 2003
Chair, Laboratory Monitoring Group, NIH TrialNet	2002 - 2005
International Advisory Board, Universita' Campus Bio-medico Di Roma	2002 - 2008
Chair, Medical Science Review Committee, Juvenile Diabetes Research	2003 - 2005

Chair, Medical Science Review Committee, Juvenile Diabetes Research Foundation	2003 - 2005
Council Chair, Section on Immunology, Immunogenetics, and Transplantation, American Diabetes Association	2003 - 2005
Planning Committee Member, Rachmiel Levine Symposium	2003 - 2008
Scientific Advisory Board Member, Entelos/ADA In Silico Models for Type 1 Diabetes	2003 - 2008
Scientific Sessions Planning Committee, American Diabetes Association	2003 - 2005
NIH Conference on "GAD and Autoimmune Disease", Conference Organizer	2004
EASD/JDRF Meeting on Type 1 Diabetes Prevention, Oxford University, Conference Co-organizer	2004
Laboratory Monitoring Group, NIH TrialNet	2005 - 2008
Scientific Advisor, NIH/NIDDK Conference on Statutory Funding for Type 1 Diabetes	2005, 2008
Sample Access Review Panel, NIDDK Central Repositories	2005 - 2008
External Advisory Board Member, Wellcome Trust / JDRF Center on Genetics of Type 1 Diabetes	2005 - 2010
Member, NIDDK Group B (Training) Review	2005 - 2007
Chair, NIH Workgroup on Special Statutory Funding for Type 1 Diabetes Research, NIDDK	2005 - 2006
Member, Brehm Coalition for Type 1 Diabetes	2006 - present
External Advisor, Columbia University Diabetes Center	2006 - 2007
Genzyme Scientific Advisory Committee, Type 1 Diabetes	2006 - 2011
Chair, JDRF Expert Panel on Special Statutory Funding for Type 1 Diabetes Research	2006 - 2007
Member, T1D RAID/Biomedical Research Models Advisory Panel	2006 - 2010
Meeting Co-Organizer, NYAS: Animal Models of Type 1 Diabetes and Multiple Sclerosis	2006
Executive Director, JDRF nPOD	2007 - present
Co-Chair, 9 th International Meeting of the Immunology of Diabetes Society	2007
Member, Clinical Affairs work group (CAWG), JDRF	2007 - 2009
University of Florida HHMI program professor	2007 - 2014

Member, Diabetes Advisory Board, Glaxo-Smith Kline	2008 - 2009
Member, Organizing Committee, Rachmael Levine Symposium	2008 - 2010
Member, JDRF Autoimmunity Centers of Excellence Group	2008 - 2012
Chair, Diabetes Advisory Committee for Special Program Funding, NIH	2008
Chair and Organizer, JDRF Advisory Meeting on the Role of MSC Therapies in Type 1 Diabetes	2008
Member, Type 1 Diabetes Advisory Committee, Sanford Health	2008 - 2010
Member, University of Florida Genetics Institute	2008 - present
Member, Helmsley Trust Type 1 Diabetes Advisory Board	2009 - 2012
Member, Scientific Advisory Board, Tolerex	2009 - 2010
Member, Joslin Diabetes Medalist Program Advisory Panel	2009
Member, T1D Exchange Advisory Committee	2010 - -2011
Chair and Organizer, FOCIS Special Meeting on the Use of Human Tissues in Type 1 Diabetes Research	2010
International Ambassador/Advisor, Life for a Child (IDF)	2010 - present
Chair, JDRF Microbiome Consortium	2010 - 2014
Chair, NIH TrialNet Prioritization Committee	2010 - 2014
Member, NIH TrialNet Ancillary Studies Committee	2010 - 2014
Member, JDRF "Blue Ribbon" External Advisory Panel	2011 - 2012
Chair and Organizer, JDRF Meeting on Lessons Learned from Clinical Trials in Type 1 Diabetes (Lisbon)	2011
NIH Beta Cell Biology Consortium (BCBC) External Evaluation Committee Member	2011 - 2014
Section Editor, Type 1 Diabetes, <i>Diapedia</i>	2011 - present
Lead Investigator and Committee Chair, Use of TSO to Prevent Type 1 Diabetes, NIH TrialNet	2011 - 2013
Member, Diabetes Advisory Board, Takeda Pharmaceuticals	2012 - 2013
Member, Diabetes Advisory Board, Grifols Pharmaceuticals	2012 - 2013
Member, Diabetes Advisory Board, Sanofi Pharmaceuticals	2012 - 2014
Member, NIH ITN/JDRF Preclinical Models Consortium	2012 - present
President and Board Chair, Insulin for Life USA	2012 - present

	President and Board Chair, Insulin for Life USA	2012 - present
	Member, NIDDK Group B (Training) Review	2012 - 2015
	Member, The Lancet Commission on Type 1 Diabetes	2013 - present
	Member, International Diabetes Federation Insulin Task Force	2013 - 2014
	Ad hoc Editor-in-Chief, <i>Diabetes</i>	2013 - present
	Member, Broad Institute Scientific Advisory Committee	2013 - 2014
	Ad hoc Editor-in-Chief, <i>Diabetes Care</i>	2014 - present
	Member, ACCISS Advisory Group on Global Insulin Access	2013 - present
	Director, University of Florida Diabetes Institute Executive Committee	2014 - present
	Member, NIH TrialNet Biomarkers Working Group	2014 - present
	Chair, JDRF Open Access Data Working Group	2014 - present
	Chair, Trans Network Committee, Human Islet Research Network	2014 - present
	Chair, Consortium on Death cell Death and Survival (CDBS), Human Islet Research Network	2014 - present
	Member, Mechanistic Outcomes Committee, NIH TrialNet	2014 - present
	Director, nPOD-H (Heterogeneity) Working Group	2015 - present
TEACHING:	Discussion group leader in the medical student (phase B) <i>Medical Immunology course</i>	1990 - 2001
	Lecturer in GMS 6140, <i>Principles of Immunology</i>	1993 - 1997
	Director/Lecturer, GMS 6646, <i>Experimental Pathology and Immunology</i>	1993 - 1997
	Director/Lecturer, GMS 7920, Colloquium in Experimental Pathology and Immunology	1993 - 1997
	Director/Lecturer, GMS 6381, <i>Advanced Topics in Immunology</i>	1993 - 1997
	Director/Lecturer, GMS 6921, Immunology/Microbiology Journal Colloquy	1993 - 1997
	Director/Lecturer, GMS 6032, <i>Mechanisms of Host Defense</i>	1997 - 1998
	Lecturer in the medical student (phase B) <i>Pathology course</i>	1997 - 2000
	Lecturer in GMS 6390, <i>Seminar in Pathology</i>	1997 - 1999
	Lecturer in DEN 6350, <i>Dental Pathology</i>	1997 - 2000
	Lecturer in GMS 6033, Autoimmunity, Transplantation Immunology	2000 - 2004
	Advanced Immunology	2000 - 2007

Additional service includes positions on numerous Graduate and Medical Education committees, and primary research mentoring of 13 post-doctoral fellows, 17 Ph.D. trainees, and 6 M.S. students (as of 6/2019)

HONORS AND AWARDS:

Division of Sponsored Research Award, University of Florida	1986
Medical Guild Research Award for Graduate Research, University of Florida	1987
Post-Doctoral Fellowship, Juvenile Diabetes Research Foundation	1988
Post-Doctoral Fellowship (Mentor Based), American Diabetes Association	1988
Research Development Award (CDA), American Diabetes Association	1990
National Institutes of Health FIRST Award	1992
Diabetes Research and Education Foundation Award	1992
Career Development Award, Juvenile Diabetes Association	1993
The University of Florida, Pew Scholar Nominee	1993
Partners for a Cure Award, American Diabetes Association (Florida)	1996
Mary Jane Krugal Research Award, Juvenile Diabetes Research Foundation	1997
Sebastian Family / American Diabetes Association Endowed Chair	1998
Elected Executive Board Member, Immunology of Diabetes Society	1998
University of Florida Research Foundation Professorship	1998
Mary Jane Krugal Research Award, Juvenile Diabetes Research Foundation	1999
Congressional Briefing on Type 1 Diabetes, United States Congress	1999
Named "Distinguished Faculty", Juvenile Diabetes Research Foundation	2000
Outstanding Research Achievement Award, American Diabetes Association (South Costal Region)	2000
Faculty Basic Science Research Award, College of Medicine, University of Florida	2001
Gerold & Kayla Grodsky Award for Major Contributions to Diabetes Research, Juvenile Diabetes Research Foundation	2003
Mary Jane Krugal Research Award, Juvenile Diabetes Research Foundation	2003

Distinguished Visiting Professor, Johns Hopkins University School of Medicine	2003
Mary Tyler Moore and S. Robert Levine Clinical Research Award, Juvenile Diabetes Research Foundation	2004
Eli Lilly Award for Outstanding Scientific Achievement, American Diabetes Association	2004
Hilborn Scholar, UCLA School of Medicine	2005
David Rumbough Award for Scientific Excellence, JDRF	2005
University of Florida Research Professor	2006
American Diabetes Association, Distinguished Service Award for serving as Chair of the Immunology, Immunogenetics, and Transplantation Council	2006
UF/ Howard Hughes Medical Institute undergraduate professor	2007
Mary Tyler Moore and S. Robert Levine Clinical Research Award, Juvenile Diabetes Research Foundation	2008
Cure Award, American Diabetes Association, for efforts seeking to reverse type 1 diabetes	2009
Exemplary Teacher Award, University of Florida, College of Medicine	2009
Honorary Lecturer (with Award), Edwin Gale Retirement event	2010
Service Award, American Diabetes Association, for efforts as Associate Editor of the journal Diabetes	2011
Davis Award, Children with Diabetes Foundation	2012
Julio Santiago Award, Washington University St. Louis	2014
Mary Tyler Moore and S. Robert Levine Clinical Research Award, Juvenile Diabetes Research Foundation	2015
Claes Hellerstrom Award, Upsalla, Sweden	2016
University of Florida College of Medicine Lifetime Achievement Award	2018
American Diabetes Association Albert Renold Award	2018
American Diabetes Association Humanitarian Award	2018
JDRF's Alex and Ani Invisible Angel Award	2018
Novo Nordisk Jacobaeus Award	2019

**REPRESENTATIVE
DESCRIPTIONS OF
MAJOR AWARDS:**

The David Rumbough Award for Scientific Excellence was established in 1974 by actress Dina Merrill in honor of her late son, David. JDRF presents this award annually to recognize sustained commitment and achievement in the field of diabetes research.

The Gerold and Kayla Grodsky Award was established by a gift from the Grodskys to JDRF in 1994. The award is presented annually to a Ph.D. researcher who has made outstanding contributions to the field of diabetes research.

The Mary Tyler Moore and S. Robert Levine, M.D., Excellence in Clinical Research Award was established by these individuals in 2002. The award is overseen by the Juvenile Diabetes Research Foundation International and is given in recognition of outstanding contributions to the clinical translation of diabetes research.

The Outstanding Scientific Achievement Award by the American Diabetes Association. The award, established in 1956 and often referred to as “the Lilly Award”, is given each year to recognize demonstrated research in the field of diabetes, taking into consideration originality and independence of thought. The sought-after award is presented to an individual medical researcher under the age of 45 who has made an outstanding contribution to diabetes research.

The Davis Award, presented at the Carousel of Hope Ball, was given to Dr. Atkinson by the Children’s Diabetes Foundation in recognition of his long-standing efforts to identify a means to prevent type 1 diabetes.

The American Diabetes Association Albert Renold Award is presented annually in the memory of Dr. Albert Renold to recognize an individual who has a career distinguished by outstanding achievements in mentorship, and/or creation of a robust environment for diabetes research.

The Novo Nordisk Jacobaeus Award was established in 1939 to commemorate the Swedish professor Hans Christian Jacobaeus. The award is given annually to a distinguished international researcher who is invited to give a lecture on their research on a topic within physiology or endocrinology.

SOCIETY MEMBERSHIPS:	American Diabetes Association	1985 - present
	American Association for the Advancement of Sciences	1991 - present
	Juvenile Diabetes Research Foundation	1992 - present
	Immunology of Diabetes Society	1996 - present
	American Society for Gene Therapy	2002 - 2006
	Society for Experimental Diabetes Research	2004 - 2006
	European Association for the Study of Diabetes	2004 - present
	International Society for Pediatric and Adolescent Diabetes	2011 - present
EDITORIAL:	<i>Diabetes Countdown</i> – Editorial Board	1992 - 2010
	<i>Diabetes</i> – Advisory Board	1995 - 1998
	<i>Molecular Medicine</i> – Advisory Board	1999 - 2003

<i>Diabetes</i> – Advisory Board	2005 - 2011
<i>Diabetologia</i> – Advisory Board	2005 - 2008
<i>Diabetes</i> – Associate Editor	2006 - 2011
<i>Diabetes</i> – Section Editor (type 1 diabetes)	2011 - present
<i>Diabetes</i> – Ad hoc Editor-in-Chief	2013 - present
<i>Diabetes Care</i> – Ad hoc Editor-in-Chief	2014 - present
<i>Proceedings National Academy of Sciences USA</i> – Guest Editor	2015
Ad hoc reviewer for <i>Diabetes</i> , <i>Diabetes Care</i> , <i>The New England Journal of Medicine</i> , <i>The Journal of Clinical Investigation</i> , <i>Analytical Biochemistry</i> , <i>The Journal of Neurochemistry</i> , <i>Pancreas</i> , <i>Metabolism</i> , <i>Science</i> , <i>The Journal of Clinical Endocrinology and Metabolism</i> , <i>The Journal of Immunology</i> , <i>Nature Medicine</i> , <i>Nature</i> , <i>The Lancet</i> , <i>Clinical Chemistry</i> , <i>Diabetologia</i> , <i>Diabetes and Metabolism Reviews</i> , <i>Proceedings of The National Academy of Sciences U.S.A.</i> , <i>Nature</i> , <i>Science Translational Medicine</i> , <i>The Lancet Diabetes and Endocrinology</i> , <i>Nature Reviews Diabetes and Endocrinology</i> , <i>Pediatric Diabetes</i> , amongst many others.	

CORPORATE CONSULTATION:

Syntex Pharmaceuticals / SYVA Diagnostics	1993 - 1996
Diamyd Pharmaceuticals	1998 - present
Diabetogen	2000 - 2003
Sankyo Pharmaceuticals	2002 - 2006
Entelos	2004 - 2008
Elan/Wyeth Pharmaceuticals	2005 - 2008
Genzyme	2005 - 2012
Diakine Pharmaceuticals	2006 - 2010
Kinexum	2006 - 2008
Health Advances	2008 - 2015
Biomedical Research Models	2007 - 2011
Gerson Lehrman Group	2009 - 2015
Glaxo-Smith Kline	2009 - 2011
Amylin	2009 - 2011
Exsulin	2010 - 2012
Sanofi	2011 - 2013
Grifols	2011 - 2012
Takeda	2011 - 2013
Miromatrix Medical	2012 - 2014
Medistem	2012 - 2013
OneVax (co-founder)	2012 - present
SynAlpha Therapeutics	2014 - 2015
Novo Nordisk	2014 - present
Mercia Pharmaceuticals	2015 - present
Janssen Pharmaceuticals	2016 - present
Eli Lilly	2016 - 2017
Medimmune/AZ	2016 - 2017
Merck Pharmaceuticals	2016 - 2017

Cogen Therapeutics	2018 - present
SQZ Technologies	2018 - present
Forkhead Biotherapeutics	2018 - present

**GRANT SUPPORT
(ACTIVE):**

U54 HL142766 Atkinson (PI)
NIH/HuMAP
"A 3D Tissue Map of the Human Lymphatic System"
Funding Period: 09/14/2018 - 06/30/2022
Role: PI

T32 DK108736 Atkinson (PI)
NIH
"Interdisciplinary Graduate Program in Type 1 Diabetes and Biomedical Engineering"
Funding Period: 09/01/17- 08/31/22
Role: PI

UC4DK106993 Krischer (PI)
Univ. of South Florida/NIH/NIDDK
"NIDDK Type 1 Diabetes TrialNet Data Coordinating Center"
Funding Period: 03/01/2018 - 02/28/2019
Role: Science Advisor

1UC4DK108132-01 Atkinson (PI)
NIH/NIDDK
"Single-Cell Analyses of Human Islets in T1D Using Highly Multiplexed Imaging"
Funding Period: 09/24/2015 - 06/30/2020
Total award: \$3,600,000
Role: PI

NIH P01 AI42288 Atkinson (PI)
"Immune Function and the Progression to Type 1 Diabetes"
Funding Period: 06/20/2018 - 05/31/2023
Total Award: \$5,922,240
Role: PI

JDRF 5-SRA-2018-557-Q-R Atkinson (PI)
Juvenile Diabetes Research Foundation
"Network for Pancreatic Organ Donors with Diabetes - Coordinating Center"
Funding Period: 01/01/2018 - 12/31/2022
Total Award: \$15,101,575
Role: PI

2017PG-T1D017 Atkinson (PI)
The Leona M. & Harry B. Helmsley Charitable Trust
"Human Atlas of the Neonatal Development and Early Life Pancreas (Handel-P)"
Funding Period: 02/01/2017 - 01/31/2020
Role: PI

R01 DK098589 Keselowsky (PI)
NIH/NIDDK
"Biomaterial Delivery System for Type 1 Diabetes Vaccine"
Funding Period: 07/01/2014 - 06/30/2019 (NCE)
Total Award: \$374,186

R01 DK098589 Keselowsky (PI)
NIH/NIDDK
"Biomaterial Delivery System for Type 1 Diabetes Vaccine"
Funding Period: 07/01/2014 - 06/30/2019 (NCE)
Total Award: \$374,186
Role: Co-I

DP3 Qian (PI)
PNNL/NIH
"Serum protein biomarkers for predicting type 1 diabetes development"
Funding Period: 07/01/2016 - 06/30/2019
Total Award: \$225,000
Role: Co-I

UC4 DK112232 Powers (PI)
Vanderbilt/NIH/NIDDK
"Integrated Program for Human Pancreas Procurement and Analysis"
Funding Period: 12/01/2016 - 11/30/2021
Total Award: \$2,418,170
Role: Multi-PI

R01 DK120357-01 LaBaer (PI)
Arizona State University/NIH/NIDDK
"Identification of anti-neo-antigen antibodies in Type 1 Diabetes"
Funding Period: 09/20/2018 - 08/31/2019
Total Award: \$188,034
Role: Subcontract-PI

**ENDOWMENT
FUNDING (ACTIVE):**

F007367
Type 1 Diabetes Research Endowment
Annual Distribution: \$39,353.70
Principle: \$1,200,000

F013907
American Diabetes Association Eminent Scholar
Annual Distribution: \$112,500
Principle: \$3,300,000

F021401
Salisbury Diabetes Research Endowment
Annual Distribution: \$14,720
Principle: \$542,825

F008339
Keene Translational Diabetes Research Endowment
Annual Distribution: \$56,388.54
Principle: \$1,790,000

F004665
Kriser Foundation Diabetes Research Fund
Principle: \$91,124

PREVIOUS (selected from 1992 onward; only PI or CO-PI; ~40 other support grants not noted): JDRF 25-2013-268 Atkinson (PI)
Juvenile Diabetes Research Foundation
"Network for Pancreatic Organ Donors with Diabetes - Administrative Core"
Funding Period: 01/01/2013 - 12/31/2017
Total Award: \$15,101,575
Role: PI

JDRF 25-2013-268 Atkinson (PI)
Juvenile Diabetes Research Foundation
"Network for Pancreatic Organ Donors with Diabetes – OPPC Core"
Funding Period: 01/01/2013 - 12/31/2017
Total Award: \$3,018,455
Role: PI

HCT CU15-0070 Elgi (PI)
Columbia Univ/Helmsley Charitable Trust
"Helmsley Trust Diabetes Cell Repository"
Funding Period: 01/01/2015 - 12/31/2016
Total Award: \$55,800
Role: Co-I

JDRF 25-2012-770 Atkinson (PI)
Juvenile Diabetes Research Foundation
"The JDRF nPOD Viral Work Group: nPOD V"
Funding Period: 09/01/2012 - 08/31/2016
Total Award: \$2,737,575
Role: PI

DP3 DK101120 Campbell-Thompson (PI)
NIH/NIDDK
"Pancreatic Volume in Preclinical Type 1 Diabetes"
Funding Period: 09/20/2013 – 08/31/2016
Total Award: \$934,026
Role: Co-I

UC4 DK097835 Krischer (PI)
USF/NIH/NIDDK
"TrialNet Core Biomarkers and Mechanisms Panel"
Funding Period: 09/01/2015 - 08/30/2016
Total Award: \$23,040
Role: Co-I

R56 DK099174 Zhang (PI)
National Institutes of Health
"Protein Markers to Type 1 Diabetes Progression"
Funding Period: 09/01/2014 - 08/31/2015
Total Award: \$8,483 (Atkinson portion)
Role: Co-PI

Battelle Memorial Institute Pacific Northwest Division
"Pancreatic Tissue & Serum Progression Marker Discovery"
Funding Period: 12/04/2013 - 08/31/2015
Total Award: \$16,994
Role: Co-PI

JDRF 25-2012-380
Juvenile Diabetes Research Foundation
"nPOD Expansion"
Funding Period: 09/01/2012 - 08/31/2013
Total Award: \$345,950
Role: PI

JDRF 17-2012-541
Juvenile Diabetes Research Foundation
"Ex Vivo Analysis of the Cell Educator System"
Funding Period: 09/01/2012 - 08/31/2013
Total Award: \$118,932
Role: PI

JDRF/UCF 17-2011-286/22208036
Juvenile Diabetes Research Foundation/ University of Central Florida
"Evaluate Optimal Dose and Therapeutics"
Funding Period: 04/01/2011 - 03/31/2014
Total Award: \$164,399
Role: Co-PI

ADA 7-12-MN-03
American Diabetes Association
"Identifying the Contribution of Beta Cell Dysfunction and Autoimmunity to the Pathogenesis of Type 1 Diabetes"
Funding Period: 07/01/2012 - 06/03/2016
Total Award: \$171,000
Mentor based Post-doctoral Fellowship
Role: PI

09PG-T1D0010
The Leona M. and Harry B. Helmsley Charitable Trust
"To Arrest the Immune Assault on Beta Cells in Vivo"
Funding Period: 2009 - 2012
Total Award: \$600,000
Role: PI

09-PGT1D022
The Leona M. and Harry B. Helmsley Charitable Trust
"Reversing Type 1 Diabetes After it is Established – Master Trial Center"
Funding Period: 09/01/2009 - 05/31/2015
Total Award: \$911,570
Role: PI

Sanford Health
"Combinational Therapy in Type 1 Diabetes"
Funding Period: 12/01/2009 - 11/30/2015
Total Award: \$190,000
Role: PI

JDRF 3-2011-51
Juvenile Diabetes Research Foundation
"The Role of the Beta Cell (dys)function"
Funding Period: 03/01/2011 - 02/28/2014
Total Award: \$144,372
Role: Mentor (Patrick Rowe Fellowship)

09AG-118598
The Leona M. and Harry B. Helmsley Charitable Trust
"Creating a Cell and Serum Storage Facility for Advanced Studies of Cell
Functioning in Type 1 Diabetes"
Funding Period: 2009 - 2012
Total Award: \$372,876
Role: PI

R21 DK078863
National Institutes of Health
"Short Course G-CSF as Immunomodulatory Therapy for Type 1 Diabetes"
Funding Period: 2008 - 2010
Annual: \$198,267
Role: Co-PI

JDRF 4-2007-1065
Juvenile Diabetes Research Foundation
"Cord Blood Therapies for Type 1 Diabetes"
Funding Period: 09/01/2007 - 08/31/2013
Total Award: \$1,240,595
Role: PI

JDRF 17-2007-1045
Harvard University Subcontract
"Identification of Autoantigens in Type 1 Diabetes by Protein Microarrays"
Funding Period: 2007 - 2010
Total Award: \$114,807
Role: Co-PI

JDRF 17-2007-1045
Juvenile Diabetes Research Foundation
Program Project, Research Grant
"Autoantigen Identification"
Funding Period:
Total Award: \$ 117,344
Role: PI

Juvenile Diabetes Foundation Innovative Award
"Expansion of Regulatory T cells from Umbilical Cord Blood"
Total award: \$55,000
Funding period: 2007 - 2008
Role: PI

Juvenile Diabetes Foundation Innovative Award
"Phenotype/Genotype Studies of CD25 In Type 1 Diabetes"
Total award: \$40,000
Funding period: 2007 - 2008
Role: PI

R01 DK047858
National Institutes of Health
Program Project, Research Grant
"A study of model beta cells in diabetes treatment"
Funding Period: 2006 - 2011
Total Award: \$1,296,445
Role: Co-PI

JDF 7-2005-875
Juvenile Diabetes Research Foundation
"Novel Mechanisms and Therapies Targeting Dysfunctional Endothelium"
Funding years: 2006 - 2009
Total Award: \$660,000
Role: Co-PI

Juvenile Diabetes Foundation
Program Project Research Grant
"Immunoregulatory Based Therapies for the Prevention and Reversal of Type 1 Diabetes"
Funding period: 2006 - 2009
Total award: \$545,000
Role: PI

American Diabetes Association
Research Grant
"Mechanisms and Characterization of Regulatory T Cell Defects in Human Type 1 Diabetes"
Funding period: 2006 - 2009
Total award: \$300,000
Role: PI

R21-DK077580
National Institutes of Health
"Cord Blood Immunoregulation of Type 1 Diabetes"
Funding years: 2006 - 2009
Total Award: \$272,600
Role: PI

JDRF/Benaroya 9-2012-22/12703602
JDRF/ITN Partnership in Immune Tolerance
Funding Period: 01/01/2012 - 12/31/2013
\$50,000 per year
Role: local PI

Lawson Wilkins Pediatric Endocrine Society
Research Fellowship
Funding period: 2005 - 2007
Total award: \$105,000
Role: PI

National Institutes of Health
"Characterization & Therapeutic Efficacy of Insulin-Producing Cells Generated in vitro from Adult Hepatic Oval Stem Cells"
Funding period: 2003 - 2008

National Institutes of Health
"Characterization & Therapeutic Efficacy of Insulin-Producing Cells Generated
in vitro from Adult Hepatic Oval Stem Cells"
Funding period: 2003 - 2008
Total Award: \$350,000
Role: Mentor
Trainee: Lijun Yang, M.D.

R21 63422
National Institutes of Health
"Dendritic Cells and the Prevention of Type 1 Diabetes"
Funding Period: 2002 - 2004
Total award: \$435,125
Role: Co-PI

UF 96022928
American Diabetes Association
"Cytokine Gene Therapy for the Prevention of Insulin Dependent Diabetes"
Funding period: 2002 - 2004
Total award: \$200,000
Role: PI

P01AI42288-10
National Institutes of Health
"Immune Function in High and Low Risk Genotypes in Insulin Dependent
Diabetes"
Funding period: 2001 - 2006
Total Award: \$5,203,000.00
Role: PI

U42 RR16586
National Institutes of Health
National Gene Vector Laboratory Toxicology Center. Project 1
Total award: \$736,539
Funding period: 2001 - 2006
Role: PI

National Kidney Foundation
Fellowship Training Program
"The Role of Heme Oxygenase-1 in Pancreatic B-cell Survival"
Funding period: 2001 – 2003
Total award: \$82,000.00
Role: Mentor/ PI
Fellow trainee: Matthias Kapturczak, M.D., Ph.D.

Juvenile Diabetes Research Foundation
"The JDFI Gene Therapy Center for the Prevention of Diabetes and it's
Complications at the University of Florida and the University of Miami"
Funding period: 2000 - 2005
Total award: \$10,600,000.00
Role: PI

P01DK58327
National Institutes of Health.
"Recombinant AAV for Correction of Genetic Abnormalities. Core C"
Immunology/Pathology.

National Institutes of Health
"DQB1*0602 Relatives: Mechanisms Conferring diabetes Protection"
Funding period: 1999 - 2002
Total award: \$210,967
P.I.: Carla Greenbaum, M.D. (University of Washington).
Role: co-PI

Juvenile Diabetes Research Foundation
"Cytokine Mediated Gene Therapy for the Prevention & Reversal of Insulin
Dependent Diabetes"
Funding Period: 1999 - 2001
Total Award: \$199,686
Role: PI

Juvenile Diabetes Research Foundation
"The Role for B-Lymphocytes in the Development of Anti-GAD & Anti
Coxsackie Viral Immune Responses in NOD Mice"
Funding Period: 1998 - 2000
Total award: \$192,702
Role: PI

P01AI42288
National Institutes of Health.
"Immune Function in High and Low Risk Genotypes in Insulin Dependent
Diabetes"
Funding period: 1997 - 2001
Total award: \$5,818,473.00
Role: PI

2RO1AI39250
National Institutes of Health
"Mechanisms of Immunotherapy in IDD Prevention Trials"
Funding period: 1996 - 2001
Total award: \$1,094,264.00
Role: PI

Juvenile Diabetes Research Foundation
"Insulin Secretion & Lymphocyte Insulin Receptor Expression: Key Variables
to the Rate of Beta Cell Destruction"
Funding Period: 1996 - 1998
Total award: \$98,120
Role: PI

National Dairy Council
"The Role of Infant Nutrition in the Pathogenesis of Insulin Dependent
Diabetes"
Funding period: 1995 - 1997
Total award: \$50,000
Role: PI

R29 DK4532
National Institutes of Health
"Cellular Immunity to Glutamate Decarboxylase in IDD"
Funding Period: 1992 - 1997
Total award: \$112,989

Role: PI

Type 1 Diabetes Biomarkers; US20160195546A1; Joshua Labaer, Ji Qiu, Xiaofang Bian, Desmond A. Schatz, Clive H. Wasserfall and Mark A. Atkinson; Date of Patent: January 7, 2016.

Combination therapies for treating type 1 diabetes; US20140301973A1; Mark A. Atkinson; Date of Patent: June 22, 2014.

Compositions for treatment and/or prevention of autoimmune disorders; US20160022793A1; Joseph Larkin and Mark A. Atkinson; Date of Patent: March 18, 2014

Novel type 1 diabetes vaccines, and methods of use; US20140271718A1; Joseph Larkin and Mark A. Atkinson; Date of Patent: March 17, 2014

Materials and methods for modulating immune responses; US20150147388A1; Clive Henry Wasserfall, Mark A. Atkinson, Benjamin George Keselowsky and Young Mee Yoon; Date of Patent: June 25, 2012

Antigen-specific, tolerance-inducing microparticles and uses thereof; US20130287729A1; Benjamin George Keselowsky, Jamal' Lewis, Abhinav Acharya, Michael J. Clare-Salzler, Mark A. Atkinson, Clive Henry Wasserfall, Chang Qing Xia and Todd M. Brusko; Date of Patent: October 24, 2011.

Lactobacillus supplement for alleviating type 1 diabetes; US20120183513A1; Josef Neu, Graciela Liliana Lorca, Eric W. Triplett, Mark A. Atkinson and Desmond A. Schatz; Date of Patent: February 18, 2010

Combination therapies for treating type 1 diabetes; US8758761B2; Mark A. Atkinson, Scott Eisenbeis, Donna Armentano, Abraham Scaria and Tracey Lodie; Date of Patent: September 30, 2008.

Materials and Methods for the Detection, Prevention and Treatment of Autoimmune Disease; US20100178652A1; Sally A. Litherland, Marcia McDuffie, Laurence Morel, Federica Seydel, Erin Garrigan, Nicole A. Belkin, Bryan Stutevoss, Michael J. Clare-Salzler, Mark A. Atkinson, Clive Henry Wasserfall, Ammon B. Peck and Abdolreza Davoodi-Semiromi; Date of Patent: January 7, 2008.

Nanoparticles for protection of cells from oxidative stress; US20100172994A1; Wolfgang M. Sigmund, Yi-Yang Tsai, Ioannis Constantinidis, Jenny Dorley, Jose Antonio Oca-Cossio, Carol Ann Sweeney, Nicholas Edward Simpson and Mark A. Atkinson; Date of Patent: November 23, 2007

Materials and Methods for Reversing Type 1 Diabetes; US20090162345A1; Mark A. Atkinson, Gregory Simon, Clive Henry Wasserfall, Abraham Scaria, Desmond A. Schatz, Donna Armentano and Srinivas Shankara; Date of Patent: November 29, 2006

Biomarkers for differentiating between type 1 and type 2 diabetes; WO2005094200A3; Tamir M. Ellis, Alba Esther Morales, Mark A. Atkinson

Type 1 Diabetes Biomarkers; US20160195546A1; Joshua Labaer, Ji Qiu, Xiaofang Bian, Desmond A. Schatz, Clive H. Wasserfall and Mark A. Atkinson; Date of Patent: January 7, 2016.

Combination therapies for treating type 1 diabetes; US20140301973A1; Mark A. Atkinson; Date of Patent: June 22, 2014.

Compositions for treatment and/or prevention of autoimmune disorders; US20160022793A1; Joseph Larkin and Mark A. Atkinson; Date of Patent: March 18, 2014

Novel type 1 diabetes vaccines, and methods of use; US20140271718A1; Joseph Larkin and Mark A. Atkinson; Date of Patent: March 17, 2014

Materials and methods for modulating immune responses; US20150147388A1; Clive Henry Wasserfall, Mark A. Atkinson, Benjamin George Keselowsky and Young Mee Yoon; Date of Patent: June 25, 2012

Antigen-specific, tolerance-inducing microparticles and uses thereof; US20130287729A1; Benjamin George Keselowsky, Jamal' Lewis, Abhinav Acharya, Michael J. Clare-Salzler, Mark A. Atkinson, Clive Henry Wasserfall, Chang Qing Xia and Todd M. Brusko; Date of Patent: October 24, 2011.

Lactobacillus supplement for alleviating type 1 diabetes; US20120183513A1; Josef Neu, Graciela Liliana Lorca, Eric W. Triplett, Mark A. Atkinson and Desmond A. Schatz; Date of Patent: February 18, 2010

Combination therapies for treating type 1 diabetes; US8758761B2; Mark A. Atkinson, Scott Eisenbeis, Donna Armentano, Abraham Scaria and Tracey Lodie; Date of Patent: September 30, 2008.

Materials and Methods for the Detection, Prevention and Treatment of Autoimmune Disease; US20100178652A1; Sally A. Litherland, Marcia McDuffie, Laurence Morel, Federica Seydel, Erin Garrigan, Nicole A. Belkin, Bryan Stutevoss, Michael J. Clare-Salzler, Mark A. Atkinson, Clive Henry Wasserfall, Ammon B. Peck and Abdolreza Davoodi-Semiromi; Date of Patent: January 7, 2008.

Nanoparticles for protection of cells from oxidative stress; US20100172994A1; Wolfgang M. Sigmund, Yi-Yang Tsai, Ioannis Constantinidis, Jenny Dorley, Jose Antonio Oca-Cossio, Carol Ann Sweeney, Nicholas Edward Simpson and Mark A. Atkinson; Date of Patent: November 23, 2007

Materials and Methods for Reversing Type 1 Diabetes; US20090162345A1; Mark A. Atkinson, Gregory Simon, Clive Henry Wasserfall, Abraham Scaria, Desmond A. Schatz, Donna Armentano and Srinivas Shankara; Date of Patent: November 29, 2006

Biomarkers for differentiating between type 1 and type 2 diabetes; WO2005094200A3; Tamir M. Ellis, Alba Esther Morales, Mark A. Atkinson and Clive Henry Wasserfall; Date of Patent: June 21, 2004

ORIGINAL PUBLICATIONS:

1. ***Atkinson, M.A.**; Maclaren, N.K.; Riley, W.J.; Winter, W.E.; Fisk, D.D.; Spillar, R.P.: Are Insulin Autoantibodies Markers for Insulin-Dependent Diabetes Mellitus? Diabetes 35 (8): 894-898, 1986.
2. ***Atkinson, M.A.**; Fisk, D.D.; Spillar, R.P., MacLaren N.K.: Insulin Autoantibodies As Markers For Insulin-Dependent Diabetes Mellitus (IDD). Diabetes 35: A87-A87, 1986.
3. *Beppu, H.; Winter, W.E.; **Atkinson, M.A.**; Fujita, K.; Takahashi, H.: Immune Response to Bovine Serum-Albumin (BSA) in NOD Mice - Possible Relevance to Diabetes. Diabetes 35: A184-A184, 1986.
4. *Beppu, H.; Winter, W.E.; **Atkinson, M.A.**; Maclaren, N.K.; Fujita, K.; Takahashi, H.: Bovine Albumin Antibodies in NOD Mice. Diabetes Research 6: 67-69, 1987.
5. *Maclaren, N.; Riley, W.; Skordis, N.; **Atkinson, M.**; Spillar, R.; Silverstein, J.; Klein, R.; Rotter, J.: Inherited Susceptibility to Insulin Dependent Diabetes is Associated with HLA-DR 1, While DR5 is Protective. Autoimmunity 1: 197-205, 1988.
6. ***Atkinson, M.A.**; Maclaren, N.K.: Autoantibodies in Non-Obese Diabetic Mice Immunoprecipitate and Mr 64,000 Islet Cell Antigen. Diabetes 37: 1587-1590, 1988.
7. ***Atkinson, M.A.**; Winter, W.E.; Skordis, N.K.; Beppu, H.; Riley, W.J.; Maclaren, N.K.: The Effect of Dietary Protein Restriction Reduces the Frequency and Delays the Onset of Insulin Dependent Diabetes in BB Rats. Autoimmunity 2: 11-19, 1988.
8. *Riley, W.J, **Atkinson, M.A.**; MacLaren, NK: Insulin autoantibodies in pre-diabetes. Advances In Experimental Medicine and Biology 246: 45-51, 1988.
9. ***Atkinson, M.A.**; Winter, W.E.; Skordis, N.; Beppu, H.; Riley, W.M.; Maclaren, N.K.: Dietary Protein Restriction Reduces the Frequency and Delays the Onset of Insulin Dependent Diabetes in BB Rats. Autoimmunity 2 (1): 11-19, 1988.
10. *Riley, W.J.; **Atkinson, M.A.**; Schatz, D.A.; Maclaren, N.K.: Comparison of Islet Autoantibodies in "Pre-diabetes" and Recommendations for Screening. The Journal of Autoimmunity 3: 47-52, 1990.
11. ***Atkinson, M.A.**; Maclaren, N.K.; Holmes, L.A.; Scharp, D.W.; Lacy, P.E.; Riley, W.J.: The Natural History and Predictive Value of Mr 64,000 Autoantibodies for Insulin Dependent Diabetes Mellitus. The Journal of Autoimmunity 3: 41-45, 1990.
12. ***Atkinson, M.A.**; Maclaren, N.K.; Riley, W.J.; Scharp, D.W.; Lacy, P.E.: Mr 64,000 Autoantibodies as Predictors of Insulin Dependent Diabetes. The Lancet 335: 1357-1360, 1990.
13. **Atkinson, M.A.**; Maclaren, N.K.: What Causes Diabetes? Scientific American 62: 66-71, 1990.
14. ***Atkinson, M.A.**; N.K. Maclaren; Luchetta, R.; Burr, I.: Insulinitis and Diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 39: 933-937, 1990.
15. *Kampe, O.; Velloso, L.; Andersson, A.; Karlsson, A.; **Atkinson, M.A.**; Maclaren N.K.: No Role for 65 kD Heat-Shock Protein in Diabetes. The Lancet 336 (8725): 1250-1251, 1990.
16. ***Atkinson, M.A.**; Maclaren, N.K.; Scharp, D.W.: No Evidence for HSP 65 in Insulin Dependent Diabetes. The Lancet 336: 1250-1251, 1990.
17. ***Atkinson, M.A.**; Holmes, L.A.; Sharp, D.W.; Lacy, P.E.; Maclaren, N.K.: No Evidence for Serological Autoimmunity To Islet Cell Heat Shock Proteins in Insulin Dependent Diabetes. The Journal of Clinical

Investigation 87: 721-724, 1991.

18. *Kaufman, D.L.; Elander, M.G.; Clare-Salzler, M.; **Atkinson, M.A.**; MacLaren, N.K.: GAD Autoimmunity in IDDM. Diabetes: Proceedings of the 14th International Diabetes Federation, 1991.
19. *Kaufman, D.L.; Erlander, M.G.; Clare-Salzler, M.C.; **Atkinson, M.A.**; Maclaren, N.K.; Tobin, A.J.: Autoimmunity to Two Forms of Glutamate Decarboxylase in Insulin Dependent Diabetes Mellitus. The Journal of Clinical Investigation 89: 283-292, 1992.
20. ***Atkinson, M.A.**; Kaufman, D.L.; Campbell, L.; Gibbs, K.A.; Shah, S.C.; Bu, D.F.; Erlander, M.G.; Tobin, A.J.; Maclaren, N.K.: Response of Peripheral-Blood Mononuclear Cells to Glutamate Decarboxylase in Insulin-Dependent Diabetes. The Lancet 339: 548-549, 1992.
21. *Maclaren, N.K.; **Atkinson, M.A.**: Is Insulin-Dependent Diabetes Mellitus Environmentally Induced? The New England Journal of Medicine 327: 348-349, 1992.
22. *Harrison, L.C.; Honeyman, M.C.; DeAizpurua, H.J.; Schmidli, R.S.; Colman, P.G.; **Atkinson, M.**: Inverse Relation Between Humoral and Cellular Immunity to Glutamic Acid Decarboxylase in Subjects at Risk of Insulin-Dependent Diabetes. The Lancet 341 (8857): 1365-1369, 1993.
23. ***Atkinson, M.**; Campbell, L.; Kaufman, D.L.; Tian, J.D.: Conformational Epitope Dependency for Islet Cell Cytoplasmic Autoantibodies (ICA) Reactive to Glutamate-Decarboxylase (GAD) in Insulin- Dependent Diabetes (IDD). Diabetes 42: A114-A114, 1993.
24. *Huang, L.; **Atkinson, M.A.**; Dush, P.; Kennedy, R.T.: Amperometric Monitoring of individual Exocytosis events in pancreatic beta cells. Analytical Chemistry 65: 1882-1887, 1993.
25. ***Atkinson, M.A.**; Maclaren, N.K.: Islet Cell Autoantigens in Insulin Dependent Diabetes. The Journal of Clinical Investigation 92: 1608-1616, 1993.
26. *Kaufman, D.L.; Clare-Salzler, M.C.; Sercarz, E.E.; Tobin, A.J.; **Atkinson, M.A.**; Lehmann, P.: Spontaneous Loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature Publishing Group 366: 69-72, 1993.
27. ***Atkinson, M.A.**; Bowman, M.A.; Kao, K.J.; Campbell, L.; Dush, P.J.; Simmel, O.; Maclaren, N.K.: Lack of Immune Responses to Bovine Serum Albumin in Insulin Dependent Diabetes. The New England Journal of Medicine 329: 1853-1858, 1993.
28. *Maclaren, N.; Muir, A.; Silverstein, J.; Song, Y.H.; She, J.X.; Krischer, J.; **Atkinson, M.**; Schatz, D.: Early Diagnosis and Specific Treatment of Insulin-Dependent Diabetes. Annals of New York Academy of Science 696: 342-350, 1993.
29. *Silverstein, J.; Song, Y.; Jinx, S.; Krischer, J.; **Atkinson, M.A.**: Early Diagnosis and Specific Treatment of Insulin-Dependent Diabetes. Immunosuppressive and Anti-inflammatory Drugs: 342, 1993.
30. *Ayoub, E.M.; **Atkinson, M.**; Alsaied, K.; Schiffenbauer, J.: Association of 70 Kd molecule with HLA-DR of Rheumatic Fever Patients. ZENTRALBLATT FUR BAKTERIOLOGIE-SUPPLEMENT: 528-528, 1993.
31. ***Atkinson, M.**; Kaufman, D.L.; Newman, D.; Tobin, A.J.; Maclaren, N.K.: Islet Cell Cytoplasmic Autoantibody Reactivity to Glutamate Decarboxylase in Insulin-Dependent Diabetes. Journal of Clinical Investigation 91 (1): 350, 1993.
32. *Bowman, M.A.; Leiter, E.H.; **Atkinson, M.A.**: Prevention of Diabetes in the NOD Mouse: Implications for Therapeutic Intervention in Human Disease. Immunology Today 15: 115-120, 1994.
33. ***Atkinson, M.A.**; Kao, K.J.; Maclaren, N.K.: Lack of Immunity to Bovine Serum Albumin in Insulin Dependent Diabetes. The New England Journal of Medicine 330: 1616-1617, 1994.
34. Doesch, H.M.; Karjalainen, J.; Vandermeulen, J.; **Atkinson, M.A.**; Kao, K.J.; Maclaren, N.K.: Lack of Immunity to Bovine Serum Albumin in Insulin-Dependent Diabetes Mellitus. Authors Reply. The New

England Journal of Medicine 330(22): 1616-17, 1994.

35. *Leslie, R.D.G.; **Atkinson, M.A.**: Inverse Relation Between Humoral and Cellular Immunity to Glutamic Acid Decarboxylase in Subjects at Risk of Insulin-Dependent Diabetes. The Journal of Endocrinological Investigation 17: 581-584, 1994.
36. ***Atkinson, M.A.**; Bowman, M.A.; Campbell, L.; Kaufman, D.L.; Maclaren, N.K.: Cellular Immunity to a Determinant Common to Glutamate Decarboxylase and Coxsackie Virus in Insulin Dependent Diabetes. The Journal of Clinical Investigation 94: 2125-2129, 1994.
37. ***Atkinson, M.A.**; Maclaren, N.K.: The Pathogenesis of Insulin Dependent Diabetes Mellitus. The New England Journal of Medicine 331: 1428-1436, 1994.
38. *Gerling, I.; **Atkinson, M.A.**; Leiter, E.H.: The Thymus as a Site for Evaluating the Potency of Candidate β Cell Autoantigens in NOD mice. The Journal of Autoimmunity 7: 851-858, 1994.
39. *Schott, M.; Schatz, D.; **Atkinson, M.**; Krischer, J.; Mehta, H.; Vold, B.; Maclaren, N.: GAD₆₅ Autoantibodies Increase the Predictability but not the Sensitivity of Islet Cell and Insulin Autoantibodies for Developing Insulin Dependent Diabetes Mellitus. The Journal of Autoimmunity 7: 865-872, 1994.
40. **Atkinson, M.A.**; Ellis, T.M.: Should We Replace Islet Cell Antibody Assay For The Prediction of Insulin Dependent Diabetes. Diabetes Prevention & Therapy 8: 33-34, 1994.
41. *Hanson, M.S.; Serreze, D.V.; **Atkinson, M.A.** et al: Clonal Diversion of T Cell Responses from Th1 to Th2: A Possible Mechanism of Diabetes Resistance in NOD-*Ea*^d Transgenic Mice. Autoimmunity 21: 52-56, 1995.
42. **Atkinson, M.A.**; Schatz, D.S.: Cow's Milk and IDDM: Only Time Will Tell. Diabetes Prevention & Therapy 9: 1-2, 1995.
43. *Huang, L.; Shen, H.; **Atkinson, M.A.**; Kennedy, R.T.: Detection of Exocytosis at Individual Pancreatic β cells by Amperometry at a Chemically Modified Microelectrode. Proceedings of The National Academy of Sciences, USA 92: 9608-9612, 1995.
44. *Daw, K.; Ujihara, N.; **Atkinson, M.A.**; Powers, A.C.: Glutamic Acid Decarboxylase Autoantibodies in Stiff-Man Syndrome and Insulin Dependent Diabetes Mellitus Exhibit Similarities and Differences in Epitope Recognition. The Journal of Immunology 156: 818-825, 1996.
45. *Ellis, T.M.; **Atkinson, M.A.**: The Clinical Significance of an Autoimmune Response against Glutamic Acid Decarboxylase. Nature Medicine 2: 148-153, 1996.
46. Roll, U.; Aanstoot, H.J.; Kang, S.M.; Knip, M.; **Atkinson, M.**; Landin, M.; Bruining, J.; Maclaren, N.; Akerblom, H.K.; Baekkeskov S: Identification and characterization of glima 38, a glycosylated islet membrane antigen of 38KD, which together with GAD65 and IA2 marks the early phases of autoimmune response in type 1 diabetes. Molecular Biology of the Cell 7: 3468-3468, 1996.
47. *Bowman, M.A.; Campbell, L.; Darrow, B.; Suresh, A.; Clare-Salzler, M.; **Atkinson, M.A.**: Immunological and Metabolic Effects of Prophylactic Insulin Therapy in Insulin the NOD-scid/scid adoptive transfer model of IDDM. Diabetes 45: 205-208, 1996.
48. *Tian, J.; **Atkinson, M.A.**; Clare-Salzler, M.; Herschenfeld, A.; Forsthuber, T.; Lehmann, P.V.; Kaufman, D.L.: Nasal Administration of Glutamate Decarboxylase (GAD 65) Peptides Induces Th2 Responses and Prevents Murine Insulin-Dependent Diabetes. The Journal of Experimental Medicine 183: 1561-1567, 1996.
49. *Ellis, T.M.; **Atkinson, M.A.**: Early Infant Diets and Insulin Dependent Diabetes. The Lancet 347: 1464-1465, 1996.
50. *Aanstoot, H.J.; Kim, J.; Knip, M.; **Atkinson, M.A.**; Mose-Larsen, P.; Fey, S.; Fu, Q.; Ludvigsson, J.; Landin, M.; Bruining, J.; Maclaren, N.K.; Akerblom, H.K.; Baekkeskov, S.: Identification and Characterization of Glimma38, a Glycosylated Islet Cell Membrane Antigen, Which Together with GAD65

50. *Aanstoot, H.J.; Kim, J.; Knip, M.; **Atkinson, M.A.**; Mose-Larsen, P.; Fey, S.; Fu, Q.; Ludvigsson, J.; Landin, M.; Bruining, J.; Maclaren, N.K.; Akerblom, H.K.; Baekkeskov, S.: Identification and Characterization of Glim38, a Glycosylated Islet Cell Membrane Antigen, Which Together with GAD65 and IA2 Marks the Early Phases of Autoimmune Response in T1 Diabetes. The Journal of Clinical Investigation 97: 2772-2783, 1996.
51. *Hanson, M.S.; Cetkovic-Cvrlje, M.; Ramiya, V.K.; **Atkinson, M.A.**; Maclaren, N.K.; Singh, B.; Elliott, J.F.; Serreze, D.V.; Leiter, E.K.: Quantitative Thresholds of MHC Class II I-E Expressed on Hematopoietically Derived APC in Transgenic NOD/Lt Mice Determine Levels of Diabetes Resistance and Indicate Mechanism of Protection. The Journal of Immunology 157: 1279-1287, 1996.
52. *Bowman, M.A.; Simell, O.G.; Peck, A.B.; Cornelius, J.; Luchetta, R.; Look, Z.; Maclaren, N.K.; **Atkinson, M.A.**: Pharmacokinetics of Aminoguanidine Administration and Effects on the Diabetes Frequency in Nonobese Diabetic Mice. The Journal of Pharmacology and Experimental Therapeutics 279: 790-794, 1996.
53. *Maclaren, N.K.; **Atkinson, M.A.**: Insulin-Dependent Diabetes Mellitus: the Hypothesis of Molecular Mimicry Between Islet Cell Antigens and Microorganisms. Molecular Medicine 3: 76-83, 1997.
54. ***Atkinson, M.A.**: Diet, Genetics, and Diabetes: The Role of Infant Nutrition in the Pathogenesis of Insulin Dependent Diabetes. Food Technology 51: 77-79, 1997.
55. *Unanue, E.; Delovitch, T.; Lafferty, K.J.; **Atkinson, M.A.**; McDevitt, H.O.; Wong, F.S.; Janeway, C.A.; Mathis, D.; Bach, J.F.: The NOD mouse-Discussion. Research Immunology 148(5): 359-66, 1997.
56. *Cetkovic-Cvrlje, M.; Gerling, I.C.; Muir, A.; **Atkinson, M.A.**; Elliot, J.F.; Leiter, E.H.: Retardation or acceleration of diabetes in NOD/Lt mice mediated by Intrathymic Administration of Candidate Beta-Cell Antigens. Diabetes 46: 1975-1983, 1997.
57. *Tian, J.; Clare-Salzler, M.C.; Herschenfeld, A.; Middleton, B.; Newman, D.; Evans, C.; **Atkinson, M.A.**; Mueller, R.; Mullen, Y.; Sarvetnick, N.; Tobin, A.J.; Kaufman, D.L.: Modulating Autoimmune Responses to GAD Inhibits Disease Progression and Prolongs Islet Graft Survival in Diabetes-Prone Mice. Nature Medicine 2: 1348-1353, 1996.
58. ***Atkinson, M.A.**; Gendreau, P.; Rinker, C.; Ellis, T.; Petitto, J.: NOD Mice as a Model for Inherited Deafness. Diabetologia 40: 868, 1997.
59. ***Atkinson, M.A.**; Ellis, T.M.: Infant Diets and Insulin Dependent Diabetes: Evaluating the "Cows Milk Hypothesis" and a Role for anti-Bovine Serum Albumin Immunity. Journal of the American College of Nutrition 16: 334-340, 1997.
60. Schiffenbauer, J.; Xie, T.; Clare-Salzler, M.; **Atkinson, M.A.**: The Effect of Superantigen Administration on the Natural History of IDD in NOD Mice. Diabetologia 40: 257-257, 1997.
61. ***Atkinson, M.A.**: Molecular Mimicry and the Pathogenesis of Insulin Dependent Diabetes Mellitus: Still Just an Attractive Hypothesis. Annals of Medicine 29: 393-399, 1997.
62. *Ellis, T.M.; Hardt, N.S.; **Atkinson, M.A.**: Cellular Immune Activities in Women with Silicone Breast Implants: A preliminary investigation. Annals of Allergy, Asthma, & Immunology 79: 151-154, 1997.
63. **Atkinson, M.A.**: Mechanisms Underlying the Loss of Self-Tolerance in NOD Mice. Research in Immunology 148: 301-306, 1997.
64. Ellis, T.M.; Hardt, N.S.; Atkinson, M.A.: Antipolymer antibodies, silicone breast implants, and fibromyalgia. The Lancet 349 (9059): 1173, 1997.
65. *Wilson, S.B.; Kent, S.C.; Patton, K.T.; Orban, T.; Jackson, R.A.; Exley, M.; Porcelli, S.; Schatz, D.A.; **Atkinson, M.A.**; Balk, S.P.; Strominger, J.L.; Hafler, D.A.: Extreme Th1 Bias of Invariant $\alpha 24\text{J}\alpha\text{Q}$ T Cells in Type 1 Diabetes. Nature 391: 177-181, 1998.
66. *Zechel, M.A.; Elliott, J.F.; **Atkinson, M.A.**; Singh, B.: Characterization of Novel T-cell Epitopes on 65

67. *Cetkovic-Cvrlje, M.; Gerling, I.C.; Muir, A.; **Atkinson, M.A.**; Elliot, J.F.; Leiter, E.H.: Retardation or acceleration of diabetes in NOD/Lt mice mediated by Intrathymic Administration of Candidate Beta-Cell Antigens (vol 46, pg 1975, 1997). Diabetes 47(2): 303, 1998.
68. *Ellis, T.; Schatz, D.; Ottendorffer, E.; Wasserfall, C.; Lan, M.; Notkins, A.; Maclaren, N.; **Atkinson, M.**: Relationship Between Humoral and Cellular Immunity to IA-2 in Insulin Dependent Diabetes. Diabetes 47: 566-569, 1998.
69. *Ellis, T.; Jodoin, E.; Schatz, D.; Ottendorffer, E.; She, J.S.; **Atkinson, M.**: Cellular Immune Responses Against β Casein: Elevated but not Specific for Individuals with Insulin Dependent Diabetes. Diabetologia 41: 731-735, 1998.
70. *Schatz, D.; Ellis, T.; Ottendorffer, E.; Jodoin, E.; Salisbury, P.; Barrett, D.; **Atkinson, M.**: Aging and the Immune Response to Tetanus Toxoid: Diminished Frequency and Level of Cellular Immune Reactivity to Antigenic Stimulation. Clinical Diagnostic Laboratory Immunology 5: 894-896, 1998.
71. *Song, S.; Morgan, M.; Ellis, T.; Poirer, A.; Chesnut, K.; Wang, J.; Brantly, M.; Byrne, B.J.; **Atkinson, M.**; Flotte, T.R.: Sustained Secretion of Human Alpha-1-Antitrypsin from Murine Muscle Transduced with Adeno-Associated Virus Vector. Proceedings of The National Academy of Science 95: 14384-14388, 1998.
72. *Leslie, D.; **Atkinson, M.A.**; Notkins, A. L.: Autoantigens IA-2 and GAD in Type 1 (Insulin Dependent) Diabetes. Diabetologia 42: 3-14, 1999.
73. Ellis, T.; Jodoin, E.; Ottendorffer, E.; Salisbury, P.; She, J.X.; Schatz, D.; **Atkinson, M.A.**: Cellular Immune Responses Against Proinsulin: No Evidence for Enhanced Reactivity in Individuals with IDDM. Diabetes 48: 299-303, 1999.
74. Wilson, S.B.; Kent, S.C.; Patton, K.T.; Orban, T.; Jackson, R.A.; Exley, M.; Porcelli, S.; Schatz, D.A.; **Atkinson, M.A.**; Balk, S.P.; Strominger, J.L.; Hafler, D.A.: Extreme Th1 Bias of Invariant V α 24J α Q T cells in Type 1 Diabetes. Nature 399: 84, 1999.
75. *Falta, M.T.; Magin, G.K.; Allegretta, M.; Steinman, L.; **Atkinson, M.A.**; Brostoff, S.W.; Albertini, R.: Selection of hprt Mutant T Cells as Surrogates for Dividing Cells Reveals a Restricted T Cell Receptor BV Repertoire in Insulin-Dependent Diabetes Mellitus. Clinical Immunology 90: 340-351, 1999.
76. ***Atkinson, M.A.**; Leiter, E.H.: The NOD Mouse Model of Type 1 Diabetes Mellitus: As Good As It Gets? Nature Medicine 5: 601-604, 1999.
77. *She, J.X.; Ellis, T.; Wilson, B.; Wasserfall, E.; Kent, S.; Hafler, D.; Schatz, D.; Muir, A.M.; Strominger, J.; **Atkinson, M.**: Heterophile Antibodies Segregate in Families and are Associated with Protection from Type 1 Diabetes. Proceedings of The National Academy of Sciences, USA 96: 8116-8119, 1999.
78. *Ottendorffer, E.; Ellis, T.M.; Bahjat, K.S.; Clare-Salzler, M.; **Atkinson, M.A.**: No Alteration in T Lymphocyte Expression of CD40 Ligand (CD154) in Individuals with or at Increased Risk for Insulin-Dependent Diabetes Mellitus. The Journal of Clinical Endocrinology and Metabolism 84: 4068-4072, 1999.
79. Roep, B.O., **Atkinson, M.A.**; van Endert, P.M.; Gottlieb, P.A.; Wilson, .B.; Sachs, J.A.; for the Workshop Participants: Autoreactive T-cell Responses in Insulin-Dependent (Type 1) Diabetes Mellitus: Report of the First International Workshop for Standardization of T-cell Assays. The Journal of Autoimmunity 13: 267-282, 1999.
80. **Atkinson, M.A.**; Ellis, T.M.; Serreze, D.V.: Control of Autoimmune Diabetes in NOD Mice by GAD Expression or Suppression in β Cells. Science 287: 191-192, 2000.
81. *Wasserfall, C.; **Atkinson, M.**; Jodoin, E.; Schatz, D.; She, J.X.; Ellis, T.M.: Glutamic Acid Decarboxylase and IA-2 Autoantibodies in Type 1 Diabetes; Comparing Sample Substrates for Autoantibody Determination. Pediatric Diabetes 1: 10-16, 2000.
82. *Serreze, D.; Ottendorffer, E.; Gauntt, C.; Ellis, T.M.; **Atkinson, M.A.**: Acceleration of Insulin Dependent

Diabetes Mellitus by a Coxsackievirus Infection Requires a Preexisting Critical Mass of Autoreactive T cells in Pancreatic Islets. Diabetes 49: 708-711, 2000.

83. ***Atkinson, M.**; Honeyman, M.; Peakman, M.; Roep, B.: T-cell markers in Type 1 Diabetes: Progress, Prospects and Realistic Expectations. Diabetologia 43: 819-20, 2000.
84. *Falta, M. T.; **Atkinson, M.**; Allegretta, M.; Vacek, P.M.; Albertini, R.J.: Azathioprine Associated T-Cell Mutations in Insulin-Dependent Diabetes Mellitus. Scandinavian Journal of Immunology 51: 626-633, 2000.
85. **Atkinson, M.**: The \$64,000 Question in Diabetes Continues. The Lancet 356: 4-6, 2000.
86. Haskins, K.: **Atkinson, M.**: Prediction of Diabetes and Response to Therapy in Individual Animals: Are There Lessons for Man? The Journal of Autoimmunity 16: 15-19, 2001.
87. *Flotte, T.; Song, S.; Wang, J.; Chesnut, K.; Wasserfall, C.; Kapturczak, M.; Ellis, T.; Agarwal, A.; Nick, H.; **Atkinson, M.**: Efficient Ex Vivo Transduction of Pancreatic Islet Cells with Recombinant Adeno-Associated Virus Vectors. Diabetes 50: 515-20, 2001.
88. *Bingley, P.J.; Bonifacio, E.; Ziegler, A.G.; Schatz, D.; **Atkinson, M.**; Eisenbarth, G.: Proposed Guidelines on Screening for Risk of Type 1 Diabetes. Diabetes Care 24: 398, 2001.
89. Kapturczak, M.H.; Flotte, T.R.; **Atkinson, M.A.**: Adeno-Associated Virus (AAV) as a Vehicle for Therapeutic Gene Delivery: Improvements in Vector Design and Viral Production Enhance Potential to Prolong Graft Survival in Pancreatic Islet Cell Transplantation for the Reversal of Type 1 Diabetes. Current Molecular Medicine 1: 245-258, 2001.
90. *Tisch, R.; Wang, B.; **Atkinson, M.A.**; Serreze, D.V.; Friedline, R.: A Glutamic Acid Decarboxylase 65-Specific Th2 Cell Clone Immunoregulates Autoimmune Diabetes in Nonobese Diabetic Mice. The Journal of Immunology 166: 6925-6936, 2001.
91. ***Atkinson, M.**; Eisenbarth, G.: Type 1 Diabetes: New Perspectives on Disease Pathogenesis and Treatment. The Lancet 358: 221-229, 2001.
92. *Goudy, K.; Song, S.; Wasserfall, C.; Zhang, Y.C.; Kapturczak, M.; Muir, A.; Powers, M.; Scott-Jorgensen, M.; Campbell-Thompson, M.; Crawford, J.M.; Ellis, T.M.; Flotte, T.R.; **Atkinson, M.A.**: Adeno-Associated Virus Vector Mediated Interleukin-10 Gene Delivery Prevents Type 1 Diabetes in NOD Mice. Proceedings of The National Academy of Sciences, USA 98: 13913-13918, 2001.
93. *Peakman, M.; Tree, T.I.; Endl, J.; Endert, P.V.; **Atkinson, M.A.**; Roep, B.O.: Characterization of Preparations of Glutamic Acid Decarboxylase-65, Proinsulin and the Islet Tyrosine Phosphatase IA-2 for Use in Detection of Autoreactive T Cells in Type 1 Diabetes Mellitus. Report of Phase II of the Second International Immunology of Diabetes Society Workshop for Standardization of T cell Assays in Type 1 Diabetes Mellitus. Diabetes 50: 1749-54, 2001.
94. *Bonifacio, E.; **Atkinson, M.A.**; Eisenbarth, G.S.; Kay, T.W.H.; Serreze, D.V.; Chan, E.L.; Singh, B.L.: International Workshop on Lessons from Animal Models for Human Type 1 Diabetes: Identification of Insulin but not Glutamic Acid Decarboxylase or IA-2 as Specific Autoantigens of Humoral Autoimmunity in Nonobese Diabetic Mice. Diabetes 50: 2451-2458, 2001.
95. *Brod, S.A.; Orlander, P.R.; Lavia, V.R.; Brosnan, P.G.; Hardin, D.S.; Hanninger, E.; **Atkinson, M.A.**, Riley, W.J.: Ingested IFN-Alpha Preserves Residual Beta Cell Function in Type 1 Diabetes. Journal of Interferon and Cytokine Research 21:1021-1031, 2001.
96. *Kapturczak, M.; Zolotukhin, S.; Cross, J.; Powers, M.; Jehle, K.; Inverardi, L.; Pileggi, A.; Flotte, T.R.; Nick, H.; **Atkinson, M.**; Agarwal, A.: Transduction of Human and mouse Pancreatic Islet Cells Using a Bicistronic Recombinant Adeno-Associated Viral Vector. Molecular Therapy 5: 154-160, 2002.
97. Bonifacio, E.; **Atkinson, M.**; Eisenbarth, G.; Serreze, D.; Kay, T.W.H.; Lee-Chan, E.; Singh, B.: International Workshop on Lessons from Animal Models for Human Type 1 Diabetes: Analyzing Target Autoantigens of Humoral Immunity in Non-Obese Diabetic Mice. Annals New York Academy of Sciences

97. Bonifacio, E.; **Atkinson, M.**; Eisenbarth, G.; Serreze, D.; Kay, T.W.H.; Lee-Chan, E.; Singh, B.: International Workshop on Lessons from Animal Models for Human Type 1 Diabetes: Analyzing Target Autoantigens of Humoral Immunity in Non-Obese Diabetic Mice. Annals New York Academy of Sciences 958: 1-2, 2002.
98. *Bowman, M.; **Atkinson, M.**: Heat Shock Protein Therapy Fails to Prevent Diabetes in NOD Mice. Diabetologia 45: 1350-1351, 2002.
99. *Zhang, Y.C.; Molano, R.D.; Pileggi, A.; Powers, M.; Wasserfall, C.; Brusko, T.; Flotte, T.; Ellis, T.M.; Ricordi, C.; **Atkinson, M.A.**; Inverardi, L.: Adeno-Associated Virus Transduction of Islets with Interleukin-4 Results in Impaired Metabolic Function in Syngeneic Marginal Islet Mass Transplantation. Transplantation 74: 1184-1186, 2002.
100. **Atkinson, M.A.**; Wilson, S.B.: Fatal Attraction: Chemokines and Type 1 Diabetes. Journal of Clinical Investigation 110: 1611-1613, 2002.
101. *Zhang, Y.C.; Pileggi, A.; Agarwal, A.; Molano, R.D.; Powers, M.; Brusko, T.; Wasserfall, C.; Goudy, K.; Zahr, E.; Poggioli, R.; Scott-Jorgensen, M.; Campbell-Thompson, M.; Crawford, J.M.; Nick, H.; Flotte, T.R.; Ellis, T.M.; Ricordi, C.; Inverardi, L.; **Atkinson, M.A.**: Adeno-Associated Virus Mediated Interleukin-10 Gene Therapy Inhibits Autoimmune Diabetes Recurrence in Syngeneic Islet Transplanted NOD Mice. Diabetes 52: 708-716, 2003.
102. *Chen, S.; Agarwal, A.; Glushakova, O.Y.; Jorgensen, M.S.; Salgar, S.; Croker, B.P.; Madsen, K.M.; **Atkinson, M.A.**; Hauswirth, W.H.; Berns, K.I.; Tisher, C.C.: Gene Delivery in Renal Tubular Epithelial Cells Using Recombinant Adeno-Associated Viral Vectors. Journal American Society of Nephrology 14: 947-958, 2003.
103. *Litherland, S.A.; She, J.X.; Schatz, D.; Fuller, K.; Hutson, A.D.; Li, Y.; Grebe, K.M.; Whittaker, D.S.; Bahjat, K.; Hoplins, D.; Fang, Q.; Wasserfall, C.; Cook, R.; Dennis, M.A.; Crockett, S.; Sleasman, J.; Kocher, J.; Muir, A.; Silverstein, J.; **Atkinson, M.**; Clare-Salzler, M.J.: Aberrant Monocyte Prostaglandin Synthase 2 Expression in Type 1 Diabetes Before and After Disease onset. Pediatric Diabetes 4: 10-18, 2003.
104. *Qin, H.Y.; Mahon, J.L.; **Atkinson, M.A.**; Chaturvedi, P.; Chan, E.L.; Singh, B.: Type 1 Diabetes Alters Anti-hsp90 Autoantibody Isotype. Journal of Autoimmunity 20: 237-45, 2003.
105. *Loiler, S.A.; Conlon, T.J.; Song, S.; Warrington, K.H.; Agarwal, A.; Kapturczak, M.; Li, C.; Ricordi, C.; **Atkinson, M.A.**; Muzyczka, N.; Flotte, T.R.: Targeting Recombinant Adeno-Associated Virus Vectors to Enhance Gene Transfer to Pancreatic Islets and Liver. Gene Therapy 10: 1551-58, 2003.
106. Burkhardt, B.R.; Loiler, S.A.; Anderson, J.A.; Kilberg, M.; Crawford, J.M.; Flotte, T.R.; Goudy, K.S.; Ellis, T.M.; **Atkinson, M.A.**: Glucose-Responsive Expression of the Human Insulin Promoter in HEP G2 Human Hepatoma Cells. New York Academy of Sciences 1005: 237-241, 2003.
107. Yu, L.; Eisenbarth, G.; Bonifacio, E.; Thomas, J.; **Atkinson, M.**; Wasserfall, C.: The Second Murine Autoantibody Workshop: Remarkable Inter-laboratory Concordance for Radiobinding Assays to Identify Insulin Autoantibodies in Non-Obese Diabetic Mice. New York Academy of Sciences 1005: 1-12, 2003.
108. *Goudy, K.; Wasserfall, C.; Burkhardt, B.; Brusko, T.; Sobel, E.; Song, S.; Ellis, T.; Flotte, T.; **Atkinson, M.**: Systemic Over Expression of IL-10 Induces CD4+CD25+ Cell Populations In Vivo and Ameliorates Type 1 Diabetes in Nonobese Diabetic Mice in a Dose-Dependent Fashion. Journal of Immunology 171: 2270-2278, 2003.
109. **Atkinson, M.**; Gale, E.: Infant Diets and Type 1 Diabetes: Too Early, Too Late, or Just Too Complicated? Journal of the American Medical Association 290: 1771-72, 2003.
110. *Schatz, D.A.; Gale, E.; **Atkinson, M.A.**: Why Can't We Prevent Type 1 Diabetes? Maybe it's Time to Try a Different Combination. Diabetes Care 26: 3326-3328, 2003.
111. *Song, S.; Goudy, K.; Campbell-Thompson, M.; Wasserfall, C.; Scott-Jorgensen, M.; Wang, J.; Tang, Q.; Ellis, T.; Crawford, J.M.; **Atkinson, M.A.**; Flotte, T.R.: Recombinant Adeno-Associated Virus-Mediated

112. *Zhang, Y.C.; Powers, M.; Wasserfall, C.; Brusko, T.; Sihong Song, S.; Flotte, T.R.; Snyder, R.; Potter, M.; Scott-Jorgensen, M.; Campbell-Thompson, M.; Crawford, J.M.; Ellis, T.M.; **Atkinson, M.A.**: Immunity to Adeno-Associated Virus Serotype 2 Delivered Transgenes Imparted by Genetic Predisposition to Autoimmunity. Gene Therapy 11: 233-240, 2004.
113. *Lu, Y.; Dang, H.; Middleton, B.; Zhang, Z.; Washburn, L.; Campbell-Thompson, M.; **Atkinson, M.A.**; Gambhir, S.S.; Tian, J.; Kaufman, D.L.: Bioluminescent Monitoring of Islet Graft Survival After Transplantation. Molecular Therapy 9: 428-435, 2004.
114. Gale, E.; **Atkinson, M.**: A Piece of Nucleic Acid Surrounded By Controversy: Coxsackieviruses and the Causes of Type 1 Diabetes. Diabetic Medicine 21: 503-506, 2004.
115. **Atkinson, M.A.**: Timing of Initial Cerebral Exposure in Infancy and Risk of Islet Autoimmunity. Journal of Pediatrics 144: 684-685, 2004.
116. *Tang, DQ. ; Cao, L.; Burkhardt, B.R.; Xia, C.; **Atkinson, M.**; Yang, L.: In Vivo and In Vitro Characterization of Insulin-Producing Cells Obtained from Murine Bone Marrow. Diabetes 53: 1721-1732, 2004.
117. *Schatz, D.; Cuthbertson, D.; **Atkinson, M.**; Salzler, M.C.; Winter, W.; Muir, A.; Silverstein, J.; Cook, R.; Maclaren, N.K.; She, J.X.; Greenbaum, C.; Krisner, J: Preservation of C-Peptide Secretion in Subjects at High-Risk of Developing Type 1 Diabetes Mellitus- A New Surrogate Measure of Non-Progression? Pediatric Diabetes 5: 72-29, 2004.
118. Zhang, Y.C.; **Atkinson, M.A.**: Gene Therapy for Type 1 Diabetes: Metabolism, Immunity, Islet Cell Preservation and Regeneration. Current Opinions in Endocrinology and Diabetes 11: 91-97, 2004.
119. Gou D; Li M; Zhang Y; Yang p; Eckenrode S; Hopkins D; Zheng W; Purohit S; Podolsky RH. ; Muir A; Wang J; Dong Z; Brusko T; **Atkinson M**; Pozzilli P; Zeidler A; Raffel LJ; Jacob CO; Park Y; Serrano-Rios M; Larrad MT; Zhang Z; Garchon HJ; Bach JF; Rotter JI; She JX; Wang CY.: A Functional Variant of SUMO4, a New I Kappa B Alpha Modifier, is Associated with Type 1 Diabetes. Nature Genetics 36: 937-841, 2004.
120. Hannon, W.H., **Atkinson, M.A.**; Ball, D.J.; Lorenz R.G.; Matsson, P.N.J.; Moore, D.M.: Assessing the quality of immunoassay systems: Radioimmunoassays and enzyme, fluorescence, and luminescence immunoassays; approved guideline. NCCLS document I/LA23-I: 23-27, 2004.
121. *Kapturczak, M.H.; Wasserfall, C.; Brusko, T.; Campbell-Thompson, M.; Ellis, T.M.; **Atkinson, M.A.**; Agarwal, A.: Heme Oxygenase-1 Modulates Early Inflammatory Responses: Evidence from the HO-1 Deficient Mouse. American Journal of Pathology 165: 1045-1053, 2004.
122. *Morales, A.; Wasserfall, C.; Schatz, D.; Ellis, T.; Silverstein, J.; **Atkinson, M.**: Adiponectin and Leptin Concentrations May Aid in Discriminating Disease Forms in Children and Adolescents with Type 1 and Type 2 Diabetes. Diabetes Care 27: 2010-2014, 2004.
123. *You, S.; Chen, C.; Lee, H.L.; Brusko, T.; **Atkinson, M.**; Liu-C.P.; Presence of Diabetes-Inhibiting, Glutamic Acid Decarboxylase-Specific IL-10-Dependent Regulatory T Cells in Naïve Non-Obese Diabetic Mice. Journal of Immunology 173: 6777-6785, 2004.
124. *Roep, B.O.; **Atkinson, M.A.**: Animal Models Have Little to Teach Us About Type 1 Diabetes. Diabetologia 47: 1650-1656, 2004.
125. *Haller, M.J.; Brusko, T.; **Atkinson, M.**; Schatz, D.; Rosenbloom, A.; Silverstein, J.: Radial Artery Tonometry Demonstrates Arterial Stiffness in Children with Type 1 Diabetes. Diabetes Care 27: 2911-2917, 2004.
126. *Roep, B.O.; **Atkinson, M.**; Von-Herrath.: Satisfaction (Not) Guaranteed: Re-evaluating the Use of Animal Models of Type-1 Diabetes. Nature Reviews Immunology 4: 989-997, 2004.
127. Pearce, D.A.; **Atkinson, M.A.**, Tagle, D.: Glutamic Acid Decarboxylase Autoimmunity in Batten Disease

and Other Disorders. Neurology 14: 2001-2005, 2004.

128. *Greenbaum, C.J.; Eiesenbarh, G.; **Atkinson, M.**; Yu, L.; Babu, S.; Schatz, D.; Zeidler, A.; Orban, T.; Wasserfall, C.; Cuthbertson, D.; Krischer, J.; the DPT-1 study group: High Frequency of Abnormal Glucose Tolerance in DQA1*02/DQB1*0602 Relatives Identified as Part of the Diabetes Prevention Trial--Type 1 Diabetes. Diabetologia 48: 68-74, 2005.
129. *Stalvey, M.S.; **Atkinson, M.A.**: Lessons from attempts to prevent type 1 diabetes—potential implications for type 2 diabetes. The Pancreatic Cell at the Forefront of Type 2 Diabetes 27(4): 338-44, 2005.
130. Gale, E.A.M.; **Atkinson, M.**: Viruses and Diabetes-Reply. Diabetic Medicine 22(7): 958, 2005.
131. *Serreze D.V.; Wasserfall C.; Ottendorfer E.W.; Stalvey M.; Pierce M.A.; Gaunnt C.; O'Donnell B.; Flanagan J.B.; Campbell-Thompson M.; Ellis T.M.; **Atkinson M.A.**: Diabetes Acceleration or Prevention by Coxsackievirus B4 Infection: Critical Requirements for Both Interleukin-4 and Gamma Interferon. Journal of Virology 79: 1045-1052, 2005.
132. **Atkinson, M.A.**; Rhodes, C.J.; Meier, J.J.; Bhushan A.; Butler, A.E.; Rizza, R.A.; Butler, P.C.: Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Commentary. Diabetologia 48(11): 2221-8, 2005.
133. *Liang, Y.; Huang, T.; Zhang, C.; Todorov, I.; **Atkinson, M.**; Kandeel, F.; Forman, S.; Zeng, D.: Donor CD8⁺ T Cells Facilitate Induction of Chimerism and Tolerance Without GVHD in Autoimmune NOD Mice Conditioned with Anti-CD3 mAb. Blood 105: 2180-2188, 2005.
134. *Cresawn, K.O.; Wasserfall, C.; **Atkinson, M.A.**; Mah, C.; Zolotukhin, I.; Porvasnik, S.; Lewis, M.; Fraites, T.J.; Byrne, B.J.: Impact of Humoral Immune Response on Distribution and Efficacy of Recombinant Adeno-Associated Virus-Derived Acid Alpha-Glucosidase in a Model of Glycogen Storage Disease Type II. Hum Gene Therapy 16: 68-80, 2005.
135. *Chen, S.; Kapturczak, M.; Loiler, S.A.; Zolotukhin, S.; Glushakova, O.Y.; Li, C.; Madsen, K. M.; Samulski, R. J.; Hauswirth, W.W.; Campbell-Thompson, M.; Berns, K. I.; Flotte, T. R.; **Atkinson, M. A.**; Tisher, C. C.; Agarwal, A.: Efficient Transduction of Vascular Endothelial Cells with Recombinant Adeno-Associated Virus Serotype 1 and 5 Vectors. Human Gene Therapy 16: 235-247, 2005.
136. *Ramirez-Montealegre, D.; Chattopadhyay, S.; Curran, T.M., Wasserfall, C.; Pritchard, L.; Schatz, D.; Petitto, J.; Hopkins, D.; She, J.X.; Rothberg, P.G.; **Atkinson, M.**; Pearce, D.A.: Autoimmunity to Glutamic Acid Decarboxylase in the Neurodegenerative Disorder Batten Disease. Neurology 64: 743-5, 2005.
137. ***Atkinson, M.A.**: ADA Outstanding Scientific Achievement Lecture 2004: Thirty Years of Investigating the Autoimmune Basis for Type 1 Diabetes: Why Can't We Prevent this Disease? Diabetes 54: 1253-63, 2005.
138. *Neu, J.; Reverte, C.M.; Mackey, L.K.; Tuhace, L.M.; Hatch, M.; Li N.; Schatz, D.A.; Neu, J., **Atkinson, M.** Changes in Intestinal Morphology and Permeability in the Biobreeding Rat Before the Onset of Type 1 Diabetes. Journal of Pediatric Gastroenterology and Nutrition 40: 589-95, 2005.
139. *Brusko, T.; Wasserfall, C.; Ellis, T.; Clare-Salzler, M.; Schatz, D.; **Atkinson, M.A.**; Functional Defects and the Influence of Age on the Frequency of CD4⁺CD25⁺T-Cells in Type 1 Diabetes. Diabetes 54: 1404-14, 2005.
140. *Caicedo, R.A.; Neu, J.; Schatz, D.; **Atkinson, M.**; Li, N.: Neonatal Nutritional Interventions in the Prevention of Type 1 Diabetes. Neonatal Reviews 6: 220-6, 2005.
141. *Brusko, T.; Agarwal, A.; Wasserfall, C.; **Atkinson, M.A.**; An Integral Role for Heme-Oxygenase-1 and Carbon Monoxide in Maintaining Peripheral Tolerance by CD4⁺CD25⁺ Regulatory T Cells. Journal of Immunology 174: 5181-86, 2005.
142. *Chen, S.; Kapturczak, M.H.; Wasserfall, C.; Glushakova, O.Y.I Campbell-Thompson, M.; Deshane, J.S.; Joseph, R.; Hauswirth, W.W.; Madsen, K.M.; Croker, B.P.; Berns, K.I.; **Atkinson, M.A.**; Flotte, T.R.; Tisher, C.C.; Agarwal, A.: Interleukin-10 Attenuates Neointimal Proliferation and Inflammation in Aortic

- Allografts Via a Heme Oxygenase Dependent Pathway. Proceedings of The National Academy of Sciences, USA 102: 7251-7256, 2005.
143. *Li, M.; Guo, D.; Eizirik, D.L.; **Atkinson, M.**; She, J-X.; Wang, C-Y.: SUMO Wrestling with Type 1 Diabetes. Journal of Molecular Therapy 83: 504-13, 2005.
 144. *Beck, R.D.; Wasserfall C.; Ha G.K.; Cushman J.D.; Huang Z.; **Atkinson M.**; Petitto J.M.: Changes in Hippocampal IL-15, Related Cytokines and Neurogenesis in IL-2 Deficient Mice. Brain Research 1041: 223-30, 2005.
 145. **Atkinson, M.A.**; Gale, E.A.M.: 9th Annual EASD/JDRF Oxford Workshop Mechanisms and Prevention of Type 1 Diabetes. Diabetologia 2005.
 146. *Litherland, S.A.; Grebe, K.M.; Belkin, N.S.; Paek, E.; Elf, J.; **Atkinson, M.A.**; Morel, M; Clare-Salzler, M.J.; McDuffie, M.: Nonobese Diabetic mouse Congenic Analysis Reveals Chromosome 11 Locus Contributing to Diabetes Susceptibility, Macrophage STAT5 Dysfunction & Granulocyte-Macrophage Colony-Stimulating Factor Overproduction. Journal of Immunology 175: 4561-65, 2005.
 147. **Atkinson, M.A.**; Rhodes, C.J: Pancreatic Regeneration in Type 1 Diabetes: Dreams on a Deserted Islet? Diabetologia 48: 2220-2222, 2005.
 148. *Lee, C.H.; Reifsnyder, P.C; Naggert, J.K.; Wasserfall, C.; **Atkinson, M.A.**; Chen, J.; Leiter, E.H.: Novel Leptin Receptor Mutation in NOD/LTJ Mice Suppresses Type 1 Diabetes Progression: 1. Pathophysiological Analysis. Diabetes 54: 2525-32, 2005.
 149. Kapturczak, M.H.; Burkhardt, B.; **Atkinson, M.A.**: Gene Therapy for Prevention and Treatment of Type 1 Diabetes. Laboratory Techniques in Biochemistry and Molecular Biology 31: 125-59, 2005.
 150. Haller, M.J.; **Atkinson, M.A.**; Schatz, D.: Type 1 Diabetes Mellitus: Etiology, Presentation, and Management. Pediatric Clinics North America 52: 1553-1578, 2005.
 151. *Shoda, L.K.M.; Young, D.L.; Ramanujan, S.; Whiting, C.C.; **Atkinson, M.A.**; Bluestone, J.A.; Eisenbarth, G.S.; Mathis, D.; Rossini, A.A.; Campbell, S.E.; Kahn, R.; Kreuwel, H.T.: A Comprehensive Review of Interventions in the NOD Mouse and Implications for Translation. Immunity 23: 115-26, 2005.
 152. Schatz, D.A.; **Atkinson, M.A.**: Islet Cell Autoantibodies: A Case of a Premature Obituary. Pediatric Diabetes 6: 181-183, 2005.
 153. Zhang, Y.C.; Pileggi, A.; Molano, R.D.; Wasserfall, C.; Campbell-Thompson, M.; Ricordi, C.; **Atkinson, M.A.**; Inverardi, L.: Systemic Overexpression of Interleukin-10 Fails to Protect Allogeneic Islet Transplants in Nonobese Diabetic Mice. Transplantation 80: 530-533, 2005.
 154. *Loiler, S.A.; Tang, Q.; Clarke, T.; Campbell-Thompson, M.L.; Chiodo, V.; Hauswirth, W.; Cruz, P.; Perret-Gentil, M.; **Atkinson, M.A.**; Ramiya, V.K.; Flotte, T.R.: Localized Gene Expression Following Administration of Adeno-Associated Viral Vectors Via Pancreatic Ducts. Molecular Therapy 12: 519-27, 2005.
 155. *Fudge, E.; Carol, J.; She, J.X.; Dosch, M.; **Atkinson, M.A.**; Hoffman, W.; Muir, A.: Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Two Children with Type 1 Diabetes Mellitus. Pediatric Diabetes 6: 244-248, 2005.
 156. *Mu, W.; Ouyang, X.; Agarwal, A.; Long, D.A.; Cruz, P.E.; Roncali, C.A.; Glushakova, O.Y.; Chiodo, V.A.; **Atkinson, M.A.**; Hauswirth, W.W.; Flotte, T.R.; Rodriguez-Iturbe, B.; Johnson, R.J.: Interleukin-10 Suppresses Chemokines, Inflammation and Fibrosis in a Model of Chronic Renal Disease. Journal of the American Society of Nephrology 16: 3651-3660, 2005.
 157. Burkhardt, B.R.; Parker, M.J.; Zhang, YC.; Song, S.; Wasserfall, CH.; **Atkinson, M.A.**: Glucose Transporter-2 (GLUT2) Promoter Mediated Transgenic Insulin Production Reduces Hyperglycemia in Diabetic Mice. FEBS Letters 579: 5759-5764. 2005.
 158. *Burkhardt, B.R.; Lyle, R.; Qian, K.; Arnold, A.; Cheng, H.; **Atkinson, M.A.**; Zhnag, C.: Efficient Delivery

- of siRNA into Cytokine-Stimulated Insulinoma Cells Silences Fas Expression and Inhibits Fas-Mediated Apoptosis. FEBS Letters 580: 553-560, 2006.
159. Lee, C.H.; Chen, Y.G.; Chen, J.; Reifsnnyder, P.C.; Serreze, D.V.; Clare-Salzler, M.; Rodriguez, M.; Wasserfall, C.; **Atkinson, M.A.**; Leiter, E.H.: Novel Leptin Receptor Mutation in NOD/LtJ Mice Suppresses Type 1 Diabetes Progression: II. Immunologic Analysis. Diabetes 55: 171-178, 2006.
 160. Wasserfall, C.H.; **Atkinson, M.A.**: Autoantibody Markers for the Diagnosis and Prediction of Type 1 Diabetes. Autoimmun Rev 5: 424-428, 2006.
 161. *Lu, Y.; Dang, H.; Middleton, B.; Zhang, Z.; Washburn, L.; Stout, D.B.; Campbell-Thompson, M.; **Atkinson, M.A.**; Phelps, M.; Gambhir, S.S.; Tian, J.; Kaufman, D.L.: Noninvasive Imaging of Islet Grafts Using Positron-Emission Tomography. Proc Natl Acad Sci U S A 103: 11294-11299, 2006
 162. *Muller, C.; Braag, S.A.; Herlihy, J.D.; Wasserfall, C.H.; Chesrown, S.E.; Nick, H.S.; **Atkinson, M.A.**; Flotte, T.R.: Enhanced IgE Allergic Response to Aspergillus fumigatus in CFTR-/- Mice. Laboratory Investigation 86: 130-140, 2006.
 163. *Nakagawa, T.; Sato, W.; Sautin, Y.Y.; Glushakova, O.; Croker, B.; **Atkinson, M.A.**; Tisher, C.C.; Johnson, R.J.: Uncoupling of Vascular Endothelial Growth Factor with Nitric Oxide as a Mechanism for Diabetic Vasculopathy. Journal American Society of Nephrology 17: 736-45, 2006.
 164. *Lu, Y.; Tang, M.; Wasserfall, C.; Kou, Z.; Campbell-Thompson, M.; Gardemann, T.; Crawford, J.; **Atkinson, M.**; Song, S.: Alpha1-Antitrypsin Gene Therapy Modulates Cellular Immunity and Efficiently Prevents Type 1 Diabetes in Nonobese Diabetic Mice. Human Gene Therapy 17: 625-634, 2006.
 165. *Tang, D.Q.; Cao, L.Z.; Chou, W.; Shun, L.; Farag, C.; **Atkinson, M.A.**; Li, S.W.; Chang, L.J.; Yang, L.J.: Role of Pax4 in Pdx1-VP16-Mediated Liver-to-Endocrine Pancreas Transdifferentiation. Laboratory Investigation 86: 829-841, 2006.
 166. *Burkhardt, B.R.; Greene, S.R.; White, P.; Wong, R.K.; Brestelli, J.E.; Yang, J.; Robert, C.E.; Brusko, T.M.; Wasserfall, C.H.; Wu, J.; **Atkinson, M.A.**; Gao Z, Kaestner KH, Wolf BA. PANDER-Induced Cell-Death Genetic Networks in Islets Reveal Central Role for Caspase-3 and Cyclin-Dependent Kinase Inhibitor 1A (p21). Gene 369: 134-41, 2006.
 167. *Stalvey, M.S.; Muller, C.; Schatz, D.A.; Wasserfall, C.H.; Campbell-Thompson, M.L.; Theriaque, D.W.; Flotte, T.R.; **Atkinson, M.A.**: Cystic Fibrosis Transmembrane Conductance Regulator Deficiency Exacerbates Islet Cell Dysfunction After Beta-Cell Injury. Diabetes 55: 1939-1945, 2006.
 168. *Chen, S.; Wasserfall, C.; Kapturczak, M.H.; **Atkinson, M.**; Agarwal, A.: Freeze-Thaw Increases Adeno-Associated Virus Transduction of Cells. American J Physiology Cellular Physiology 291: 386-392, 2006.
 169. *Schwartz, R.F.; Neu, J.; Schatz, D.; **Atkinson, M.A.**; Wasserfall, C.: Antibiotic Treatment Partially Protects Against Type 1 Diabetes in the Bio-Breeding Diabetes-Prone Rat. Is the Gut Flora Involved in the Development of Type-1 Diabetes? Diabetologia 49: 2105-2108, 2006.
 170. *Scumpia, P.O.; Delano, M.J.; Kelly, K.M.; O'Malley, K.A.; Efron, P.A.; McAuliffe, P.F.; Brusko, T.; Ungaro, R.; Barker, T.; Wynn, J.L.; **Atkinson, M.A.**; Reeves, W.H.; Salzler, M.J.; Moldawer, L.L.: Increased Natural CD4+CD25+ Regulatory T cells and Their Suppressor Activity Do Not Contribute to Mortality in Murine Polymicrobial Sepsis. Journal of Immunology 177: 7943-7949, 2006.
 171. *Lu, Y.; Dang, H.; Middleton, B.; Campbell-Thompson, M.; **Atkinson, M.A.**; Gambhir, S.S.; Tian, J.; Kaufman, D.L.: Long-term Monitoring of Transplanted Islets Using Positron Emission Tomography. Molecular Therapy 14: 851-856, 2006.
 172. *Blenman, K.R.; Duan, B.; Xu, Z.; Wan, S.; **Atkinson, M.A.**; Flotte, T.R.; Croker, B.P.; Morel L.: KR, Duan B, Xu Z, Wan S, Atkinson MA, Flotte TR, Croker BP, Morel L.: IL-10 Regulation of Lupus in the NZM2410 Murine Model. Laboratory Investigation 86: 1136-1148, 2006.
 173. *Tang, D.Q.; Cao, L.Z.; Chou, W.; Shun, L.; Farag, C.; **Atkinson, M.A.**; Li, S.W.; Chang, L.J.; Yang, L.J.: Role of Pax4 in Pdx1-VP16-mediated liver-to-endocrine pancreas transdifferentiation. Laboratory

Investigation 86: 829-841, 2006.

174. *Chen, S.; Wasserfall, C.; Kapturczak, M.H.; **Atkinson, M.A.**; Agarwal, A.: Freeze-Thaw Increases Adeno-Associated Virus Transduction of Cells. American Journal Physiology & Cell Physiology 291: 386-392, 2006.
175. *Nakagawa, T.; Sato, W.; Sautin, Y.Y.; Glushakova, O.; Croker, B.; **Atkinson, M.A.**; Tisher, C.C.; Johnson, R.J.: Uncoupling of Vascular Endothelial Growth Factor with Nitric Oxide as a Mechanism for Diabetic Vasculopathy. Journal of American Society of Nephrology 17: 736-745, 2006.
176. *Muller, C.; Braag, S.A.; Herlihy, J.D.; Wasserfall, C.H.; Chesrown, S.E.; Nick, H.S., **Atkinson, M.A.**; Flotte, T.R.: Enhanced IgE Allergic Response to Aspergillus Fumigatus in CFTR-/- Mice. Laboratory Investigation 86: 130-140, 2006.
177. *Nakagawa, T.; Sato, W.; Glushakova, O.; Heinig, M.; Clarke, T.; Campbell-Thompson, M.; Yuzawa, Y.; **Atkinson, M.A.**; Johnson, R.J.; Croker, B.: Diabetic Endothelial Nitric Oxide Synthase Knockout Mice Develop Advanced Diabetic Nephropathy. Journal of American Society of Nephrology 18: 539-550, 2007.
178. Schwartz, R.F.; Neu, J.; Schatz, D.; **Atkinson, M.A.**; Wasserfall, C.: Comment on: Brugman S et al. (2006) Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes? Diabetologia 50(1): 220-221, 2007.
179. *Zhang, C.; Todorov, I.; Lin, C.L.; **Atkinson, M.**; Kandeel, F.; Forman, S.; Zeng, D.F.: Elimination of Insulitis and Augmentation of Islet β Cell Regeneration Via Induction of Chimerism in Overtly Diabetic NOD Mice. Proceedings National Academy of Sciences USA. 104: 2337-2342, 2007.
180. *Brusko, T.; Wasserfall, C.; McGrail, K.; Schatz, R.; Viener, H.L.; Schatz, D.; Haller, M.; Rockell, J.; Gottlieb, P.; Clare-Salzler, M.; **Atkinson, M.**: No Alterations in the Frequency of FOXP3+ Regulatory T Cells in Type 1 Diabetes. Diabetes 56: 604-612, 2007.
181. *Zhang, B.; Lu, Y.; Campbell-Thompson, M.; Spencer, T.; Wasserfall, C.; **Atkinson, M.**; Song, S.: Alpha 1-Antitrypsin Protects Beta-Cells from Apoptosis. Diabetes 56: 1316-1323, 2007.
182. *Pileggi, A.; Molano, R.D.; Song, S.; San Jose, S.; Villate, S.; Wasserfall, C.; Ricordi, C.; **Atkinson, M.A.**; Inverardi, L.: Alpha-1 antitrypsin treatment of spontaneously diabetic NOD mice receiving islet allografts. Xenotransplantation 14(5): 497-498, 2007.
183. Zheng, Y.; Kreuwel, H.T.; Young, D.L.; Shoda, L.K.; Ramanujan, S.; Gadkar, K.G.; **Atkinson, M.A.**; Whiting, C.C.: The Virtual NOD Mouse: Applying Predictive Biosimulation to Research in Type 1 Diabetes. Annals of New York Academy of Science 1103: 45-62, 2007.
184. *Chen, B.; Kapturczak, M.H.; Joseph, R.; George, J.F.; Campbell-Thompson, M.; Wasserfall, C.H.; **Atkinson, M.A.**; Tisher, C.C.; Flotte, T.R.; Agarwal, A.; Chen, S.: Adeno-Associated Viral Vector-Mediated Interleukin-10 Prolongs Allograft Survival in a Rat Kidney Transplantation Model. American Journal of Transplantation 7: 1112-1120, 2007.
185. *Delano, M.J.; Scumpia, P.O.; Weinstein, J.S.; Coco, D.; Nagaraj, S.; Kelly-Scumpia, K.M.; O'Malley, K.A.; Wynn, J.L.; Antonenko, S.; Al-Quran, S.Z.; Swan, R.; Chung, C.S.; **Atkinson, M.A.**; Ramphal, R.; Gabrilovich, D.I.; Reeves, W.H.; Ayala, A.; Phillips, J.; Laface, D.; Heyworth, P.G.; Clare-Salzler, M.; Moldawer, L.I.: MyD88-Dependent Expansion of an Immature GR-1(+)CD11b(+) Population Induces T Cell Suppression and Th2 Polarization in Sepsis. The Journal of Experimental Medicine 204: 1463-1474, 2007.
186. *Guleria, L.; Gubbels Bupp, M.; Dada, S.; Fife, B.; Tang, Q.; Ansari, M.J.; Trikudanathan, S.; Vadivel, N.; Fiorina, P.; Yagita, H.; Azuma, M.; **Atkinson, M.**; Bluestone, J.A.; Sayegh, M.H.: Mechanisms of PDL1-Mediated Regulation of Autoimmune Diabetes. Clinical Immunology 125: 16-25, 2007.
187. *Montoya, C.J.; Pollard, D.; Martinson, J.; Kumari, K.; Wasserfall, C.; Mulder, C.B.; Rugeles, M.T.; **Atkinson, M.A.**; Landay, A.L.; Wilson, S.B.: Characterization of Human Invariant Natural Killer T Subsets in Health and Disease Using a Novel Invariant Natural Killer T Cell-Clonotypic Monoclonal Antibody, CB11.

- Immunology 122: 1-14, 2007.
188. *Lowe, CE.; Cooper, JD.; Brusko, T.; Walker, NM.; Smyth, DJ.; Bailey, R.; Bourget, K.; Plagnol, V.; Field, S.; **Atkinson, M.**; Clayton, DG.; Wicker, LS.; Todd, JA.: Large-Scale Genetic Fine Mapping and Genotype-Phenotype Associations Implicate Polymorphism in the IL2RA Region in Type 1 Diabetes. Nature Genetics 39: 1074-1082, 2007.
 189. *Scumpia, PO.; Delano, MJ.; Kelly-Scumpia, KM.; Weinstein, JS.; Wynn, JL.; Winfield, RD.; Xia, C.; Chung, CS.; Ayala, A.; **Atkinson, MA.**; Reeves, WH.; Clare-Saltzer, MJ.; Moldawer, LL.: Treatment with GITR Agonistic Antibody Corrects Adaptive Immune Dysfunction in Sepsis. Blood 110: 3673-3681, 2007.
 190. *Brusko, TM; Hulme, MA; Myhr, CB; Haller, MJ; **Atkinson, MA.**: Assessing the in Vitro Suppressive Capacity of Regulatory T Cells. Immunological Investigations 36: 607-628, 2007.
 191. *Tsai, YY; Oca-Cossio, J; Agering, K; Simpson, NE; **Atkinson, MA**, Wasserfall, CH; Constantinidis, I; Sigmund, W.: Novel Synthesis of Cerium Oxide Nanoparticles for Free Radical Scavenging. Nanomed 3: 325-332, 2007.
 192. *Brusko, T.; **Atkinson, M.**: Treg in Type 1 Diabetes. Cell Biochemistry and Biophysics 48(2-3):165-175, 2007.
 193. *King, M; Pearson, T; Shultz, LD; Leif, J; Bottino, R; Trucco, M; **Atkinson, MA**; Wasserfall, C; Herold, KC; Woodland, RT; Schmidt, MR; Woda, BA; Thompson, MJ; Rossini, AA; Greiner, DL.: A New Hu-PBL Model for the Study of Human Islet Alloreactivity Based on NOD-Scid Mice Bearing a Targeted Mutation in the IL-2 Receptor Gamma Chain Gene. Clinical Immunology 129: 309-314, 2008.
 194. *Caicedo, RA; Li, N; DES Robert, C; Scumpia, PO; Hubsher, CP; Wasserfall, CH; Schatz, DA; **Atkinson, MA**; Neu, J.: Neonatal Formula Feeding Leads to Immunological Alterations in an Animal Model of Type 1 Diabetes. Pediatric Research 63: 303-307, 2008.
 195. *Koya, V; Shun, L; Sun, YP; Purich, DL; **Atkinson, MA**; Li, SW; Yang, LJ.: Reversal of Streptozotocin-Induced Diabetes in Mice by Cellular Transduction with Recombinant Pancreatic Transcription Factor Pdx1-A Novel Protein Transduction Domain Based Therapy. Diabetes 57: 757-769, 2008.
 196. *Simon, G; Parker, M; Ramiya, V; Wasserfall, C; Huang, Y; Bresson, D; Fletcher Schwartz, R; Campbell-Thompson, M; Tenace, L; Brusko, T; Xue, S; Scaria, A; Lukason, M; Eisenbeis, S; Williams, J; Clare-Salzler, M; Schatz, D; Kaplan, B; Von Herrath, M; Womer, K; **Atkinson, MA.**: Murine Anti-Thymocyte Globulin Therapy Alters Disease Progression in NOD Mice by a Time Dependent Induction of Immunoregulation. Diabetes 57: 405-414, 2007.
 197. *Brusko, T; **Atkinson, M.**: Treg in Type 1 Diabetes. Cell Biochemistry and Biophysics 48: 165-175, 2007.
 198. *Scumpia, PO; Delano, MJ; Kelly-Scumpia, KM; Weinstein, JS; Wynn, JL; Winfield, RD; Xia, C; Chung, CS; Ayala, A; **Atkinson, MA**; Reeves, WH; Clare-Salzler, MJ; Moldawer, LL.: Treatment with GITR Agonistic Antibody Corrects Adaptive Immune Dysfunction in Sepsis. Blood 110: 3673-3681, 2007.
 199. *George JF, Braun A, Brusko TM, Joseph R, Bolisetty S, Wasserfall CH, **Atkinson MA**, Agarwal A, Kapturczak MH: Suppression by CD4+CD25+ Regulatory T Cells is Dependent on Expression of Heme Oxygenase-1 in Antigen-Presenting Cells. American Journal of Pathology 173: 154-160, 2008.
 200. *Pileggi A, Molano RD, Song S, Zahr E, SanJose S, Villate S, Wasserfall C, Ricordi C, **Atkinson MA**, Inverardi L: Alpha-1 Antitrypsin Treatment of Spontaneously Diabetic Nonobese Diabetic Mice Receiving Islet Allografts. Transplantation Proceedings 40: 457-8, 2008.
 201. *Nayak, S.; Hoffman, B.; Cooper, M.; **Atkinson, M.A.**; Cao, O.; Herzog, R.W.: A Prophylactic Protocol for the Prevention of Inhibitor Formation in Gene Therapy for Hemophilia B by Shifting the Balance from an Effector to a Regulatory T Cell Response. Blood 112(11): 3531, 2008.
 202. *Molano RD, Pileggi A, Song S, Zahr E, San Jose S, Molina J, Fort A, Wasserfall C, Ricordi C, **Atkinson MA**, Inverardi L: Prolonged Islet Allograft Survival by Alpha-1 Antitrypsin: The Role of Humoral Immunity.

202. *Molano RD, Pileggi A, Song S, Zahr E, San Jose S, Molina J, Fort A, Wasserfall C, Ricordi C, **Atkinson MA**, Inverardi L: Prolonged Islet Allograft Survival by Alpha-1 Antitrypsin: The Role of Humoral Immunity. Transplantation Proceedings 40: 455-456, 2008.
203. *Haller MJ, Viener HL, Wasserfall C, Brusko T, **Atkinson MA**, Schatz DA: Autologous Umbilical Cord Blood Infusion for Type 1 Diabetes. Experimental Hematology 36: 710-715, 2008.
204. *Abdi, R.; Fiorina P, Adra CN, **Atkinson M**, Sayegh MH: Immunomodulation by Mesenchymal Stem Cells: A Potential Therapeutic Strategy for Type 1 Diabetes. Diabetes 57: 1759-1767, 2008.
205. *Sato W, Kosugi T, Zhang L, Roncal CA, Heinig M, Campbell-Thompson M, Yuzawa Y, **Atkinson MA**, Grant MB, Croker BP, Nakagawa T: The Pivotal Role of VEGF on Glomerular Macrophage Infiltration in Advanced Diabetic Nephropathy. Laboratory Investigation 88: 949-961, 2008.
206. *Lu Y, Parker M, Pileggi A, Zhang B, Choi YK, Molano RD, Wasserfall C, Ricordi C, Inverardi L, Brantly M, Schatz D, **Atkinson M**, Song S. Human Alpha 1-Antitrypsin Therapy Induces Fatal Anaphylaxis in Non-Obese Diabetic Mice. Clinical and Experimental Immunology 154: 15-21, 2008.
207. *Stalvey MS, Brusko TM, Mueller C, Wasserfall CH, Schatz DA, **Atkinson MA**, Flotte TR. CFTR Mutations Impart Elevated Immune Reactivity in a Murine Model of Cystic Fibrosis Related Diabetes. Cytokine 44: 154-159, 2008.
208. *Vaarala, O.; **Atkinson, M.A.**; Neu, J.: The "Perfect Storm" for Type 1 Diabetes: The Complex Interplay Between Intestinal Microbiota, Gut Permeability, and Mucosal Immunity. Diabetes 57: 362-368, 2008.
209. Sanjeevi, C.B.; Schatz, D.A.; **Atkinson, M.A.**: The IDS Conducts Standardization of Assays for the Measurement of Autoantibodies and of T Cells in Autoimmune Diabetes. Annals of New York Academy of Science 1150: xiii, 2008.
210. *Xiu, S.; Parker, M.; Wasserfall, C.; McGrail, S.; McGrail, K.; Campbell-Thompson, M.; Schatz, D.A.; **Atkinson, M.A.**; Haller, M.J.: Exendin-4 Therapy in New Onset NOD Mice Increases Regulatory T Cell Frequency and Function. Annals of New York Academy of Science 1150: 152-156, 2008.
211. *Yang, P.; Li M, Guo D, Gong F, Adam BL, **Atkinson MA**, Wang CY.: Comparative Analysis of the Islet Proteome Between NOD/Lt and ALR/Lt Mice. Annals of New York Academy of Science 1150: 68-71, 2008.
212. *Suarez-Pinzon WL, Power RF, Yan Y, Wasserfall C, **Atkinson M**, Rabinovitch A.: Combination Therapy with Glucagon-Like Peptide-1 and Gastrin Restores Normoglycemia in Diabetic NOD Mice. Diabetes 57: 3281-3288, 2008.
213. *Huang, Y.; Parker, M.; Xia, C.Q.; Wasserfall, C.; Chowdhry, T.; Williams, J.; Clare-Salzler, M.; **Atkinson, M.A.**; Wormer, K.L.: Anti-mouse Thymocyte Globulin Administration Alters Dendritic Cell Profile and Function in NOD Mice to Suppress Diabetogenic Responses. American Journal of Transplantation 9: 720, 2009.
214. *Putnam, A.L.; Brusko, T.M.; Lee, M.R.; Liu, W.; Szot, G.L.; Ghosh, T.; **Atkinson, M.A.**; Bluestone, J.A.: Expansion of Human Regulatory T Cells from Patients with Type 1 Diabetes. Diabetes 58: 652-662, 2009.
215. *Pashuck TD, Franz SE, Altman MK, Wasserfall CH, **Atkinson MA**, Wronski TJ, Flotte TR, Stalvey MS. Murine Model for Cystic Fibrosis Bone Disease Demonstrates Osteopenia and Sex-Related Differences in Bone Formation. Pediatric Research 65: 311-316, 2009.
216. *Campbell-Thompson M, Dixon LR, Wasserfall C, Monroe M, McGuigan JM, Schatz D, Crawford JM, **Atkinson MA**: Pancreatic Adenocarcinoma Patients with Localised Chronic Severe Pancreatitis show an Increased Number of Single Beta Cells, Without Alterations in Fractional Insulin Area. Diabetologia 52: 262-270, 2009.
217. Wasserfall, C.; **Atkinson, M.A.**: Taking a Daily Vitamin to Prevent Type 1 Diabetes? Diabetes 58: 24-5,

218. *Valle, A.; Jofra, T.; Stabilini, A.; Chatenoud, L.; **Atkinson, M.**; Roncarolo, M.G.; Bataglia, M.: Rapamycin Blocks and Reverts Tolerance Induced in NOD Mice by Anti-CD3 Treatment. Diabetes 58: 875-881, 2009.
219. *Roesch, L.F.W.; Casella, G.; Simell, O.; Krischer, J.; Wasserfall, C.; Schatz, D.; **Atkinson, M.A.**; Neu, J.; Triplett, E.W.: Influence of Fecal Sample Storage on Bacterial Community Diversity. The Open Microbiology Journal 3: 40-46, 2009.
220. *Huang, Y.; Parker, M.; Xia, C.; Peng, R.; Wasserfall, C.; Clark, T.; Wu, L.; Campbell-Thompson, M.; Salzler, M.C.; **Atkinson, M.A.**; Womer, K.L.: Rabbit Polyclonal Anti-Mouse Thymocyte Globulin Administration Alters Dendritic Cell Profile and Function in NOD Mice. Journal of Immunology 182: 4608-4615, 2009.
221. *Rowe, P.; Campbell-Thompson, M.; Wasserfall, C.; Martino, M.; Albanese-O'Neil, A.; Schatz, D.; **Atkinson M.**: Network for pancreatic organ donors with diabetes (nPOD): donor demographics and early progress report. Hormone Research 72:156-157, 2009.
222. *Kosugi, T.; Heining, M.; Connor, T.; Yuzawa, Y.; Qiuong, L.P.; Hauswirth, W.V.; Grant, M.B.; Croker, B.P.; Campbell-Thompson, M.; Zhang, L.; **Atkinson, M.A.**; Segal, M.S.; Nakagawa, T. Lowering Blood Pressure Blocks Mesangiolysis and Mesangial Nodules, but not Tubulointerstitial Injury, in Diabetic eNOS Knockout Mice. American Journal of Pathology 174: 1221-1229, 2009.
223. *Verma, A.; Han, P.Y.; Nakagawa, T.; Johnson, R.J.; Grant, M.B.; Campbell-Thompson, M.; **Atkinson, M.A.**; Segal, M.S.; Hauswirth, W.W.; Li, Q.: Diabetic eNOS Knockout Mice Develop Accelerated Retinopathy. Investigative Ophthalmology and Visual Science 50(13): 5908, 2009.
224. *Roesch, L.F.; Lorca, G.L.; Casella, G.; Giongo, A.; Naranjo, A.; Pionzio, A.M.; Li, N.; Mai, V.; Wasserfall, C.H.; Schatz, D.; **Atkinson, M.A.**; Neu, J.; Triplett, E.W.: Culture Independent Identification of Gut Bacteria Correlated with the Onset of Diabetes in a Rat Model. International Society of Microbial Ecology Journal 3: 536-548, 2009.
225. ***Atkinson, M.A.**, Gianani, R.: The Pancreas in Human Type 1 Diabetes – Providing New Answers to Age Old Questions. Current Opinions in Diabetes, Endocrinology and Obesity. 16: 279-285, 2009.
226. *Fiorina, P.; Jurewicz, M.; Augello, A.; Vergani, A.; Dada, S.; La Rosa, S.; Selig, M.; Godwin, J.; Law, K.; Placidi, C.; Smith, RN; Capella, C.; Rodig, S.; Adra, CN; **Atkinson, M.**; Sayegh, MH; Abdi, R.: Immunomodulatory Function of Bone Marrow-Derived Mesenchymal Stem Cells in Experimental Autoimmune Type 1 Diabetes. Journal of Immunology. 183: 993-1004, 2009.
227. *Araya, C.; Diaz, L.; Wasserfall, C.; **Atkinson, M.**; Mu, W.; Johnson, R.; Garin, E.: T Regulatory Cell Function in Idiopathic Minimal Lesion Nephrotic Syndrome. Pediatric Nephrology 24: 1691-1698, 2009.
228. *Nayak, S. Cao, O.; Hoffman, B.E.; Cooper, M.; **Atkinson, M.A.**; Herzog, R.W.; Prophylactic Immune Tolerance Induced by Changing the Ratio of Antigen-Specific Effector to Regulatory T Cells. Journal of Thrombosis and Haemostasis 7: 1523-1532, 2009.
229. *Parker, M.J.; Xue, S.; Alexander, J.J.; Wasserfall, C.H.; Campbell-Thompson, M.L.; Battaglia, M.; Gregori, S.; Mathews, C.E.; Song, S.; Troutt, M.; Eisenbeis, S.; Williams, J.; Schatz, D.A.; Haller, M.J.; **Atkinson, M.A.**: Immune Depletion with Cellular Mobilization Imparts Immunoregulation and Reverses Autoimmune Diabetes in Nonobese Diabetic Mice. Diabetes 58: 2277-2284, 2009.
230. *Haller, M.J.; Wasserfall, C.H.; McGrail, K.M.; Cintron, M.; Brusko, T.M.; Wingard, J.R.; Kelly, S.S.; Shuster, J.J.; **Atkinson, M.A.**; Schatz, D.A.: Autologous Umbilical Cord Blood Transfusion in Very Young Children with Type 1 Diabetes. Diabetes Care 32: 2041-2046, 2009.
231. *Yip, L.; Su, L.; Sheng, D.; Chang, P.; **Atkinson, M.**; Czesak, M.; Albert, P.R.; Collier, A.R.; Turley, S.J.; Fathman, C.G.; Creusot, R.J.: Deaf1 Isoforms Control the Expression of Genes Endocing Peripheral Tissue Antigens in the Pancreatic Lymph Nodes During Type 1 Diabetes. Nature Immunology 10: 1026-33, 2009.

232. *Haller, M.J.; **Atkinson, M.A.**; Schatz, D.A.: The Road Not Taken: A Path to Curing Type 1 Diabetes? Eur J. Immunology 39: 2054-8, 2009.
233. *Bierschenk, L.; Alexander, J.; Wasserfall, C.; Haller, M.; Schatz, D.; **Atkinson, M.**: Vitamin D Levels in Subjects With and Without Type 1 Diabetes Residing in a Rich Environments. Diabetes Care 32: 1977-9, 2009.
234. *Xue, S.; Wasserfall, C.; Parker, M.; McGrail, S.; McGrail, K.; Campbell-Thompson, M.; Schatz, D.; **Atkinson, M.A.**; Haller, M.J.: Exendin-4 Treatment of Nonobese Diabetic Mice Increases Beta-Cell Proliferation and Fractional Insulin Reactive Area. Journal of Diabetes and Its Complications 24: 163-167, 2010.
235. *Gianani, R.; Campbell-Thompson, M.; Sarkar, S.A.; Wasserfall, C.; Pugliese, A.; Kent, S.C.; Hering, B.J.; Bonner-Weir, S.; **Atkinson, M.A.**; Coppieters, K.; von Herrath, M.; Eisenbarth, G.S.: Dimorphic Histopathology of Long Standing Childhood Onset Diabetes. Diabetologia 53: 1811-2, 2010.
236. *Gianani, R.; Campbell-Thompson, M.; Wasserfall, C.; Pugliese, A.; Kent, S.; Hering, B.; Bonner-Weir, S.; **Atkinson, M.A.**; Eisenbarth, G.S.: Dimorphic Histopathology of Long Standing Childhood Onset Diabetes. Diabetologia 53: 690-8, 2010.
237. *Valladares, R.; Sankar, D.; Li, N.; Williams, E.; Lai, K.K.; Abdelgelil A.S.; Gonzalez, C.F.; Wasserfall, C.H.; Larkin, J.; Schatz, D.; **Atkinson, M.A.**; Triplett, E.W.; Neu, J.; Lorca, G.L.: *Lactobacillus johnsonii* N6.2 Mitigates the Development of Type 1 Diabetes in BB-DP Rats. PLoS One 6:e10507, 2010.
238. *Zhang, C.; Wang, M.; Racine, J.J.; Liu, H.; Lin, C.L.; Nair, I.; Lau, J.; Yu-An, C.; Todorov, I.; **Atkinson, M.**; Zeng, D.; Zhao, D.; Cao, Y.: Induction of Chimerism Permits Low-Dose Islets Grafts in the Liver or Pancreas to Reverse Refractory Autoimmune Diabetes. Diabetes 59: 2228-36, 2010.
239. *Gagliani, N.; Jofra, T.; Stabilini A.; Valle, A.; **Atkinson, M.**; Roncarolo, M.G.; Battaglia, M.: Antigen-Specific Dependence of Tr1-Cell Therapy in Preclinical Models of Islet Transplant. Diabetes 59: 433-9, 2010.
240. *Garrigan, E.; Han, Z.; Seydel, F.; Belkin, N.; Riggs, C.; Amick, M.; Cdebaca, A.; Pilant, T.; Bober, R.; Wasserfall, C.; **Atkinson, M.**; Clare-Salzler, M.J.; Morel, L.; McDuffie, M.; Litherland, S.A.: A model for studying the impact of nurture on nature: Development of diabetes in multicongenetic mice with an epigenetic gene expression dysregulation defect from the nonobese diabetic mouse (NOD). Journal of Immunology 175(7): 4561-5, 2010.
241. *Rowe, P.A.; Campbell-Thompson, M.L.; Schatz, D.A.; **Atkinson, M.A.**: The Pancreas in Human Type 1 Diabetes. Seminars Immunopathology 33: 29-43, 2010.
242. *Shoda, L.; Kreuwel, H.; Gadkar, K.; Zheng, Y.; Whiting, C.; **Atkinson, M.**; Bluestone, J.; Mathis, D.; Young, D.; Ramanujan, S.: The Type 1 Diabetes PhysioLab® Platform: A Validated Physiologically Based Mathematical Model of Pathogenesis in the Non-Obese Diabetic Mouse. Clinical and Experimental Immunology 161: 250-67, 2010.
243. *Nierras, C.R.; **Atkinson, M.A.**; Goldstein, R.A.: The Juvenile Diabetes Research Foundation at Forty: Updates of Research in Type 1 Diabetes. Diabetes 59: 1575-7, 2010.
244. *Brusko, TM.; Wasserfall, CH.; McGrail, K.; Huegel, AL.; Schatz, D.; **Atkinson, MA.**: Influence of Serum and CD25 Stability on Regulatory T cell Activity: Implications for Immune Regulation. PLoS One 4: e7980, 2010.
245. *Cabrera, R.; Ararat, M.A., Nelson, D.R., **Atkinson, M.A.**, Cao, M., Xu, Y., Wasserfall, C., Lui, C.: Hepatocellular Carcinoma Immunopathogenesis: Clinical Evidence for Global T Cell Defects and An Immunomodulatory Role for Soluble CD25 (sCD25). Digestive Diseases and Sciences 55(2): 484-95, 2010.

246. *Ma, H.; Lu, Y.; Li, H.; Campbell-Thompson, M.; Parker, M.; Wasserfall, C.; Haller, M.; Brantly, M.; Schatz, D.; **Atkinson, M.**; Song, S.: Intradermal Alpha1-Antitrypsin Therapy Avoids Fatal Anaphylaxis, Prevents Type 1 Diabetes and Reverses Hyperglycaemia in the NOD Mouse Model of the Disease. Diabetologia 53: 2198-204, 2010.
247. *Tao, B.; Pietropaolo, M.; **Atkinson, M.A.**; Schatz, D.; Taylor, D.: Estimating the Cost of Type 1 Diabetes in the U.S.: A Propensity Score Matching Method. PLoS One 5(7):e11501, 2010.
248. *Vergani, A.; D'Addio, F.; Jurewicz, M.; Dada, S.; Watanabe, T.; Law, K.; Chin, M.; Mocci, A.; Schuetz, C.; Ricchiuti, V.; Orsenigo, E.; Shaoping, D.; Rodig, S.; Staudacher, C.; Abdi, R.; Williams, J.; Markmann, J.; **Atkinson, M.A.**; Sayegh, M.; Fiorina, P.: A Novel Clinically Relevant Strategy to Abrogate Autoimmunity and Regulate Alloimmunity in NOD Mice. Diabetes 59: 2253-64, 2010.
249. *Zhang, C.; Wang, M.; Racine, J.; Todorov, I.; Lin, C.; Zhao, D.; Nair, I.; Lau, J.; Cao, Y.; **Atkinson, M.**; Zeng, D.: Induction of Chimerism Permits Low-Dose Islet Grafts in the Liver or Pancreas to Reverse Refractory Autoimmune Disease. Diabetes 59: 2228-36, 2010.
250. *Cabrera, R.; Ararat, M.; Eksioglu, E.A.; Cao, M.; Xu, Y.; Wasserfall, C.; **Atkinson, M.A.**; Liu, C.; Nelson, D.R.: Influence of Serum and Soluble CD25 (sCD25) on Regulatory and Effector T-Cell Function in Hepatocellular Carcinoma. Scandinavian Journal of Immunology 72: 293-301, 2010.
251. *Jurewicz, M.; Yang, S.; Augello, A.; Godwin, J.G.; Moore, R.F.; Azzi, J.; Fiorina, P.; **Atkinson, M.**; Sayegh, M.H.; Abdi, R.: Congenic Mesenchymal Stem Cell Therapy Reverses Hyperglycemia in Experimental Type 1 Diabetes. Diabetes 59: 3139-47, 2010.
252. *Haller, M.J.; **Atkinson, M.A.**; Schatz, D.A.: Efforts to Prevent and Halt Autoimmune Beta Cell Destruction. Endocrinology Metabolism Clinics of North America 39:527-39, 2010.
253. *Schatz, D.A.; Haller, M.J.; **Atkinson, M.A.**: Type 1 Diabetes. Preface. Endocrinology Metabolism Clinics of North America 39:xvii-xviii, 2010.
254. *Li, N.; Hatch, M.; Wasserfall, C.H.; Douglas-Escobar, M.; **Atkinson, M.A.**; Schatz, D.A.; Neu, J.: Butyrate and Type 1 Diabetes Mellitus: Can We Fix the Intestinal Leak? Journal of Pediatric Gastroenterology and Nutrition 51: 414-7, 2010.
255. *Brusko, T.M.; Koya, R.C.; Zhu, S.; Lee, M.R.; Putnam, A.L.; McClymont, S.A.; Nishimura, M.I.; Han, S.; Chang, L.J.; **Atkinson, M.A.**; Ribas, A.; Bluestone, J.A.: Human Antigen-Specific Regulatory T cells Generated by T Cell Receptor Gene Transfer. PloS One 22:5(7):e11726, 2010. PMID: [PMC2908680]
256. *Matthews, J.B.; Staeva, T.P.; Bernstein, P.L.; Peakman, M.; von Herrath, M.; ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group: Developing Combination Immunotherapies for Type 1 Diabetes: Recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clinical and Experimental Immunology 160(2): 176-84, 2010.
257. *Soundarapandian, M.M.; Nieves, M.L.; Pasquier, R.; Bergstrom, U.; **Atkinson, M.A.**; Tyrberg, B.: Genetic Control of B-Cell Mass Homeostasis. The Open Endocrinology Journal 4: 11-24, 2010.
258. *El Haddad, N.; Heathcote, D.; Moore, R.; Yang, S.; Azzi, J.; Akiyoshi, T.; Mfarrej, B.; **Atkinson, M.A.**; Sayegh, M.; Lee, J-S.; Ashton-Rickardt, P.G.; Abdi, R.: Mesenchymal Stem Cells Express Serine Protease Inhibitor to Evade Host Immune Response. Blood 117(4): 1176-83, 2011.
259. *Racine, J.; Wang, M.; Zhang, C.; Lin, C.L.; Liu, H.; Todorov, I.; **Atkinson, M.**; Zeng, D.: Induction of mixed chimerism with MHC-mismatched but not matched bone marrow transplants results in thymic deletion of host-type autoreactive T-cells in NOD mice. Diabetes 60(2): 555-64, 2011.

260. *Giongo, A.; Gano, K.A.; Crabb, D.B.; Mukherjee, N.; Novelo, L.L.; Casella, G.; Drew, J.C.; Ilonen, J.; Knip, M.; Hyvoty, H.; Veijola, R.; Simell, T.; Simell, O.; Neu, J.; Wasserfall, C.H.; Schatz, D.; **Atkinson, M.A.**; Triplett, E.W.: Toward Defining the Autoimmune Microbiome for Type 1 Diabetes. ISME Journal 5(1): 82-91, 2011.
261. ***Atkinson, M.A.**: It's Time to Consider Changing the Rules – The Rationale for Rethinking Control Groups for Clinical Trials Aimed at Reversing Type 1 Diabetes. Diabetes 60(2): 361-3, 2011.
262. **Atkinson, M.A.**: Response to Comment on: Atkinson. It's Time to Consider Changing the Rules: The Rationale for Rethinking Control Groups for Clinical Trials Aimed at Reversing Type 1 Diabetes. Diabetes 60(6): e18, 2011.
263. *Lau, K.; Benitez, P.; Ardisson, A.; Wilson, T.D.; Collins, E.L.; Lorca, G.; Li, N.; Sankar, D.; Wasserfall, C.; Neu, J.; **Atkinson, M.A.**; Schatz, D.; Triplett, E.W.; Larkin, J.: Inhibition of Type 1 Diabetes Correlated to a *Lactobacillus Johnsonii* N6.2-mediated Th17 Bias. Journal of Immunology 186: 3538-46, 2011.
264. *Jurczyk, A.; Yang, C.; Racki, W.J.; Brehm, M.A.; **Atkinson, M.A.**; Powers, A.C.; Shultz, L.D.; Greiner, D.L.; Bortel, R.: Hyperglycemia-induced proliferation of adult human beta cells engrafted into spontaneously diabetic immunodeficient NOD-Rag1null IL2rynull Ins2Akita mice. Pancreas 40(7): 1147, 2011.
265. *Grimstein, C.; Choi, Y.K.; Wasserfall, C.H.; Satoh, M.; **Atkinson, M.A.**; Brantly, M.L.; Campbell-Thompson, M.; Song, S.: Alpha-1 Antitrypsin Protein and Gene Therapies Decrease Autoimmunity and Delay Arthritis Development in Mouse Model. Journal of Translational Medicine 9: 21, 2011. PMID: [PMC3050720]
266. *Greenbaum, C.; **Atkinson, M.A.**: Persistence is the Twin Sister of Excellence: An Important Lesson for Attempts to Prevent and Reverse Type 1 Diabetes. Diabetes 60: 693-4, 2011.
267. *Yong, J.; Rasooly, J.; Dang, H.; Lu, Y.; Middleton, B.; Zhang, Z.; Hon, L.; Namavari, M.; Stout, D.B.; **Atkinson, M.A.**; Tian, J.; Gambhir, S.S.; Kaufman, D.L.: Multimodality Imaging of B-Cells in Mouse Models of Type 1 and 2 Diabetes. Diabetes 60: 1383-92, 2011.
268. ***Atkinson, M.A.**; Bluestone, J.; Eisenbarth, G.S.; Hebrok, M.; Herold, K.C.; Accili, D.; Pietropaolo, M.; Arvan, P.; von Herrath, M.; Markel, D.S.; Rhodes, C.J.: How Does Type 1 Diabetes Develop: The Notion of Homicide or B-Cell Suicide Revisited. Diabetes 60: 1370-9, 2011.
269. *Rowe, P.A.; Campbell-Thompson, M.L.; Schatz, D.A.; **Atkinson, M.A.**: The Pancreas in Human Type 1 Diabetes. Seminars Immunopathology 33: 29-43, 2011.
270. *Ize-Ludlow, D.; Lightfoot, Y.L.; Parker, M.; Xue, S.; Wasserfall, C.; Haller, M.J.; Schatz, D.; Becker, D.J.; **Atkinson, M.A.**; Matthews, C.E.: Progressive Erosion of Beta Cell Function Precedes the Onset of Hyperglycemia in the NOD Mouse Model of Type 1 Diabetes. Diabetes 60: 2086-91, 2011.
271. *El Haddad, N.; Moore, R.; Heathcote, D.; Mounayar, M.; Azzi, J.; Mfarrej, B.; Batal, I.; Ting, C.; **Atkinson, M.**; Sayegh, M.H.; Ashton-Rickardt, P.G.; Abdi, R.: The Novel Role of SERPINB9 in Cytotoxic Protection of Human Mesenchymal Stem Cells. Journal of Immunology 187: 2252-60, 2011.
272. *Cheng, H.; Zhang, Y.C.; Wolfe, S.; Valencia, V.; Qian, K.; Shen, L.; Tang, Y.L.; Hsu, W.H.; **Atkinson, M.A.**; Phillips, M.I.: Combinatorial Treatment of Bone Marrow Stem Cells and Stromal Cell-Derived Factor 1 Improves Glycemia and Insulin Production in Diabetic Mice. Molecular and Cellular Endocrinology 345: 88-96, 2011.
273. *Kelly-Scumpia, K.M.; Scumpia, P.O.; Weinstein, J.S.; Delano, M.J.; Cuenca, A.G.; Nacionales, D.C.; Wynn, J.L.; Lee, P.Y.; Kumagai, Y.; Efron, P.A.; Akira, S.; Wasserfall, C.; **Atkinson, M.A.**; Moldawer, L.L.: B Cells Enhance Early Innate Immune Responses During Bacterial Sepsis. Journal of Experimental Medicine 208: 1673-82, 2011.

274. *Blanton, D.; Han, Z.; Bierschenk, L.; Linga-Reddy, M.V.; Wang, H.; Clare-Salzler, M.; Haller, M.; Schatz, D.; Myhr, C.; She, J.X.; Wasserfall, C.; **Atkinson, M.**: Reduced Serum Vitamin D-Binding Protein Levels Are Associated with Type 1 Diabetes. Diabetes 60: 2566-70, 2011.
275. Wasserfall, C.; Nead, K.; Mathews, C.; **Atkinson, M.A.**: The Threshold Hypothesis: Solving the Equation of Nurture vs Nature in Type 1 Diabetes. Diabetologia 54: 2232-6, 2011.
276. *Dilorio, P.; Jurczyk, A.; Yang, C.; Racki, W.; Brehm, M.; Atkinson, M.A.; Powers, A.C.; Shultz, L.D.; Greiner, D.L.; Bortell, R.: Hyperglycemia Induced Proliferation of Adult Human β -Cells Engrafted into Spontaneously Diabetic Immunodeficient NOD-*Rag1 IL2ry Ins2 Mice*. Pancreas 40: 1147-9, 2011.
277. *Giongo, A.; **Atkinson, M.A.**: Triplett, E.W.: Microbiology of Type 1 Diabetes: Possible Implications for Management of the Disease. Diabetes Management 1: 325-31, 2011.
278. *Cheng, H.; Wolfe, S.; Valencia, V.; Qian, L.S.; Hsu, W.; **Atkinson, M.A.**; Zhang, C.; Phillips, M. I.: Stem Cell Therapy of Diabetes: Effective Treatment with Stromal Cell-Derived Factor 1 plus Bone Marrow Stem Cells in the Liver of Diabetic Mice. Molecular and Cellular Endocrinology 345: 88-96, 2011.
279. ***Atkinson, M.A.**: Evaluating Preclinical Efficacy. Science Translational Medicine 3:96cm22, 2011.
280. *Michels, A.W.; Ostrov, D.A.; Zhang, L.; Nakayama, M.; Fuse, M.; McDaniel, K.; Roep, B.O.; Gottlieb, P.A.; **Atkinson, M.A.**; Eisenbarth, G.S.: Structure-Based Selection of Small Molecules To Alter Allele-Specific MHC Class II Antigen Presentation. Journal of Immunology 187: 5921-30, 2011.
281. *Serreze, D.V.; Chapman, H.D.; Dunn, R.; Kehry, M.R.; Haller, M.; Wasserfall, C.; **Atkinson, M.A.**: Natural Loss of Intra-islet CD20 Expression Reduces the Efficacy for B-lymphocyte Mediated Therapies in Type 1 Diabetes. Diabetes 60: 2914-21, 2011.
282. *Schatz, D.A.; Levine, S.L.R.; **Atkinson, M.A.**: It's Time to Mow the GRAS in Type 1 Diabetes. Diabetes 60: 2669-71, 2011.
283. *Brown, C.; Davis-Richardson, A.; Giongo, A.; Gano, K.; Crabb, D.; Mukherjee, N.; Casella, G.; Drew, J.; Ilonen, J.; Knip, M.; Hyoty, H.; Veijola, R.; Simell, O.; Neu, J.; Wasserfall, C.; Schatz, D.; **Atkinson, M.**; Triplett, E.: Gut Microbiome Metagenomics Analysis Suggests a Functional Model for the Development of Autoimmune Type 1 Diabetes. PlosOne 6:e25792, 2011.
284. *Haller, M.J.; Wasserfall, C.H.; McGrail, K.M.; Hulme, M.; Cintron, M.; Brusko, T.M.; Wingard, J.R.; Shuster, J.J.; **Atkinson, M.A.**; Schatz, D.A.: Autologous Umbilical Cord Blood Transfusion in Young Children with Type 1 Diabetes is Safe but Fails to Preserve C-Peptide. Diabetes Care 34: 2567-9, 2011.
285. *Gagliani, N.; Gregori, S.; Jofra, T.; Valle, A.; Stabilini, A.; **Atkinson, M.**; Roncarolo, M.G.; Battaglia, M.: Rapamycin Combined with Anti-CD45RB mAb and IL-10 or G-CSF Induces Tolerance in a Stringent Mouse Model of Islet Transplantation. PLoS One 6:e28434, 2011.
286. *Hulme, M.; Wasserfall, C.; **Atkinson, M.**; Brusko, T.: The Central Role for Interleukin-2 in Type 1 Diabetes. Diabetes 61: 14-22, 2012.
287. *Coppieters, K.T.; Dotta, F.; Amirian, N.; Campbell, P.D.; Kay, T.W.H.; **Atkinson, M.A.**; Roep, B.O.; von Herrath, M.G.: Demonstration of Islet-autoreactive CD8 T cells in Insulitic Lesions from Recent Onset and Long-Term Type 1 Diabetes Patients. Journal of Experimental Medicine 209: 51-60, 2012.
288. *Davoodi-Semiromi, A.; Wasserfall, C.H.; Xia, C.Q.; Cooper-DeHoff, R.M.; Wabitsch, M.; Clare-Salzler, M.; **Atkinson, M.**: The Tyrphostin Agent AG490 Prevents and Reverses Type 1 Diabetes in NOD Mice. PLoS One 7:e36079, 2012.
289. *Campbell-Thompson, M.L.; Montgomery, E.L.; Foss, R.M.; Kolheffer, K.M.; Phipps, G.; Schneider, L.; **Atkinson, M.A.**: Collection Protocol for Human Pancreas. Journal of Visualized Experiments (63), 4039,

DOI:10.3791/4039, 2012.

290. *Campbell-Thompson, M.; Albanese-O'Neill, A.; Staeva, T.; Nierras, M.; Moraski, J.; Kaddis, J.; Rowe, P.; Wasserfall, C.; Gianani, R.; Eisenbarth, G.; Pugliese, A.; Schatz, D.; Crawford, J.; **Atkinson, M.**: The Network for Pancreatic Organ Donors with Diabetes (nPOD): Tissue Biobanking for the Purpose of Understanding the Causes of and Cures for Type 1 Diabetes. Diabetes Metabolism Research and Reviews DOI:10.1002/dmrr.2316, 2012.
291. *Takiishi, T.; Korf, H.; Van Belle, T.L.; Robert, S.; Grieco, F.A.; Caluwaerts, S.; Galleri, L.; Spagnuolo, I.; Steidler, L.; Van Huynegem, K.; Demetter, P.; Wasserfall, C.; **Atkinson, M.A.**; Dotta, F.; Rottiers, P.; Gysemans, C.; Mathieu, C.: Reversal of Autoimmune Diabetes by Restoration of Antigen-Specific Tolerance Using Genetically-Modified *Lactococcus lactis* in Mice. Journal of Clinical Investigation 122: 1717-25, 2012.
292. *Wang, M.; Racine, J.J.; Song, X.; Li, X.; Nair, I.; Liu, H.; Avakian-Mansoorian, A.; Johnston, H.F.; Liu, C.; Shen, C.; **Atkinson, M.**; Todorov, I.; Kandeel, F.; Forman, S.; Wilson, B.; Zeng, D.: Mixed Chimerism and Growth Factors Augment B-Cell Regeneration and Reverse Late-Stage Type 1 Diabetes. Science Translational Medicine 4:133ra59, 2012.
293. *Tang, D.Q.; Wang, Q.; Burkhardt, B.R.; Litherland, S.A.; **Atkinson, M.A.**; Yang, L.J.: In Vitro Generation of Functional Insulin-Producing Cells from Human Bone Marrow-Derived Stem Cells, but Long-Term Culture Running Risk of Malignant Transformation. American Journal of Stem Cells 1: 114-127, 2012.
294. *Davoodi-Semiromi, A.; Hassanzadeh, A.; Wasserfall, C.H.; Droney, A.; **Atkinson, M.**: Tyrphostin AG490 Agent Modestly but Significantly Prevents Onset of Type 1 in NOD Mouse; Implication of Immunologic and Metabolic Effects of a Jak-Stat Pathway Inhibitor. Journal Clinical Immunology 32(5): 1038-47, 2012.
295. *Gregg, B.E.; Moore, P.C.; Demozay, D.; Hall, B.A.; Li, M.; Husain, A.; Wright, A.J.; **Atkinson, M.A.**; Rhodes, C.J.: Formation of a Human B-Cell Population within Pancreatic Islets Is Set Early in Life. J Clin Endocrinol Metab 97: 3197-206, 2012.
296. ***Atkinson, M.A.**; Chervonsky, A.: The Role for the Gut Microbiota in Type 1 Diabetes? Early Evidence from Humans and Animal Models of the Disease. Diabetologia 11: 2868-77, 2012.
297. *Beran, D.; Basey, M.; Wirtz, V.; Kaplan, W.; **Atkinson, M.**; Yudkin, J.S.: On the Road to the Insulin Centenary. Lancet 380:1648, 2012.
298. ***Atkinson, M.A.**: The Pathogenesis and Natural History of Type 1 Diabetes. Cold Spring Harbor Perspectives in Medicine 2(11), 2012.
299. *Cabrera, R.; Fitian, A.; Ararat, M.; Xu, Y.; Brusko, T.; Wasserfall, C.; **Atkinson, M.A.**; Liu, C.; Nelson, D.R.: Serum Levels of Soluble CD25 as a Marker for Hepatocellular Carcinoma. Oncology Letters 4: 840-6, 2012.
300. *Cabrera, R.; Ararat, M.; Xu, Y.; Brusko, T., Wasserfall, C.; **Atkinson, M.A.**; Chang, L.J.; Liu, C.; Nelson, D.R.: Immune Modulation of Effector CD4⁺ and Regulatory T Cell Function by Sorafenib in Patients with Hepatocellular Carcinoma. Cancer Immunology and Immunotherapy 62(4): 737-746, 2013.
301. *Xia, C.Q.; Chernatynskaya, A.V.; Wasserfall, C.H.; Wan, S.; Looney, B.M.; Eisenbeis, S.; Williams, J.; Clare-Salzler, M.J.; **Atkinson, M.A.**: Anti-Thymocyte Globulin (ATG) Differentially Depletes Naïve and Memory T cells and Permits Memory-Type Regulatory T cells in Nonobese diabetic Mice. BMC Immunology 13:70, 2012.
302. *Campbell-Thompson, M.; Wasserfall, C.; Montgomery, E.L.; **Atkinson, M.A.**; Kaddis, J.S.: Pancreas Organ Weight in Individuals with Disease-Associated Autoantibodies at Risk for Type 1 Diabetes. JAMA 308:2337-9, 2012.
303. *Davoodi-Semiromi, A.; Wasserfall, C.H.; Hassanzadeh, A.; Cooper-DeHoff, R.M.; Wabitsch, M.; **Atkinson, M.**: Influence of Tyrphostin AG490 on the Expression of Diabetes-Associated Markers in

303. *Davoodi-Semiromi, A.; Wasserfall, C.H.; Hassanzadeh, A.; Cooper-DeHoff, R.M.; Wabitsch, M.; **Atkinson, M.**: Influence of Tyrphostin AG490 on the Expression of Diabetes-Associated Markers in Human Adipocytes. Immunogenetics 65(1): 83-90, 2013.
304. *Zhang, Q.; Fillmore, T.L.; Schepmoes, A.A.; Clauss, T.R.W.; Crisenko, M.A.; Mueller, P.W.; Rewers, M.; **Atkinson, M.A.**; Smith, R.D.; Metz, T.O.: Serum proteomics reveals systemic dysregulation of innate immunity in type 1 diabetes. Journal Experimental Medicine 210: 191-203, 2013.
305. *Staeva, T.P.; Chatenoud, L.; Insel, R.; **Atkinson, M.A.**: Recent Lessons Learned From Prevention and Recent-Onset Type 1 Diabetes Immunotherapy Trials. Diabetes 62: 9-17, 2013.
306. *Sarikonda, G.; Sachithanantham, S.; Kupfer, T.; Posgai, A.; Wasserfall, C.; Bernstein, P.; Straub, L.; Pagni, P.; Schneider, D.; Calvo, T.R.; Coulombe, M.; Herold, K.; Gill, R.; **Atkinson, M.**; Nepom, G.; Ehlers, M.; Staeva, T.; Garren, H.; Steinman, L.; Chan, A.; von Herrath, M.: Transient B-Cell Depletion with Anti-CD20 in Combination with Proinsulin DNA Vaccine or Oral Insulin: Immunologic Effects and Efficacy in NOD Mice. PLoS One 8:e54712, 2013.
307. **Atkinson, M.**: George S. Eisenbarth, 1947-2012. Diabetologia 56: 435-8, 2013.
308. *Myhr, C.B.; Hulme, M.A.; Wasserfall, C.H.; Hong, P.J.; Lakshmi, P.S.; Schatz, D.A.; Haller, M.J.; Brusko, T.M.; **Atkinson, M.A.**: The Autoimmune Disease-Associated SNP rs917997 of *IL18RAP* Controls IFN γ Production by PBMC. Journal of Autoimmunity 44: 8-12, 2013.
309. *Villalta, S.A.; Lang, J.; Kubeck, S.; Kabre, B.; Szot, G.L.; Calderon, B.; Wasserfall, C.; **Atkinson, M.A.**; Brekken, R.A.; Pullen, N.; Arch, R.H.; Bluestone, J.A.: Inhibition of VEGFR-2 Reverses Type 1 Diabetes in NOD Mice by Abrogating Insulinitis and Restoring Islet Function. Diabetes 62: 2870-8, 2013.
310. *Gagliani, N.; Jofra, T.; Valle, A.; Stabilini, A.; Morsiani, C.; Gregori, S.; Deng, S.; Rothstein, D.M.; **Atkinson, M.A.**; Kamanaka, M.; Flavell, R.A.; Roncarolo, M.G.; Battaglia, M.: Transplant Tolerance to Pancreatic Islets is Initiated in the Graft and Sustained in the Spleen. American Journal of Transplantation 13: 1963-75, 2013.
311. *Haller, M.J.; Wasserfall, C.H.; Hulme, M.A.; Cintron, M.; Brusko, T.M.; McGrail, K.M.; Wingard, J.R.; Theriaque, D.W.; Shuster, J.J.; Ferguson, R.J.; Kozuch, M.; Clare-Salzler, M.; **Atkinson, M.A.**; Schatz, D.A.: Autologous Umbilical Cord Blood Infusion Followed by Oral Docosahexanoic Acid and Vitamin D Supplementation for C-Peptide Preservation in Children with Type 1 Diabetes (T1D). Biol Blood Marrow Transplant 19: 1126-9, 2013.
312. ***Atkinson, M.**: Trying to make a difference for those with Type 1 Diabetes: a lesson in patience as well as a willingness to fail mightily. Expert Review of Endocrinology & Metabolism 8(4): 323-7, 2013.
313. *Donelan, W.; Wang, H.; Li, S.W.; Pittman, D.; Li, Y.; Han, S.; Carter, C.; Wasserfall, C.; **Atkinson, M.**; Reeves, W.; Winter, W.E.; Yang, L.J.: Novel Detection of Pancreatic and Duodenal Homeobox 1 Autoantibodies (PAA) in Human Sera Using Luciferase Immunoprecipitation Systems (LIPS) Assay. International Journal of Clinical and Experimental Pathology 6: 1202-10, 2013.
314. *Tang, D.Q.; Shun, L.; Koya, V.; Sun, Y.; Wang, Q.; Wang, H.; Li, S.W.; Zhang, C.; Hansen, B.; Qian, K.; **Atkinson, M.**; Phillips, M.I.; Yang, L.: Genetically Reprogrammed, Liver-Derived Insulin-Producing Cells Are Glucose-Responsive, But Susceptible to Autoimmune Destruction in Settings of Murine Model of Type 1 Diabetes. American Journal of Translational Research 5: 184-99, 2013.
315. *Diabetes Research in Children Network (DirectNet) Study Group; Type 1 Diabetes TrialNet Study Group; Buckingham, B.A.; Beck, R.W.; Ruedy, K.J.; Cheng, P.; Kollman, C.; Weinzimer, S.A.; DiMeglio, L.A.; Bremer, A.A.; Slover, R.; Cantwell, M.; **Atkinson, M.**: The Effects of Inpatient Hybrid Closed-loop Therapy Initiated Within 1 Week of Type 1 Diabetes Diagnosis. Diabetes Technology and Therapeutics 15: 401-8

316. *Lantow, M.; Zeumer, L.; Wasserfall, C.; **Atkinson, M.A.**; Morel, L.: The Granulocyte Colony Stimulating Factor Pathway Regulates Autoantibody Production in a Murine Induced Model of Systemic Lupus Erythematosus. Arthritis Research and Therapy 15:R49, 2013.
317. *Moran, A.; Bundy, B.; Becker, D.J.; DiMeglio, L.A.; Gitelman, S.E.; Goland, R.; Greenbaum, C.J.; Herold, K.C.; Marks, J.B.; Raskin, P.; Sanda, S.; Schatz, D.; Wherrett, D.K.; Wilson, D.M.; Krischer, J.P.; Skyler, J.S.; Type 1 Diabetes TrialNet Canakinumab Study Group, Pickersgill, L.; de Koning, E.; Ziegler, A.G.; Boehm, B.; Badenhop, K.; Schloot, N.; Bak, J.F.; Pozzilli, P.; Mauricio, D.; Donath, M.Y.; Castano, L.; Wagner, A.; Lervang, H.H.; Perrild, H.; Mandrup-Poulsen, T.; **Atkinson, M.** IDA Study Group, Pociot, F.; Dinarello, C.A.: Interleukin-1 Antagonism in Type 1 Diabetes of Recent Onset: Two Multicentre, Randomised, Double-Blind, Placebo-Controlled Trials. Lancet 381: 1905-15, 2013.
318. *Butler, A.E.; Campbell-Thompson, M.; Gurlo, T.; Dawson, D.W.; **Atkinson, M.**; Butler, P.C.: Marked Expansion of Exocrine and Endocrine Pancreas with Incretin Therapy in Humans with Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors. Diabetes 62: 2595-604, 2013.
319. *Butler, A.E.; Campbell-Thompson, M.; Gurlo, T.; Dawson, D.W.; **Atkinson, M.**; Butler, P.C.: Response to Comments on: Butler et al. Marked Expansion of Exocrine and Endocrine Pancreas with Incretin Therapy in Humans with Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors. Diabetes 62:e19-22, 2013.
320. *Rowe, P.; Wasserfall, C.; Croker, B.; Campbell-Thompson, M.; Pugliese, A.; **Atkinson, M.**; Schatz, D.: Increased Complement Activation in Human Type 1 Diabetes Pancreata. Diabetes Care 36: 3815-7, 2013.
321. *Campbell-Thompson, M.; **Atkinson, M. A.**; Butler, A. E.; Chapman, N. M.; Frisk, G.; Gianani, R.; Giepmans, B. N.; von Herrath, M.G.; Hyoty, H.; Kay, T.W.; Korsgren, O.; Morgan, N. G.; Powers, A. C.; Pugliese, A.; Richardson, S. J.; Rowe, P. A.; Tracy, S.; In't Veld, P.A.: The Diagnosis of Insulinitis in Human Type 1 Diabetes. Diabetologia 56: 2541-3, 2013.
322. *Tian, J.; Dang, H.; Chen, Z.; Guan, A.; Jin, Y.; **Atkinson, M.A.**; Kaufman, D.L.: Gamma-Aminobutyric Acid Regulates Both the Survival and Replication of Human B-Cells. Diabetes 62: 3760-5, 2013.
323. *Beran, D.; Yudkin, J.S.; **Atkinson, M.A.**: Global Reality of Type 1 Diabetes Care in 2013. Diabetes Care 36:e144, 2013.
324. *Garrigan, E.; Belkin, N.S.; Alexander, J.J.; Han, Z.; Seydel, F.; Carter, J.; **Atkinson, M.**; Wasserfall, C.; Clare-Salzler, M.J.; Amick, M.A.; Litherland, S.A.: Persistent STAT5 Phosphorylation and Epigenetic Dysregulation of GM-CSF and PGS2/COX2 Expression in Type 1 Diabetic Human Monocytes. PLOS ONE 8:e76919, 2013.
325. ***Atkinson, M.A.**; Ogle, G.D.: Improving Diabetes Care in Resource-Poor Countries: Challenges and Opportunities. The Lancet, Diabetes & Endocrinology 1(4): 268-70, 2013.
326. *Miersch, S.; Bian, X.; Wallstrom, G.; Sibani, S.; Logvinenko, T.; Wasserfall, C.; Schatz, D.; **Atkinson, M.**; Qiu, J.; LaBaer, J.: Serological Autoantibody Profiling of Type 1 Diabetes by Protein Arrays. Journal of Proteomics 94: 486-96, 2013.
327. ***Atkinson, M.A.**: A Vision of Hope. The Lancet 382:2060, 2013.
328. *Giannopoulou, E.Z.; Puff, R.; Beyerlein, A.; von Luetichau, I.; Boerschmann, H.; Schatz, D.A.; **Atkinson, M.A.**; Haller, M.J.; Egger, D.; Burdach, S.; Ziegler, A.G.: Effect of a Single Autologous Cord Blood Infusion on Beta Cell and Immune Function in Children with New Onset Type 1 Diabetes: A Non-Randomized, Controlled Trial. Pediatric Diabetes 15(2): 100-109, 2014.
329. *Pugliese, A.; Yang, M.; Kusmarteva, I.; Heiple, T.; Wasserfall, C.; Rowe, P.; Moraski, J.; Ball, S.; Jebson, L.; Schatz, D.; Gianani, R.; Kaddis, J.; Campbell-Thompson, M.; **Atkinson, M.**: The Juvenile Diabetes Research Foundation Network for the Pancreatic Organ Donor with Diabetes (nPOD): Goals, Operational Model and Emerging Findings. Pediatric Diabetes 15(1): 1-9, 2014.

330. *Endesfelder, D.; zu Castell, W.; Ardisson, A.; Davis-Richardson, A.G.; Achenbach, P.; Hagen, M.; Pfluger, M.; Gano, K.A.; Fagen, J.R.; Drew, J.C.; Brown, C.T.; Kolaczowski, B.; **Atkinson, M.**; Schatz, D.; Bonifacio, E.; Ziegler, A.G.; Triplett, E.W.: Compromised Gut Microbiota Networks in Children with Anti-Islet Autoimmunity. Diabetes 63(6): 2006-14, 2014.
331. *Dunne, J.L.; Triplett, E.W.; Gevers, D.; Xavier, R.; Insel, R.; Danska, J.; **Atkinson, M.A.**: The Intestinal Microbiome in Type 1 Diabetes. Clinical and Experimental Immunology 177(1): 30-7, 2014.
332. *Pugliese, A.; Vendrame, F.; Reijonen, H.; **Atkinson, M.A.**; Campbell-Thompson, M.; Burke, G.W.: New Insight on Human Type 1 Diabetes Biology: nPOD and nPOD-Transplantation. Current Diabetes Report 14:530, 2014.
333. *Lewis, J.S.; Roche, C.; Zhang, Y.; Brusko, T.M.; Wasserfall, C.H.; **Atkinson, M.**; Clare-Salzler, M.J.; Keselowsky, B.G.: Combinatorial Delivery of Immunosuppressive Factors to Dendritic Cells Using Dual-Sized Microspheres. J Mater Chem B Mater Biol Med 2: 2562-2574, 2014.
334. ***Atkinson, M.**; Eisenbarth, G.S.; Michels, A.W.: Type I Diabetes. Lancet 383(9911): 69-82, 2014.
335. *Richardson SJ, Leete P, Dhayal S, Russell MA, Oikarinen M, Laiho JE, Svedin E, Lind K, Rosenling T, Chapman N, Bone A.J.; **Atkinson, M.**: nPOD-V Consortium, Foulis AK, Frisk G, Flodstrom-Tullberg M, Hober D, Hyoty H, Morgan NG. Evaluation of the fidelity of immunolabelling obtained with clone 5D8/1, a monoclonal antibody directed against the enteroviral capsid protein, VP1, in human pancreas. Diabetologia 57(2): 392-401, 2014.
336. ***Atkinson, M.A.**: Pancreatic Biopsies in Type 1 Diabetes: Revisiting the Myth of Pandora's Box. Diabetologia 57: 656-9, 2014.
337. *Robert, S.; Gysemans, C.; Takiishi, T.; Korf, H.; Sagnuolo, I.; Sebastiani, G.; Van Huynegem, K.; Steidler, L.; Caluwaerts, S.; Demetter, P.; Wasserfall, C.H.; **Atkinson, M.A.**; Dotta, F.; Rottiers, P.; Van Belle, T.L.; Matheiu, C.: Oral Delivery of Glutamic Acid Decarboxylase (GAD)-65 and IL10 by *Lactococcus lactis* Reverses Diabetes in Recent-Onset NOD Mice. Diabetes 63: 2876-2887, 2014.
338. *Xia, C.Q.; Peng, R.; Chernatynskaya, A.V.; Yuan, L.; Carter, C.; Valentine, J.; Sobel, E.; **Atkinson, M.**; Clare-Salzler, M.J.: Increased IFN- α -Producing Plasmacytoid Dendritic Cells (pDCs) in Human Th1-Mediated Type 1 Diabetes: pDCs Augment Th1 Responses Through IFN- α Production. Journal of Immunology 193(3): 1024-1034, 2014
339. *Kushner, J.A.; MacDonald, P.E.; **Atkinson, M.**: Stem Cells to Insulin Secreting Cells: Two Steps Forward and Now a Time to Pause? Cell Stem Cell 15(5): 535-6, 2014.
340. *Davis-Richardson, A.G.; Ardisson, A.N.; Simell, V.; Leonard, M.T.; Kemppainen, K.M.; Drew, J.C.; Schatz, D.; **Atkinson, M.A.**; Kolaczowski, B.; Ilonen, J.; Knip, M.; Toppari, J.; Numinen, N.; Hyoty, H.; Veijola, R.; Simell, T.; Mykkanen, J.; Simell, O.; Triplett, E.W.: *Bacteroides Dorei* Dominates Gut Microbiome Prior to Autoimmunity in Finnish Children at High Risk for Type 1 Diabetes. Frontiers in Microbiology 5:678, 2014.
341. ***Atkinson, M.A.**: Losing a Grip on the Notion of B-cell Specificity for Immune Responses in Type 1 Diabetes – Can We Handle the Truth? Diabetes 63(11): 3572-4, 2014.
342. *Purwana, I.; Zheng, J.; Li, X.; Deurloo, M.; Son, D.O.; Zhang, Z.; Liang, C.; Shen, E.; Tadmase, A.; Feng, Z.P.; Li, Y.; Hasilo, C.; Paraskevas, S.; Bortell, R.; Greiner, D.; **Atkinson, M.**; Prud'homme, G.J.; Wang, Q.: GABA Promotes Human B-cell Proliferation and Modulates Glucose Homeostasis. Diabetes 63(12): 4197-4205, 2014.
343. *Radichev, I.A.; Maneva-Radicheva, L.; Amatya, C.; Parker, C.; Ellefson, J.; Wasserfall, C.; **Atkinson, M.**; Burn, P.; Savinov, A.Y.: Nardilysin-Dependent Proteolysis of Cell-Associated VTCN1 (B7-H4) Marks Type 1 Diabetes Development. Diabetes 63(10): 3470-82, 2014.

344. *Kweh, F.A.; Miller, J.L.; Sulsona, C.R.; Wasserfall, C.; **Atkinson, M.**; Shuster, J.J.; Goldstone, A.P.; Driscoll, D.J.: Hyperghrelinemia in Prader-Willi Syndrome Begins in Early Infancy Long Before the Onset of Hyperphagia. American Journal of Medical Genetics 167A(1): 69-79, 2015.
345. Noble, J.; Lane, J.; Ahmadov, G.; Ahmedani, Y.; Fawwad, A.; Zabeen B.; **Atkinson, M.**; Silink, M.; Ogle, G.: HLA-Associated Susceptibility to Type 1 Diabetes in the Developing World Reveals Differences Among Populations; Implications for Prediction and Intervention. Tissue Antigens 85(5) 335-335, 2015.
346. *Kleffel, S.; Vergani, A.; Tezza, S.; Ben Nasr, M.; Niewczas, M.A.; Wong, S.; Bassi, R.; D'Addio, F.; Schatton, T.; Abdi, R.; **Atkinson, M.**; Sayegh, M.H.; Wen, L.; Wasserfall, C.H.; O'Connor, K.C.; Fiorina, P.: Interleukin-10+ Regulatory B Cells Arise Within Antigen-Experienced CD40+ B Cells to Maintain Tolerance to Islet Autoantigens. Diabetes 64(1): 158-71, 2015.
347. *Haller, M.J.; Gitelman, S.E.; Gottlieb, P.A.; Michels, A.W.; Rosenthal, S.M.; Shuster, J.J.; Zou, B.; Brusko, T.M.; Hulme, M.A.; Wasserfall, C.H.; Matthews, C.E.; **Atkinson, M.**; Schatz, D.A.: Anti-Thymocyte Globulin/ G-CSF Treatment Preserves β Cell Function in Patients with Established Type 1 Diabetes. Journal of Clinical Investigation 125(1): 448-55, 2015.
348. *Battaglia, M.; **Atkinson, M.**: The Streetlight Effect in Type 1 Diabetes. Diabetes 64(4):1081-90, 2015.
349. *Poudel, A.; Savari, O.; Striegel, D.A.; Periwai, V.; Taxy, J.; Milis, J.; Witkowski, P.; **Atkinson, M.**; Hara, M.: Beta-Cell Destruction and Preservation in Childhood and Adult Onset Type 1 Diabetes. Endocrinology 49(3): 693-702, 2015.
350. *Kempainen, K.; Ardisson, A.; Davis-Richardson, A.; Fagen, J.; Gano, K.; León-Novelo, L.; Vehik, K.; Casella, G.; Simell, O.; Ziegler, A.; Rewers, M.; Lernmark, Å.; Hagopian, W.; She, J.X.; Krischer, J.; Akolkar, B.; Schatz, D.; **Atkinson, M.**; Triplett, E.; TEDDY Study Group. Early Childhood Gut Microbiomes Show Strong Geographic Differences Among Subjects at High Risk for Type 1 Diabetes. Diabetes Care 38(2): 329-32, 2015.
351. ***Atkinson, M.**; Von Herrath, M.; Powers, A.C.; Clare-Salzler, M.: Current Concepts on the Pathogenesis of Type 1 Diabetes - Considerations for Attempts to Prevent and Reverse the Disease. Diabetes Care 38(6): 979-88, 2015.
352. *Yoon, Y.M.; Lewis, J.S.; Carstens, M.R.; Campbell-Thompson, M.; Wasserfall, C.H.; **Atkinson, M.A.**; Keselowsky, B.G.: A Combination Hydrogel Microparticle-Based Vaccine Prevents Type 1 Diabetes in Non-Obese Diabetic Mice. Scientific Reports 5:13155, 2015.
353. *Sivakumar, R.; **Atkinson, M.A.**; Mathews, C.; Morel, L.: G-CSF: A Friend or Foe? Immunome Res S:2, 2015.
354. *Kaddis, J.S.; Pugliese, A.; **Atkinson, M.**: A Run on the Biobank: What Have We Learned About Type 1 Diabetes from the nPOD Tissue Repository? Current Opinion in Endocrinology, Diabetes and Obesity 22(4): 290-5, 2015.
355. *Lewis, J.S.; Dolgova, N.V.; Zhang, Y.; Xia, C.Q.; Wasserfall, C.H.; **Atkinson, M.**; Clare-Salzler, M.J.; Keselowsky, B.: A Combination Dual-Sized Microparticle System Modulates Dendritic Cells and Prevents Type 1 Diabetes in Prediabetic NOD Mice. Clinical Immunology 160(1): 90-102, 2015.
356. *Li, X.; **Atkinson, M.A.** The Role for Gut Permeability in the Pathogenesis of Type 1 Diabetes – Is the Concept Leaky? Pediatric Diabetes 16(7): 485-92, 2015.
357. *Fuhrman, C.A.; Yeh, W.I.; Seay, H.; Lakshmi, P.S.; Chopra, G.; Zhang, L.; Perry, D.J.; McClymont, S.; Yadav, M.; Lopez, M.C.; Baker, H.V.; Zhang, Y.; Li, Y.; Whitley, M.; Von Schack, D.; **Atkinson, M.**; Bluestone, J.A.; Brusko, T.: Divergent Phenotypes of Human Regulatory T-Cells Expressing the Receptors TIGIT and CD226. The Journal of Immunology 195(1): 145-55, 2015.

358. *Mathews, C.E.; Xue, S.; Posgai, A.; Lightfoot, Y.L.; Xia, L.; Wasserfall, C.H.; Haller, M.J.; Schatz, D.; **Atkinson, M.A.**: Acute Versus Progressive Onset of Diabetes in NOD Mice – Potential Implications for Therapeutic Interventions in Type 1 Diabetes. Diabetes 64(11): 3885-90, 2015.
359. *Song, X.; Posgai, A.; Wasserfall, C.H.; Myhr, C.; Campbell-Thompson, M.; Mathews, C.E.; Rabinovitch, A.; Savinov, A.; Battaglia, M.; Schatz, D.; Haller, M.J.; **Atkinson, M.A.**: Combination Therapy Reverses Hyperglycemia in NOD Mice with Established Type 1 Diabetes. Diabetes 64(11): 3873-84, 2015.
360. *Insel, R.; Dunne, J.; **Atkinson, M.**; Chiang, J.; Dabelea, D.; Gottlieb, P.; Greenbaum, C.; Herold, K.; Krischer, J.; Lernmark, A.; Ratner, R.; Rewers, M.; Schatz, D.; Skyler, J.; Sosenko, J.; Ziegler, A: Staging Presymptomatic Type I Diabetes: a Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 38(10): 1964-74, 2015.
361. *Gagliani, N.; Jofra, T.; Posgai, A.L.; **Atkinson, M.A.**; Battaglia, M.: Immune Depletion in Combination with Allogeneic Islets Permanently Restores Tolerance to Self-Antigens in Diabetic NOD Mice. PlosOne 10(11):e0142318, 2015.
362. *Gill, R.G.; Pagni, P.P.; Kupfer, T.; Wasserfall, C.H.; Deng, S.; Posgai, A.; Manenkova, Y.; Hani, A.B.; Bernstein, P.; **Atkinson, M.A.**; Herold, K.C.; von Herrath, M.; Teodora, S.; Ehlers, M.R.; Nepom, G.T.: A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice. Diabetes 6:260, 2015.
363. *Li, J.; Zhang, Z.; Liu, X.; Wang, Y.; Mao, F.; Mao, J.; Lu, X.; Jiang, J.D.; Wan, Y.; Lv, J.Y.; Cao, G.; Zhang, Q.; Zhao, N.; **Atkinson, M.**; Greiner, D.L.; Prud'homme, G.J.; Jiao, Z.; Li, Y.; Wang, Q.: Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics. Frontiers in Pharmacology 6:260, 2015.
364. *Garrigan, E.; Belkin, N.S.; Seydel, F.; Han, Z.; Carter, J.; McDuffie, M.; Morel, L.; Peck, A.; Clare-Salzler, M.; **Atkinson, M.**; Wasserfall, C.; Davoodi-Semiromi, A.; Shi, J.; Haskell-Luevano, C.; Yang, L.J.; Alexander, J.; Bober, R.; CdeBaca, A.; Piliant, T.; Riggs, C.; Amick, M.; Litherland, S.A.: Csf2 and Ptgs2 Epigenetic Dysregulation in Diabetes-Prone Bi-Congenic B6.NODC11bxC1tb Mice. Genetics and Epigenetics 7: 5-17, 2015.
365. *Von Herrath, M.; Korgsren, O.; **Atkinson, M.**: Factors Impeding the Discovery of an Intervention-based Treatment for Type 1 Diabetes. Clinical & Experimental Immunology 183(1): 1-7, 2016.
366. *Campbell-Thompson, M.; Kaddis, J.S.; Wasserfall, C.H.; Haller, M.J.; Pugliese, A.; Schatz, D.A.; Shuster, J.S.; **Atkinson, M.A.**: The Influence of Type 1 Diabetes on Pancreatic Weight. Diabetologia 59(1): 217-21, 2016.
367. *Campbell-Thompson, M.; Fu, A.; Kaddis, J.S.; Wasserfall, C.H.; Schatz, D.; Pugliese, A.; **Atkinson, M.A.**: Insulinitis and β -Cell Mass in the Natural History of Type 1 Diabetes. Diabetes 65(3): 719-31 2016.
368. *Haller, M.J.; **Atkinson, M.A.**; Wasserfall, C.H.; Brusko, T.M.; Mathews, C.E.; Hulme, M.; Cintron, M.; Shuster, J.; McGrail, K.; Posgai, A.; Schatz, D: Mobilization Without Immune Depletion Fails to Restore Immunological Tolerance or Preserve Beta Cell Function in Recent Onset Type 1 Diabetes. Clinical and Experimental Immunology 183(3): 350-7, 2016.
369. *Jurczyk, A.; Nowosielska, A.; Przewozniak, N.; Aryee, K.E.; Dilorio, P.; Blodgett, D.; Yong, C.; Campbell-Thompson, M.; **Atkinson, M.**; Shultz, L.; Harlan, D.; Greiner, D.; Bortell, R.: Beyond the Brain - Disrupted in Schizophrenia 1 Regulates Pancreatic β -cell Function via Glycogen Synthase Kinase-3 β . FASEB J 30(2): 983-93, 2016.
370. *Buschard, K.; Bracey, A.W.; McElroy, D.L.; Magis, A.T.; Osterbye, T.; **Atkinson, M.A.**; Bailey, K.M.; Posgai, A.L.; Ostrov, D.A.: Sulfatide preserves insulin crystals not by being integrated in the lattice but by stabilizing their surface. Journal of Diabetes Research 2016. doi:10.1155/2016/6179635.
371. *Bian, X.; Wallstrom, G.; Davis, A.; Wang, J.; Park, J.; Throop, A.; Steel, J.; Yu, X.; Wasserfall, C.; Schatz, D.; **Atkinson, M.**; Qiu, J.; LaBaer, J.: Immunoproteomic Profiling of Antiviral Antibodies in New-

Onset Type 1 Diabetes Using Protein Arrays. *Diabetes* 65(1): 285-96, 2016.

372. *Campbell-Thompson, M.; Schatz, D.A.; Kaddis, J.S.; **Atkinson, M.**: *Pancreatic and Ductal Cell Hyperplasia/Dysplasia with Obstructive Chronic Pancreatitis: An Association with Reduced Pancreatic Weight in Type 1 Diabetes*. Reply to Kobayashi T., Aida K., Fukui T. et al [letter] and Saisho Y. [letter]: *Diabetologia* 59(4): 865-7, 2016.
373. *Hackeng, W.M.; Brosens, L.A.; Poruk, K.E.; Noe, M.; Hosoda, W.; Poling, J.S.; Rizzo, A.; Campbell-Thompson, M.; **Atkinson, M.A.**; Konukiewicz, B.; Kloppel, G.; Heaphy, C.M.; Meeker, A.K.; Wood, L.D.: Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis. *Human Pathology* 56: 93-100, 2016.
374. *Nambam, B.; Bratina, N.; Schatz, D.; Bonifacio, E.; Ziegler, A.G.; Klingensmith, G.; Shober, E.; Bingley, P.J.; Rottenkolber, M.; Theil, A.; Eugster, A.; Puff, R.; Peplow, C.; Buettner, F.; Lange, K.; Hasford, J.; Achenbach, P.; Haller, M.J.; Gitelman, S.E.; Gottlieb, P.A.; Michels, A.W.; Rosenthal, S.M.; Shuster, J.J.; Zou, B.; Brusko, T.M.; Hulme, M.A.; Wasserfall, C.A.; Mathews, C.E.; **Atkinson, M.A.**; Aronson, R.; Christiansen, J.S.; Donner, T.W.; Bosi, E.; Bode, B.W.; Pozzilli, P.; D'Addio, F.; Valderrama, V.A.; Ben Nasr, M.; Franek, E.; Zhu, D.; Li, L.; Ning, G.; Snarski, E.; Fiorina, P.; Yu, A.; Snowwhite, I.; Vendrame, F.; Rosenzweig, M.; Klatzman, D.; Pugliese, A.; Malek, T.R.; Orban, T.; Beam, C.A.; Xu, P.; Moore, K.; Jiang, Q.; Deng, J.; Muller, S.; Spain, L.; Peakman, M.: Immune Interventions for Type 1 Diabetes. *Diabetes Technology & Therapeutics* 18(S1)S-69-S-75.
375. *Wasserfall, C.; Montgomery, E.; Yu, L.; Michels, A.; Gianani, R.; Pugliese, A.; Nierras, C.; Kaddis, J.; Schatz, D.; Bonifacio, E.; **Atkinson, M.A.**: Validation of a Rapid Type 1 Diabetes Autoantibody Screening Assay for Community Based Screening of Organ Donors to Identify Subjects at Increased Risk for the Disease. *Clinical and Experimental Immunology* 185(1): 33-41, 2016.
376. *Burke, G.; Posgai, A.; Wasserfall, C.H.; **Atkinson, M.A.**; Pugliese, A.: Raising Awareness: The Need to Promote Allocation of Pancreata from Rare Non-Diabetic Donors with Pancreatic Islet Autoimmunity to Type 1 Diabetes Research. *American Journal of Transplantation* 17(1): 306-07, 2017.
377. *Philips, T.; Campbell-Thompson, M.; **Atkinson, M.**; Schatz, D.; Kusmartseva, I.; Longmate, J.; Heiple, T.; Kaddis, J.: Factors that Influence the Quality of RNA from the Pancreas of Organ Donors. *Pancreas* 46(2): 252-9, 2017.
378. *Richardson, R.M.; Rodrigues-Calvo, T.; Gerling, I.; Kaddis, J.; Russell, M.; Zeissler, M.; Krogvold, L.; Dahl-Jorgensen, K.; von-Herrath, M.; Pugliese, A.; **Atkinson, M.**; Morgan, N.G.: Islet Cell Hyperexpression of HLA Class I Antigens: A Defining Feature in Type 1 Diabetes. *Diabetologia* 59(11): 2448-58, 2016.
379. *Mahmoud, T. I.; Wang, J.; Karnell, J. L.; Wang, Q.; Wang, S.; Naiman, B.; Naiman, B.; Gross, P.; Brohawn, P.; Morehouse, C.; Aoyama, J.; Wasserfall, C.; Carter, L.; **Atkinson, M. A.**; Serreze, D. V.; Braley-Mullen, H.; Mustelin, T.; Kolbeck, R.; Herbst, R.; Ettinger, R.: Autoimmune Manifestations in Aged Mice Arise from Early-Life Immune Dysregulation. *Science Translational Medicine* 8(361): ra137, 2016.
380. *Jacobsen, L. M.; **Atkinson, M. A.**; Campbell-Thompson, M.; Schatz, D. A.: Presumptive Type 1 Diabetes with Co-Morbidities and Rapid Progression Despite Numerous Insulin Positive Islets. *Diabetes Care* 39(7): 1292-4, 2016.
381. *Haller, M.J.; Gitelman, S.; Gottlieb, P.; Michels, A.; Perry, D.; Schultz, A.; Hulme, M.; Shuster, J.; Zou, B.; Wasserfall, C.; Posgai, A.; Mathews, C.; Brusko, T.; **Atkinson, M.**; Schatz, D.: Anti-thymocyte Globulin + G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders with Established Type 1 Diabetes. *Diabetes* 65(12): 3765-75, 2016.
382. *Endesfelder, D.; Engel, M.; Davis-Richardson, A.G.; Ardisson, A. N.; Achenbach, P.; Hummel, S.; Winkler, C.; **Atkinson, M.**; Schatz, D.; Triplett, E.; Ziegler, A.G.; zu Castell, W.: Towards a Functional

Hypothesis Relating Anti-Islet Autoimmunity to the Dietary Impact on Microbial Communities and Butyrate Production. Microbiome 26(4), 17, 2016.

383. *Liu, C.; Yogini, J.; **Atkinson, M.**; Zhang, Q.: Type 1 Diabetes Cadaveric Human Pancreata Exhibit a Unique Exocrine Tissue Proteomic Profile. Proteomics 16(9): 1432-1446, 2016.
384. *Bonifacio, E.; Mathieu, C.; Nepom, G.; Ziegler, A-G.; Anhalt, H.; Haller, M.; Harrison, L. C.; Hebrok, M.; Kuschner, J.; Norris, J. M.; Peakman, M.; Powers, A. C.; Todd, J. A.; **Atkinson, M.**: Rebranding Asymptomatic Type 1 Diabetes: The Case for Autoimmune Beta Cell Disorder as a Pathological and Diagnostic Entity. Diabetologia 60(1): 35-38, 2017.
385. Editorial: Centennial Celebration – An Interview with Dr. **Mark Atkinson** on 100 Years of Type 1 Diabetes Care and Research: Endocrinology 157(11): 4087-90, 2016.
386. *Ziegler, A-G.; Bonifacio, E.; Powers, A.; Todd, J.; Harrison, L.; **Atkinson, M. A.**: Type 1 Diabetes Prevention – A Goal Dependent on Accepting a Diagnosis of Asymptomatic Disease. Diabetes 65(11): 3233-39, 2016.
387. *Seay, H.R.; Yusko, E.; Rothweiler, S.; Zhang, L.; Posgai, A.; Campbell-Thompson, M.; Vignali, M.; Emerson, R.; Kaddis, J.; Ko, D.; Nakayama, M.; Smith, M.J.; Cambier, J.C.; Pugliese, A.; **Atkinson, M.A.**; Robins, H.; Brusko, T.M.: Tissue Distribution and Clonal Diversity of the T and B Cell Repertoire in Type 1 Diabetes. JCI Insight 1(20), e88242, 2016.
388. *Bian, X.; Wasserfall, C.; Wallstrom, G.; Wang, J.; Wang, H.; Barker, K.; Schatz, D.; **Atkinson, M.**; Qiu, J.; LaBaer, J.: Tracking the Antibody Immunome in Type 1 Diabetes Using Protein Arrays. Journal of Proteome Research 16(1): 195-203, 2017.
389. *Michels, A. W.; Landry, L. G.; McDaniel, K. A.; Yu, L.; Campbell-Thompson, M.; Kwok, W. W.; Jones, K. L.; Gottlieb, P. A.; Kappler, J. W.; Tang, Q.; Roep, B. O.; **Atkinson, M. A.**; Mathews, C. E.; Nakayama, M.: Islet-derived CD4 T-cells Targeting Proinsulin in Human Autoimmune Diabetes. Diabetes 2017 Mar;66(3):722-734. DOI: 10.2337/db16-1025.
390. *Babon, J. A. B.; DeNicola, M.; Blodgett, D. M.; Crevecoeur, I.; Buttrick, T. S.; Maehr, R.; Bottino, R.; Naji, A.; Kaddis, J.; Elyaman, W.; James, E.; Haliyur, R.; Brissova, M.; Overbergh, L.; Mathieu, C.; Delong, T.; Haskins, K.; Campbell-Thompson, M.; Mathews, C.; **Atkinson, M. A.**; Powers, A. C.; Harlan, D. M.; Kent, S. C.: Analysis of Self-Antigen Specificity of Islet Infiltrating T Cells from Human Donors with Type 1 Diabetes. Nature Medicine 22(12): 1482-87, 2016.
391. *Babon, J. A. B.; DeNicola, M. E.; Blodgett, D. M.; Crevecoeur, I.; Buttrick, T. S.; Maehr, R.; Bottino, R.; Naji, A.; Kaddis, J.; Elyaman, W.; James, E. A.; Haliyur, R.; Brissova, M.; Overbergh, L.; Mathieu C.; Delong, T.; Haskins, K.; Pugliese, A.; Campbell-Thompson, M.; Mathews, C.; **Atkinson, M. A.**; Powers, A. C.; Harlan, D. M.; Kent, S. C.: Corrigendum: Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes. Nature Med 23(8): 1004, 2017.
392. *Campbell-Thompson, M. L.; **Atkinson, M. A.**; Butler A. E.; Giepmans, B. N.; von Herrath, M. G.; Hyoty, H.; Kay, T. W.; Morgan, N. G.; Powers, A. C.; Pugliese, A.; Richardson, S. J.; In't Veld, P. A.: Re-addressing the 2013 consensus guidelines for the diagnosis of insulitis in human type 1 diabetes – Is change necessary?. Diabetologia 1(3): 1432-0428, 2017.
393. *Seay, H.R.; Putnam, A.L.; Cserny, J.; Posgai, A.L.; Rosenau, E.H.; Wingard, J.R.; Girard, K.F.; Kraus, M.; Lares, A.P.; Brown, H.L.; Brown, K.S.; Balavage, K.T.; Peters, L.; Bushdorf, A.; **Atkinson, M.A.**; Bluestone, J.A.; Haller, M.J.; Brusko, T.M.: Expansion of Humand Tregs from Cryopreserved Umbilical Cord Blood for GMP-compliant Autologous Adoptive Cell Transfer Therapy. Molecular Therapy: 4(17): 178-91, 2017.
394. *Li, X.; Campbell-Thompson, M.; Wasserfall, C.H.; McGrail, K.; Posgai, A.; Brusko, T.M.; Shuster, J.;

- Liang, F.; Muir, A.; Schatz, D.; Haller, M.J.; **Atkinson, M.A.**: Serum Trypsinogen Levels in Type 1 Pre-Diabetes – A Novel Biomarker Associating with Disease Risk. *Diabetes Care*: 2017. doi: 10.2337/dc16-1774.
395. *Posgai, A.L.; Wasserfall, C.H.; Kwon, K.C.; Daniell, H.; Schatz, D.A.; **Atkinson, M.**: Plant-Based Vaccines for Oral Delivery of Type 1 Diabetes-Related Autoantigens: Evaluating Oral Tolerance Mechanisms and Disease Prevention in NOD Mice. *Scientific Reports*: 7:42372, 2017.
 396. *O’Kell, A. L.; Wasserfall, C.; Catchpole, B.; Davison, L. J.; Hess, R. S.; Kushner, J. A.; **Atkinson, M. A.**: Comparative Pathogenesis of Autoimmune Diabetes in Humans, NOD Mice, and Canines: Has a Valuable Animal Model of Type 1 Diabetes Been Overlooked?. *Diabetes*: 66(6): 1443-1452, 2017.
 397. Haller, M.; **Atkinson, M.**; Schatz, D.: Comment on: Intralymphatic Injection of Autoantigen in Type 1 Diabetes by Ludvigsson et al. *New England Journal of Medicine*: 377(4): 403, 2017.
 398. *Jacobsen, L. M.; Haller, M. J.; Parish, A.; Gurka, M. J.; Levine, S. R.; Wasserfall, C.; Campbell-Thompson, M.; Kaddis, J.; Pugliese, A.; **Atkinson, M. A.**; Schatz, D. A.: High Illicit Drug Abuse and Suicide in Organ Donors with Type 1 Diabetes. *Diabetes Care*: 2017 Sep;40(9):e122-e123. doi: 10.2337/dc17-0996.
 399. **Atkinson, M. A.**; Nierras, C. R.: Mary Tyler Moore (1936-2017): Diabetes Educator and Advocate. *Diabetes Care*: 40(6): 732-5, 2017.
 400. *Rodriguez-Calvo, T.; **Atkinson, M. A.**; von Herrath, M.: Beta cell mass versus function in type 1 diabetes: truth or dare?. *Nature Reviews Endocrinology*: 2017 Sep;13(9):1. doi: 10.1038/nrendo.2017.83.
 401. *Kemppainen, K. M.; Vehik, K.; Lynch, K. F.; Larsson, H. E.; Canepa, R. J.; Simell, V.; Koletzko, S.; Liu, E.; Simell, O.; Toppari, J.; Ziegler, A.; Rewers, M.; Lenmark, A.; Hagopian, W.; She, J.; Akolkar, B.; Schatz, D.; **Atkinson, M. A.**; Blaser, M. J.; Krischer, J. P.; Hyoty, H.; Agardh, D.; Triplett, E. W.; TEDDY Study Group: Association Between Early-Life Antibiotic Use and the Risk of Islet or Celiac Disease Autoimmunity. *JAMA Pediatrics*: 2017 Dec 1;171(12):1217-1225. doi:10.1001/jamapediatrics.2017.2905
 402. *Yip, L.; Fuhlbrigge, R.; **Atkinson, M.A.**; Fathman, C.G.: Impact of Blood Collection and Processing on Peripheral Blood Gene Expression Profiling for Type 1 Diabetes. *BMC Genomics*: 18:636, 2017.
 403. *Wasserfall, C.; Nick, H. S.; Campbell-Thompson, M.; Beachy, D.; Haataja, L.; Kusmartseva, I.; Posgai, A.; Rhodes, C.; Bonifacio, E.; Arvan, P.; **Atkinson, M.**: Persistence of Pancreatic Insulin mRNA Expression and Proinsulin Protein in Type 1 Diabetes Pancreata. *Cell Metabolism*: 2017 Sep 5;26(3):568-575.e3.
 404. *Nathan, B. M.; Boulware, D.; Geyer, S.; **Atkinson, M. A.**; Colman, P.; Goland, R.; Russel, W.; Wentworth, J.; Wilson, D. M.; Evans-Molina, C.; Wherrett, D.; Skyler, J. S.; Moran, A.; Sosenko, J. M.; Type 1 Diabetes TrialNet and Diabetes Prevention Trial of Type 1 Study Groups: Dysglycemia and Index60 as Pre-diagnostic Endpoints for Type 1 Diabetes Prevention Trials. *Diabetes Care*: 2017 Nov;40(11): 1494-1499. doi: 10.2337/dc17-0916.
 405. *O’Kell, A. L.; Garrett, T. J.; Wasserfall, C.; **Atkinson, M. A.**: Untargeted metabolomics analysis in naturally occurring canine diabetes mellitus. *Scientific Reports*: 2017 Aug 25;7(1): 9467.
 406. *Sanyoura, M.; Jacobsen, L.; Carmody, D.; del Gaudio, D.; Alkorta-Aranburu, G.; Arndt K.; Hu, Y.; Kobiernicki, F.; **Atkinson, M.**; Kusmartseva, I.; Philipson, L.; Schatz, D.; Campbell-Thompson, M.; Greeley, S. A. W.: Pancreatic Histopathology of Human Monogenic Diabetes Due to Causal Variants in KCNJ11, HNF1A, GATA6, and LMNA. *JCEM*: 2018 Jan 1;103(1): 35-45. doi.org/10.1210/jc.2017-01159.
 407. *Wan, H.; Merriman, C.; Wasserfall, C. H.; **Atkinson, M. A.**; Liang, Y.; Dai, H.: Proteioliposome-based full-length ZnT8 self-antigen for type 1 diabetes diagnosis on a plasmonic platform. *PNAS*: Sep

19;114(38): 10196-10201.

408. *Chen, J.; Chernatynskaya, A.; Li, J. W.; Kimbrell, M.; Cassidy, R.; Perry, D.; Muir, A.; Brusko, T.; **Atkinson, M.**; Mathews, C.: T cells display mitochondria hyperpolarization in human type 1 diabetes. Scientific Reports: 2017 Sep 7;7(1):10835. doi: 10.1038/s41598-017-11056-9.
409. Rodriguez-Calvo, T.; **Atkinson, M.**; von Herrath, M. T.: Response to Comment on Rodriguez-Calvo et al. Increase in Pancreatic Proinsulin and Preservation of β -Cell Mass in Autoantibody-Positive Donors Prior to Type 1 Diabetes Onset. Diabetes 2017;66:1334–1345. Diabetes: 66(9): e10-e11, 2017.
410. *Newby, B.; Brusko, T.; **Atkinson, M.**; Clare-Salzler, M.; Mathews, C.: Type 1 Interferons Potentiate Human CD8⁺ T Cell Cytotoxicity Through a pSTAT4 and Granzyme B Dependent Pathway. Diabetes: 2017 Dec;66(12): 3061-3071. doi: 10.2337/db17-0106.
411. *Wang, Q.; Racine, J.J.; Ratiu, J.J.; Wang, S.; Ettinger, R.; Wasserfall, C.; **Atkinson, M.A.**; Serreze, D.V.: Transient BAFF blockade inhibits type 1 diabetes development in NOD mice by enriching immunoregulatory B-lymphocytes sensitive to deletion by anti-CD20 co-therapy. Journal of Immunology: Dec 1;199(11): 3757-3770. doi: 10.4049/jimmunol.1700822.
412. *Newman, J.R.B.; Conesa, A.; Mika, M.; New, F.N.; Onengut-Gumuscu, S.; **Atkinson, M.A.**; Rich, S.S.; McIntyre, L.M.; Concannon, P.J.: Disease-specific Biases in Alternative Splicing and Tissue-Specific Dysregulation Revealed by Multitissue Profiling of Lymphocyte Gene Expression in Type 1 Diabetes. Genome Res: 2017 Nov;27(11): 1807-1815. doi: 10.1101/gr.217984.116
413. *Marcial, G. E.; Ford, A. L.; Haller, M. J.; Gezan, S. A.; Harrison, N. A.; Cai, D.; Meyer, J.; Perry, D. J.; **Atkinson, M. A.**; Wasserfall, C. H.; Garret, T.; Gonzalez, C. F.; Brusko, T. M.; Dahl, W. J.; Lorca, G. L.: *Lactobacillus johnsonii* N6.2 Modulates the Host Immune Response: A Double Blind, Randomized Trial in Healthy Adults. Front Immunol: 2017 Jun 12;8:655. doi: 10.3389/fimmu.2017.00655. eCollection 2017.
414. *Ratiu, J. J.; Racine, J. J.; Hasham, M. G.; Wang, Q.; Branca, J. A.; Chapman, H. D.; Zhu, J.; Donghia, N.; Philip, V.; Schott, W. H.; Wasserfall, C.; **Atkinson, M. A.**; Mills, K. D.; Leeth, C. M.; Serreze, D. V.: Genetic and Small Molecule Disruption of the AID/RAD51 Axis Protect NOD Mice from Type 1 Diabetes Through Expansion of Regulatory B-lymphocytes. Journal of Immunology: 2017 Jun 1; 198(11): 4255-4267. doi: 10.4049/jimmunol.1700024.
415. *Smith, M. J.; Rihanek, M.; Wasserfall, C.; Mathews, C. E.; **Atkinson, M. A.**; Gottlieb, P. A.; Cambier, J. C.: Loss of B Cell Anergy in Type 1 Diabetes is Associated with High Risk HLA and Non-HLA Disease Susceptibility Alleles. Diabetes: 2018 Apr;67(4): 697-703. doi: 10.2337/db17-0937.
416. *Brissova, M.; Haliyur, R.; Saunders, D.; Shrestha, S.; Dai, C.; Blodgett, D.; Bottino, R.; Campbell-Thompson, M.; Aramandla, R.; Poffenberger, G.; Pan, F.C.; Von Herrath, M.G.; **Atkinson, M.**; Harlan, D.M.; Levy, S.E.; Prasad, N.; Stein, R.; Powers, A.C.: α Cell Function and Gene Expression are Compromised in Type 1 Diabetes. Cell Reports: 2018 Mar 6;22(10): 2667-2676. doi: 10.1016/j.celrep.2018.02.032.
417. *Ostrov, D. A.; Alkanani, A.; McDaniel, K. A.; Case, S.; Baschal, E. E.; Pyle, L.; Ellis, S.; Seidl, K. J.; Shah, V. N.; Garg, S. K.; **Atkinson, M. A.**; Gottlieb, P. A.; Michels, A. W.: Methyldopa Blocks MHC Class II Binding to Disease-Specific Antigens in Autoimmune Diabetes. JCI: 2018 May 1;128(5):1888-1902. doi:10.1172/JCI97739.
418. *Bingley, P.; Wherrett, D.; Schultz, A.; Rafkin, L.; **Atkinson, M.**; Greenbaum, C.: Type 1 Diabetes TrialNet: a Multifaceted Approach to Bringing Disease-Modifying Therapy to Clinical Use in Type 1 Diabetes. Diabetes Care: 2018 Apr; 41(4): 653-661. doi: 10.2337/dc17-0806
419. *Sivakumar, R.; Abboud, G.; Mathews, C. E.; **Atkinson, M. A.**; Morel, L.: Protective Role of Myeloid Cells Expressing a G-CSF Receptor Polymorphism in an Induced Model of Lupus. Frontiers in Immunology:

2018; Volume 9, Article 1053. doi: 10.3389/fimmu.2018.01053.

420. *Perry, D.; Wasserfall, C.; Oram, R. A.; Williams, M. D.; Posgai, A.; Muir, A. B.; Haller, M.; Schatz, D.; Walleit, M. A.; Mathews, C. E.; **Atkinson, M.**; Brusko, T.: Application of a Genetic Risk Score to Racially Diverse Populations Demonstrates the Need for Diversity in Risk-Modeling. Scientific Reports: 2018 Mar 14;8(1):4529.
421. *Kusmartseva, I.; Beery, M.; Philips, T.; Selman, S.; Jadhav, P.; Wasserfall, C.; Muller, A.; Pugliese, A.; Longmate, J. A.; Schatz, D.; **Atkinson, M. A.**; Kaddis, J. S.: Hospital Time Prior to Death and Pancreas Histopathology: implications for future studies. Diabetologia: 2018 Apr;61(4): 954-958. doi: 10.1007/s00125-017-4494-x.
422. *Greenbaum, C. J.; Speake, C.; Krischer, J.; Buckner, J.; Gottlieb, P. A.; Schatz, D. A.; Herold, K. C.; **Atkinson, M. A.**: Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes—The TrialNet Experience. Diabetes: 2018 Jul; 67(7): 1216-1225. <https://doi.org/10.2337/db18-0065>.
423. *Canzano, J. S.; Nasif, N. H.; Butterworth, E. A.; Fu, D. A.; **Atkinson, M. A.**; Campbell-Thompson, M.: Islet Microvasculature Alterations with Loss of Beta-cells in Patients with Type 1 Diabetes. Journal of Histochemistry & Cytochemistry: 2018 May 1:22155418778546. doi: 10.1369/0022155418778546.
424. *Redondo, M. J.; Geyer, S.; Steck, A. K.; Sharp, S.; Wentworth, J. M.; Weedon, M. N.; Antinozzi, P.; Sosenko, J.; **Atkinson, M.**; Pugliese, A.; Oram, R. A.; Type 1 diabetes TrialNet Study Group: A type 1 diabetes genetic risk score predicts progression of islet autoimmunity and development of type 1 diabetes in individuals at risk. Diabetes Care: 2018 Jul; dc180087. <https://doi.org/10.2337/dc18-0087>.
425. *Tezza, S.; Ben Nasr, M.; D'Addio, F.; Vergani, A.; Uselli, V.; Falzoni, S.; Bassi, R.; Dellepiane, S.; Fotino, C.; Rossi, C.; Maestoni, A.; Solini, A.; Corradi, D.; Giani, E.; Mameli, C.; Bertuzzi, F.; Pezzolesi, M. G.; Wasserfall, C. H.; **Atkinson, M. A.**; Fuchtbauer, E. M.; Ricordi, C.; Folli, F.; Di Virgilio, F.; Pileggi, A.; Dhe-Paganon, S.; Zuccotti, G. V.; Fiorina, P.: Islet-derived eATP fuels autoreactive CD8+ cells and facilitates the onset of type 1 diabetes. Diabetes: 2018; 67(10): 2038-2053.
426. *Haller, M.J.; Schatz, D. A.; Skyler, J. S.; Krischer, J. P.; Bundy, B. N.; Miller, J. L.; **Atkinson, M. A.**; Becker, D. J.; Baidal, D.; DiMeglio, L. A.; Gitelman, S. E.; Goland, R.; Gottlieb, P. A.; Herold, K. C.; Marks, J. B.; Moran, A.; Rodriguez, H.; Russell, W.; Wilson, D. M.; Greenbaum, C. J.; Type 1 Diabetes TrialNet ATG-GCSF Study Group: Low-Dose Anti-Thymocyte Globulin Preserves β -Cell Function and Improves HbA_{1c} in New-Onset Type 1 Diabetes. Diabetes Care: 2018 Sep;41(9):1917-1925. <https://doi.org/10.2337/dc18-0494>.
427. *Dou, M.; Zhu, Y.; Liyu, A.; Liang, Y.; Chen, J.; Piehowski, P. D.; Xu, K.; Zhao, R.; Moore, R. J.; **Atkinson, M. A.**; Mathews, C. E.; Qian, W-J.; and Kelly, R. T.: Nanowell-Mediated Two-Dimensional Liquid Chromatography Enables Deep Proteome Profiling of <1000 Mammalian Cells. Chemical Science: 2018 Jul 18;9(34):6944-6951. DOI: 10.1039/C8SC02680G.
428. *Redondo, M. J.; Steck, A. K.; Sosenko, J.; Anderson, M.; Antinozzi, P.; Michels, A.; Wentworth, J. M.; **Atkinson, M. A.**; Pugliese, A.; Geyer, S.; Type 1 Diabetes TrialNet Study Group: Transcription Factor 7-Like 2 (*TCF7L2*) Gene Polymorphism and Progression from Single to Multiple Autoantibody Positivity in Individuals at Risk for Type 1 Diabetes. Diabetes Care: 2018 Dec;41(12):2480-2486. doi: 10.2337/dc18-0861
429. ***Atkinson, M. A.**; Roep, B. O.; Posgai, A.; Wheeler, D. C. S.; Peakman, M.: The Challenge of Modulating β -Cell Autoimmunity in Type 1 Diabetes. Lancet Diabetes and Endocrinology: 2019 Jan;7(1):52-64. DOI: [https://doi.org/10.1016/S2213-8587\(18\)30112-8](https://doi.org/10.1016/S2213-8587(18)30112-8).
430. *Ahmadov GA, Govender D, **Atkinson MA**, Sultanova RA, Eubova AA, Wasserfall CH, Mack SJ, Lane JA, Noble JA, Ogle GD. Epidemiology of childhood-onset type 1 diabetes in Azerbaijan: Incidence, clinical

- features, biochemistry, and HLA-DRB1 status. Diabetes Res Clin Pract: 2018 Oct;144:252-259. doi: 10.1016/j.diabres.2018.09.009.
431. *Yong, J.; Tian, J.; Dang, H.; Wu, T. T.; **Atkinson, M. A.**; Sun, R.; Kaufman, D. L.: Increased Risk for T Cell Autoreactivity to β -Cell Antigens in Mice Expressing the A^{vy} Obesity-Associated Gene. Scientific Reports: 2019 Mar 12;9(1):4269. doi: 10.1038/s41598-019-38905-z.
 432. *Triolo TM, Fouts A, Pyle L, Yu L, Gottlieb PA, Steck AK; Type 1 Diabetes TrialNet Study Group. Identical and Nonidentical Twins: Risk and Factors Involved in Development of Islet Autoimmunity and Type 1 Diabetes. Diabetes Care: 2019 Feb;42(2):192-199. doi: 10.2337/dc18-0288.
 433. *Campbell-Thompson ML, Filipp SL, Grajo JR, Nambam B, Beegle R, Middlebrooks EH, Gurka MJ, **Atkinson MA**, Schatz DA, Haller MJ. Relative Pancreas Volume Is Reduced in First-Degree Relatives of Patients With Type 1 Diabetes. Diabetes Care: 2019 Feb;42(2):281-287. doi: 10.2337/dc18-1512.
 434. *Bobe, A. R.; Miyoshi, J.; Moore, P.; Devkota, S.; Leone, V.; Martinez, K.; Theriault, B.; Musch, M.; Wasserfall, C.; **Atkinson, M.**; Chervonsky, A.; Rhodes, C. J.; Chang, E. B.: Development of Early-Stage Type 1 Diabetes in Germ-Free Interleukin-10 Deficient Mice. Scientific Reports: (in press).
 435. *Damond, N.; Engler, S.; Zanotelli, V. R. T.; Schapiro, D.; Wasserfall, C. H.; Kusmartseva, I.; Nick, H. S.; Thorel, F.; Herrera, P. L.; **Atkinson, M. A.**; Bodenmiller, B.: A Map of Human Type 1 Diabetes Progression by Imaging Mass Cytometry. Cell Metabolism: 2019 Mar 5;29(3):755-768.e5. doi: 10.1016/j.cmet.2018.11.014.
 436. *Wang, Y. J.; Traum, D.; Schug, J.; Gao, L.; Liu, C.; HPAP Consortium, **Atkinson, M. A.**; Powers, A. C.; Feldman, M. D.; Najj, A.; Chang, K-M.; Kaestner, K. H.: Multiplexed in situ imaging mass cytometry analysis of the human endocrine pancreas and immune system type 1 diabetes. Cell Metabolism: 2019 Mar 5;29(3):769-783.e4. doi: 10.1016/j.cmet.2019.01.003.
 437. *Dunne, J. L.; Richardson, S. J.; **Atkinson, M. A.**; Craig, M.; Dahl-Jorgensen, K.; Flodstrom-Tullberg, M.; Hyoty, H.; Insel, R. A.; Lernmark, A.; Lloyd, R.; Morgan, N. G.; Pugliese, A.: Rationale for Enteroviral Vaccination and Antiviral Therapies in Human Type 1 Diabetes. Diabetologia: 2019 May;62(5):744-753. doi: 10.1007/s00125-019-4811-7.
 438. Dunne, J. L., Richardson, S. J., **Atkinson, M. A.**, Craig, M. E., Jorgensen, K. D.; Floodstrom-Tullberg, M.; Hyoty, H.; Lloyd, R. E.; Morgan, N. G.; Pugliese, A.: Large enteroviral vaccination studies to prevent type 1 diabetes should be well founded and rely on scientific evidence. Reply to Skog O, Klingel K, Roivainen M et al [letter]. Diabetologia: 2019 June;62(6): 1100-1103. <https://doi.org/10.1007/s00125-019-4873-6>
 439. *Onengut-Gumuscu, S.; Chen, W. M.; Robertson, C.; Bonnie, J. K.; Farber, E.; Zhu, Z.; Oksenberg, J. R.; Brant, S. R.; Bridges, S. L.; Edberg, J. C.; Kimberly, R. P.; Gregersen, P. K.; Rewers, M. J.; Steck, A. K.; Black, M. H.; Dabelea, D.; Pihoker, C.; **Atkinson, M. A.**; Wagenknecht, L. E.; Divers, J.; Bell, R. A.; SEARCH for Diabetes in Youth, Type 1 Diabetes Genetics Consortium; Erlich, H. A.; Concannon, P.; Rich, S. S.: Type 1 diabetes risk in African-ancestry participants and utility of an ancestry-specific genetic risk score. Diabetes Care: 2019 Mar;42(3): 406-415. doi: 10.2337/dc18-1727.
 440. *Moin, A. S. M.; Montemurro, C.; Zeng, K.; Cory, M.; Nguyen, M.; Kulkarni, S.; Fritsch, H.; Meier, J.; Dhawan, S.; Rizza, R. A.; **Atkinson, M. A.**; Butler, A. E.: Characterization of Non-Hormone Expressing Endocrine Cells in Fetal and Infant Human Pancreas. Frontiers in Endocrinology: 2019 Jan 9;9:791. doi: 10.3389/fendo.2018.00791.
 441. *O'Kell, A. L.; Garrett, T. J.; Wasserfall, C.; **Atkinson M. A.**: Untargeted metabolomic analysis in non-fasted diabetic dogs. Metabolomics: (2019) 15: 15. doi: 10.1007/s11306-019-1477-6.
 442. *Fawwad, A.; Govender, D.; Ahmedani, M. Y.; Basit, A.; Lane, J. A.; Mack, S. J.; **Atkinson, M. A.**; Wasserfall, C. H.; Ogle, G. D.; Noble, J. A.: Clinical features, biochemistry and HLA-DRB1 status in

- youth-onset type 1 diabetes in Pakistan. Diabetes Research and Clinical Practice: 2019 Mar;149:9-17. doi: 10.1016/j.diabres.2019.01.023.
443. *Thompson, P. J.; Shah, A.; Ntranos, V.; Van Gool, F.; **Atkinson M.**; Bhushan, A.: Targeted Elimination of Senescent Beta Cells Prevents Type 1 Diabetes. Cell Metabolism: 2019 Feb 21; doi: 10.1016/j.cmet.2019.01.021.
 444. *Haller, M. J.; Long, A.; Blanchfield, J. L.; Schatz, D. A.; Skyler, J. S.; Krischer, J. P.; Bundy, B. N.; Geyer, S. M.; Warnock M. V.; Miller, J. L.; **Atkinson, M. A.**; Becker, D. J.; Baidal, D. A.; DiMeglio, L. A.; Gitelman, S. E.; Goland, R.; Gottlieb, P. A.; Herold, K. C.; Marks, J. B.; Moran, A.; Rodriguez, H.; Russell, W. E.; Wilson, D. M.; Greenbaum, C. J.; Type 1 Diabetes TrialNet ATG-GCSF Study Group: Low-dose Anti-Thymocyte Globulin Preserves C-Peptide and Reduces A1c in New Onset Type 1 Diabetes: Two Year Clinical Trial Data. Diabetes: 2019 Apr, db190057; DOI: 10.2337/db19-0057.
 445. *Kaestner, K. H.; Powers, A. C.; Naji, A.; HPAP Consortium, **Atkinson, M. A.**: NIH Initiative to Improve Understanding of the Pancreas, Islet, and Autoimmunity in Type 1 Diabetes— The Human Pancreas Analysis Program (HPAP). Diabetes: (in press).
 446. *Yi, L.; Tsai, C. F.; Dirice, E.; Swensen, A. C.; Chen, J.; Shi, T.; Gritsenko, M. A.; Chu, R. K.; Piehowski, P. D.; Smith, R. D.; Rodand, K. D.; **Atkinson, M. A.**; Mathews, C. E.; Kulkarni, R. N.; Liu, T.; Qian, W. J.: Boosting to Amplify Signal with Isobaric Labeling (BASIL) Strategy for Comprehensive Quantitative Phosphoproteomic Characterization of Small Populations of Cells. Anal Chem: 2019 Mar 15. doi: 10.1021/acs.analchem.9b00024.
 447. *Beery, M.; Jacobsen, L. M.; **Atkinson, M. A.**; Butler, A. E.; Campbell-Thompson, M.: Islet amyloidosis in a child with type 1 diabetes. Islets: 2019 May; doi: 10.1080/19382014.2019.1599707.
 448. *Redondo, M. J.; Evans-Molina, C.; Steck, A. K.; **Atkinson, M. A.**; Sosenko, J.: The Influence of Type 2 Diabetes-Associated Factors on Type 1 Diabetes. Diabetes Care: (in press).
 449. Kehlenbrink, S., Jaacks, L. M., on behalf of the Boston Declaration signatories: Diabetes in humanitarian crises: the Boston Declaration. Lancet Diabetes and Endocrinology: 2019 June; [http://dx.doi.org/10.1016/S2213-8587\(19\)30197-4](http://dx.doi.org/10.1016/S2213-8587(19)30197-4).
 450. Rosenstock, J.; Zimmet, P.; Skyler, J.; **Atkinson, M.**; Schatz, D.; Buse, J.B.; Kahn, S.; Hirsch, I.; Leroith, D.; Alberti, K.G.: Bringing Closure: Towards Achieving a Better Understanding on Israel. The Lancet: 2019 August 17;394(10198): P559. doi: 10.1016/S0140-6736(19)31760-X.
 451. *Ma, H.; Lu, Y.; Lowe, K.; van der Meijden-Erkelen, L.; Wasserfall, C.; **Atkinson, M.**; Song, S.: Regulated hAAT Expression from a Novel rAAV Vector and its Application in the Prevention of Type 1 Diabetes. Journal of Clinical Medicine: 28 Aug 2019. doi: 10.3390/jcm8091321.
 452. Ciecko, A.; Foda, B.; Barr, J.; Ramanathan, S.; **Atkinson, M.**; Serreze, D.; Geurts, A.; Lieberman, S.; Chen Y-G.: Interleukin 27 is essential for type 1 diabetes development and Sjogren syndrome-like inflammation. Cell Reports: 3 Dec 2019; 29: 3073-3086. doi: 10.1016/j.celrep.2019.11.010.
 453. Walker, A.F.; Atkinson, M.A.; Lee, A.M.; Ausilio, G.; Brusko, T.M.; Haller, M.J.; Schatz, D.A.: Teaching Type 1 Diabetes: Creating Stakeholder Engagement in Biomedical Careers through Undergraduate Research Curriculum. Medical Science Educator: 11 Dec 2019: 1-5. doi:10.1007/s40670-019-00877-0.
 454. Beam, C.A.; Wasserfall, C.; Woodwyck, A.; Akers, M.; Rauch, H.; Blok, T.; Mason, P.; Vos, D.; Perry, D.; Brusko, T.; Peakman, M.; **Atkinson, M.**: Synchronization of the Normal Human Peripheral Immune System: A Comprehensive Circadian Systems Immunology Analysis. Scientific Reports: 20 Jan 2020. 10:672. doi: 10.1038/s41598-019-56951-5.
 455. Procaccini, D.; Lin, S.; **Atkinson, M.A.**; Posgai, A.L.; Conroy, R.; Snyder, M: The Human Body at Cellular Resolution: The NIH Human BioMolecular Atlas Program. Nature: (in press).

456. Sims, E.K.; Geyer, S.; Johnson, S.B.; Libman, I.; Jacobsen, L.M.; Boulware, D.; Rafkin, L.E.; Matheson, D.; **Atkinson, M.A.**; Rodriguez, H.; Spall, M.; Larsson, H.E.; Wherrett, D.K.; Greenbaum, C.J.; Krischer, J.; DiMeglio, L.A.; Type 1 Diabetes TrialNet Study Group: Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention. Diabetes Care: (in press).
457. *Battaglia, M.; Ahmed, S.; Anderson, M.; **Atkinson, M.A.**; Becker, D.; Bingley, P.; Bosi, E.; Brusko, T.M.; Di Meglio, L.A.; Evans-Molina, C.; Gitelman, S.E.; Greenbaum, C.J.; Gottlieb, P.A.; Herold, K.C.; Hessner, M.J.; Knipp, M.J.; Jacobsen, L.; Krischer, J.P.; Long, A.S.; Lundgren, M.; McKinney, E.F.; Morgan, N.G.; Oram, R.A.; Pastinen, T.; Peters, M.C.; Petrelli, A.; Qian, X.; Redondo, M.J.; Roep, B.O.; Schatz, D.; Skibinski, D.; Peakman, M.: Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. Diabetes Care: (in press).
458. Jacobsen, L.M.; Bocchino, L.; Evans-Molina, C.; DiMeglio, L.; Goland, R.; Wilson, D.; Atkinson, M.A.; Aye, T.; Russell, W.E.; Wentworth, J.M.; Boulware, D.; Geyer, S.; Sosenko, J.M.: The Risk of Progression to Type 1 Diabetes is Highly Variable in Individuals with Multiple Autoantibodies Following Screening. Diabetologia: (in press).
459. Cardel, M.I.; **Atkinson, M.A.**; Taveras, E.M.; Holm, J.C.; Kelly, A.: The prevention and treatment of obesity among adolescents: challenges and opportunities. (in press).

CONSORTIUM BASED PUBLICATIONS

460. *Skyler, J.S.; Greenbaum, C.J.; Lachin, J.M.; Leschek, E.; Rafkin-Mervis, L.; Savage, P.; Spain, L.; **Type 1 Diabetes TrialNet Study Group**: Type 1 Diabetes TrialNet – An International Collaborative Clinical Trials Network. Ann N Y Acad Sci: 2008 Dec;1150:14-24. doi: 10.1196/annals.1447.054. PMID: 19120262.
461. *Mahon, J.L.; Sosenko, J.M.; Rafkin-Mervis, L.; Krause-Steinrauf, H.; Lachin, J.M.; Thompson, C.; Bingley, P.J.; Bonifacio, E.; Palmer, J.P.; Eisenbarth, G.S.; Wolfsdorf, J.; Skyler, J.S.; TrialNet Natural History Committee; **Type 1 Diabetes TrialNet Study Group**: The TrialNet Natural History Study of the Development of Type 1 Diabetes: Objectives, Design, and Initial Results. Pediatr Diabetes: 2009 Apr;10(2):97-104. doi: 10.1111/j.1399-5448.2008.00464.x. PMID: 18823409.
460. *Diabetes Research in Children Network (DirecNet) Study Group; **Type 1 Diabetes TrialNet Study Group**: Buckingham, B.A.; Beck, R.W.; Ruedy, K.J.; Cheng, P.; Kollman, C.; Weinzimer, S.A.; DiMeglio, L.A.; Bremer, A.A.; Slover, R.; Cantwell, M.: The Effects of Inpatient Hybrid Closed-loop Therapy Initiated within 1 Week of Type 1 Diabetes Diagnosis. Diabetes Technol Ther: 2013 May;15(5):401-408. doi: 10.1089/dia.2013.0002. PMID: 23570538.
461. *Moran, A.; Bundy, B.; Becker, D.J.; DiMeglio, L.A.; Gitelman, S.E.; Goland, R.; Greenbaum, C.J.; Herold, K. C.; Marks, J.B.; Raskin, P.; Sanda, S.; Schatz, D.; Wherrett, D.K.; Wilson, D.M.; Krischer, J.P.; Skyler, J.S.; **Type 1 Diabetes TrialNet Canakinumab Study Group**; Pickersgill, L.; de Koning, E.; Ziegler, A.G.; Böhm, B.; Badenhoop, K.; Schloot, N.; Bak, J.F.; Pozzilli, P.; Mauricio, D.; Donath, M.Y.; Castaño, L.; Wägner, A.; Lervang, H.H.; Perrild, H.; Mandrup-Poulsen, T.; AIDA Study Group: Interleukin-1 Antagonism in Type 1 Diabetes of Recent Onset: Two Multicentre, Randomised, Double-blind, Placebo-controlled Trials. Lancet: 2013 Jun 1;381(9881):1905-1915. doi: 10.1016/S0140-6736(13)60023-9. PMID: 23562090.
462. *Buckingham, B.; Beck, R.W.; Ruedy, K.J.; Cheng, P.; Kollman, C.; Weinzimer, S.A.; DiMeglio, L.A.; Bremer, A.A.; Slover, R.; Tamborlane, W.V.; Diabetes Research in Children Network (DirecNet) Study Group; **Type 1 Diabetes TrialNet Study Group**: Effectiveness of Early Intensive Therapy on β -cell Preservation in Type 1 Diabetes. Diabetes Care: 2013 Dec;36(12):4030-4035. doi: 10.2337/dc13-1074. PMID: 24130350.
463. *Pescovitz, M.D.; Greenbaum, C.J.; Bundy, B.; Becker, D.J.; Gitelman, S.E.; Goland, R.; Gottlieb, P.A.;

Marks, J.B.; Moran, A.; Raskin, P.; Rodriguez, H.; Schatz, D.A.; Wherrett, D.K.; Wilson, D.M.; Krischer, J.P.; Skyler, J.S.; **Type 1 Diabetes TrialNet Anti-CD20 Study Group**: B-lymphocyte Depletion with Rtuximab and β -cell Function: Two-year Results. Diabetes Care: 2014 Feb;37(2):453-459. doi: 10.2337/dc13-0626. PMID: 24026563.

464. *Orban, T.; Bundy, B.; Becker, D.J.; Dimeglio, L.A.; Gitelman, S.E.; Goland, R.; Gottlieb, P.A.; Greenbaum, C.J.; Marks, J.B.; Monzavi, R.; Moran, A.; Peakman, M.; Raskin, P.; Russell, W.E.; Schatz, D.; Wherrett, D.K.; Wilson, D.M.; Krischer, J.P.; Skyler, J.S.; **Type 1 Diabetes TrialNet Abatacept Study Group**: Costimulation Modulation with Abatacept in Patients with Recent-onset Type 1 Diabetes: Follow-up 1 year after Cessation of Treatment. Diabetes Care: 2014 Apr;37(4):1069-75. doi: 10.2337/dc13-0604. PMID: 24296850.
465. *Beam, C.A.; Gitelman, S.E.; Palmer, J.P.; **Type 1 Diabetes TrialNet Study Group**: Recommendations for the Definition of Clinical Responder in Insulin Preservation Studies. Diabetes: 2014 Sep;63(9):3120-7. doi: 10.2337/db14-0095. PMID: 24722251.
466. *Miao, D.; Steck, A.K.; Zhang, L.; Guyer, K.M.; Jiang, L.; Armstrong, T.; Muller, S.M.; Krischer, J.; Rewers, M.; Yu, L.; **Type 1 Diabetes TrialNet Study Group**: Electrochemiluminescence Assays for Insulin and Glutamic Acid Decarboxylase Autoantibodies Improve Prediction of Type 1 Diabetes Risk. Diabetes Technol Ther: 2015 Feb;17(2):119-27. doi: 10.1089/dia.2014.0186. PMID: 25562486.
467. *Loechelt, B.J.; Green, M.; Gottlieb, P.A.; Blumberg, E.; Weinberg, A.; Quinlan, S.; Baden, L.R.; **Type 1 Diabetes TrialNet Study Group**: Screening and Monitoring for Infectious Complications When Immunosuppressive Agents Are Studied in the Treatment of Autoimmune Disorders. J Pediatric Infect Dis Soc: 2015 Sep;4(3):198-204. doi: 10.1093/jpids/piu055. PMID: 26336066.
468. *Wherrett, D.K.; Chiang, J.L.; Delamater, A.M.; DiMeglio, L.A.; Gitelman, S.E.; Gottlieb, P.A.; Herold, K.C.; Lovell, D.J.; Orchard, T.J.; Ryan, C.M.; Schatz, D.A.; Wendler, D.S.; Greenbaum, C.J.; **Type 1 Diabetes TrialNet Study Group**: Defining Pathways for Development of Disease-modifying Therapies in Children with Type 1 Diabetes: a Consensus Report. Diabetes Care: 2015 Oct;38(10):1975-1985. doi: 10.2337/dc15-1429. PMID: 26404927.
469. *Bingley, P.J.; Boulware, D.C.; Krischer, J.P.; **Type 1 Diabetes TrialNet Study Group**: The Implications of Autoantibodies to a Single Islet Antigen in Relatives with Normal Glucose Tolerance: Development of Other Autoantibodies and Progression to Type 1 Diabetes. Diabetologia: 2016 Mar;59(3):542-9. doi: 10.1007/s00125-015-3830-2. PMID: 26676824.
470. *Pugliese, A.; Boulware, D.; Yu, L.; Babu, S.; Steck, A.K.; Becker, D.; Rodriguez, H.; DiMeglio, L.; Evans-Molina, C.; Harrison, L.C.; Schatz, D.; Palmer, J.P.; Greenbaum, C.; Eisenbarth, G.S.; Sosenko, J.M.; **Type 1 Diabetes TrialNet Study Group**: HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression. Diabetes: 2016 Apr;65(4):1109-1119. doi: 10.2337/db15-1105. PMID: 26822082.
471. *Cabrera, S.M.; Wang, X.; Chen, Y.G.; Jia, S.; Kaldunski, M.L.; Greenbaum, C.J.; **Type 1 Diabetes TrialNet Canakinumab Study Group**; Mandrup-Poulsen, T.; AIDA Study Group; Hessner, M. J.: Interleukin-1 Antagonism Moderates the Inflammatory State Associated with Type 1 Diabetes during Clinical Trials Conducted at Disease Onset. Eur J Immunol: 2016 Apr;46(4):1030-1046. doi: 10.1002/eji.201546005. PMID: 26692253.
472. *Moya, R.; Robertson, H.K.; Payne, D.; Narsale, A.; Koziol, J.; **Type 1 Diabetes TrialNet Study Group**; Davies, J.D.: A Pilot Study Showing Associations Between Frequency of CD4(+) Memory Cell Subsets at Diagnosis and Duration of Partial Remission in Type 1 Diabetes. Clin Immunol: 2016 May;166-167:72-80. doi: 10.1016/j.clim.2016.04.012. PMID: 27114212.

473. *DiMeglio, L.A.; Cheng, P.; Beck, R.W.; Kollman, C.; Ruedy, K.J.; Slover, R.; Aye, T.; Weinzimer, S.A.; Bremer, A.A.; Buckingham, B.; Diabetes Research in Children Network (DirecNet); **Type 1 Diabetes TrialNet Study Group**: Changes in Beta Cell Function During the Proximate Post-diagnosis Period in Persons with Type 1 Diabetes. Pediatr Diabetes: 2016 Jun;17(4):237-43. doi: 10.1111/pedi.12271. PMID: 25720763.
474. *Xu, P.; Krischer, J.P.; **Type 1 Diabetes TrialNet Study Group**: Prognostic Classification Factors Associated With Development of Multiple Autoantibodies, Dysglycemia, and Type 1 Diabetes-A Recursive Partitioning Analysis. Diabetes Care: 2016 Jun;39(6):1036-44. doi: 10.2337/dc15-2292. PMID: 27208341.
475. *Meah, F.A.; DiMeglio, L.A.; Greenbaum, C.J.; Blum, J.S.; Sosenko, J.M.; Pugliese, A.; Geyer, S.; Xu, P.; Evans-Molina, C.; **Type 1 Diabetes TrialNet Study Group**: The Relationship between BMI and Insulin Resistance and Progression from Single to Multiple Autoantibody Positivity and Type 1 Diabetes among TrialNet Pathway to Prevention Participants. Diabetologia: 2016 Jun;59(6):1186-1195. doi: 10.1007/s00125-016-3924-5. PMID: 26995649.
476. *Steck, A.K.; Fouts, A.; Miao, D.; Zhao, Z.; Dong, F.; Sosenko, J.; Gottlieb, P.; Rewers, M. J.; Yu, L.; **TrialNet Study Group**: ECL-IAA and ECL-GADA Can Identify High-Risk Single Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study. Diabetes Technol Ther: 2016 Jul;18(7):410-414. doi: 10.1089/dia.2015.0316. PMID: 26991969.
477. *Narsale, A.; Moya, R.; Robertson, H.K.; **Type 1 Diabetes TrialNet Study Group**; Davies, J.D.: Data on Correlations Between T Cell Subset Frequencies and Length of Partial Remission in Type 1 Diabetes. Data Brief: 2016 Aug 6;8:1348-51. doi: 10.1016/j.dib.2016.07.059. PMID: 27579340.
478. *Fouts, A.; Pyle, L.; Yu, L.; Miao, D.; Michels, A.; Krischer, J.; Sosenko, J.; Gottlieb, P.; Steck, A.K.; **Type 1 Diabetes TrialNet Study Group**: Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects? Diabetes Care: 2016 Oct;39(10):1738-1744. doi: 10.2337/dc16-0302. PMID: 27456836.
479. *Hao, W.; Gitelman, S.; DiMeglio, L.A.; Boulware, D.; Greenbaum, C.J.; **Type 1 Diabetes TrialNet Study Group**: Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose. Diabetes Care: 2016 Oct;39(10):1664-1670. doi: 10.2337/dc16-0360. PMID: 27422577.
480. *Durning, S.P.; Preston-Hurlburt, P.; Clark, P.R.; Xu, D.; Herold, K.C.; **Type 1 Diabetes TrialNet Study Group**: The Receptor for Advanced Glycation Endproducts Drives T Cell Survival and Inflammation in Type 1 Diabetes Mellitus. J Immunol: 2016 Oct 15;197(8):3076-3085. PMID: 27655844.
481. *Bundy, B.N.; Krischer, J.P.; **Type 1 Diabetes TrialNet Study Group**: A Model-based Approach to Sample Size Estimation in Recent Onset Type 1 Diabetes. Diabetes Metab Res Rev: 2016 Nov;32(8):827-834. doi: 10.1002/dmrr.2800. PMID: 26991448.
482. *Beam, C.A.; MacCallum, C.; Herold, K.C.; Wherrett, D.K.; Palmer, J.; Ludvigsson, J.; **Type 1 Diabetes TrialNet Study Group**: GAD Vaccine Reduces Insulin Loss in Recently Diagnosed Type 1 Diabetes: Findings from a Bayesian Meta-analysis. Diabetologia: 2017 Jan;60(1):43-49. PMID: 27704166.
483. *Ferrara, C.T.; Geyer, S.M.; Liu, Y.F.; Evans-Molina, C.; Libman, I.M.; Besser, R.; Becker, D.J.; Rodriguez, H.; Moran, A.; Gitelman, S.E.; Redondo, M.J.; **Type 1 Diabetes TrialNet Study Group**: Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development? Diabetes Care: 2017 May;40(5):698-701. doi: 10.2337/dc16-2331. PMID: 28202550.
484. *Liu, Y.; Rafkin, L.E.; Matheson, D.; Henderson, C.; Boulware, D.; Besser, R.E.J.; Ferrara, C.; Yu, L.; Steck, A.K.; Bingley, P.J.; **Type 1 Diabetes TrialNet Study Group**: Use of Self-Collected Capillary Blood Samples

for Islet Autoantibody Screening in Relatives: a Feasibility and Acceptability Study. Diabet Med: 2017 Jul;34(7):934-937. doi: 10.1111/dme.13338. PMID: 28226181.

485. *Bosi, E.; Boulware, D.C.; Becker, D.J.; Buckner, J.H.; Geyer, S.; Gottlieb, P.A.; Henderson, C.; Kinderman, A.; Sosenko, J.M.; Steck, A.K.; Bingley, P.J.; **Type 1 Diabetes TrialNet Study Group**: Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives. J Clin Endocrinol Metab: 2017 Aug 1;102(8):2881-2886. doi: 10.1210/jc.2017-00569. PMID: 28531305.
486. *Writing Committee for the **Type 1 Diabetes TrialNet Oral Insulin Study Group**; Krischer, J.P.; Schatz, D. A.; Bundy, B.; Skyler, J.S.; Greenbaum, C.J.: Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial. JAMA: 2017 Nov 21;318(19):1891-1902. doi: 10.1001/jama.2017.17070. PMID: 29164254.
487. *Ferrara, C.T.; Geyer, S.M.; Evans-Molina, C.; Libman, I.M.; Becker, D.J.; Wentworth, J.M.; Moran, A.; Gitelman, S.E.; Redondo, M.J.; **Type 1 Diabetes TrialNet Study Group**: The Role of Age and Excess Body Mass Index in Progression to Type 1 Diabetes in At-Risk Adults. J Clin Endocrinol Metab: 2017 Dec 1;102(12):4596-4603. doi: 10.1210/jc.2017-01490. PMID: 29092051.
488. *Ismail, H.M.; Xu, P.; Libman, I.M.; Becker, D.J.; Marks, J.B.; Skyler, J.S.; Palmer, J.P.; Sosenko, J.M.; **Type 1 Diabetes TrialNet Study Group**: The Shape of the Glucose Concentration Curve During an Oral Glucose Tolerance Test Predicts Risk for Type 1 Diabetes. Diabetologia: 2018 Jan;61(1):84-92. doi: 10.1007/s00125-017-4453-6. PMID: 28956083.
489. *Redondo, M.J.; Geyer, S.; Steck, A.K.; Sosenko, J.; Anderson, M.; Antinozzi, P.; Michels, A.; Wentworth, J.; Xu, P.; Pugliese, A.; **Type 1 Diabetes TrialNet Study Group**: *TCF7L2* Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes. Diabetes Care: 2018 Feb;41(2):311-317. doi: 10.2337/dc17-0961. PMID: 29025879.
490. *Sanda S.; **Type 1 Diabetes TrialNet Study Group**: Increasing ICA512 Autoantibody Titers Predict Development of Abnormal Oral Glucose Tolerance Tests. Pediatr Diabetes: 2018 Mar;19(2):271-276. doi: 10.1111/pedi.12542. PMID: 28707353.
491. *Evans-Molina, C.; Sims, E.K.; DiMeglio, L.A.; Ismail, H.M.; Steck, A.K.; Palmer, J.P.; Krischer, J.P.; Geyer, S.; Xu, P.; Sosenko, J.M.; **Type 1 Diabetes TrialNet Study Group**: β Cell Dysfunction Exists More Than 5 Years Before Type 1 Diabetes Diagnosis. JCI Insight: 2018 Aug 9;3(15). pii: 120877. doi: 10.1172/jci.insight.120877. PMID: 30089716.
492. *Tosur, M.; Geyer, S.M.; Rodriguez, H.; Libman, I.; Baidal, D.A.; Redondo, M.J.; **Type 1 Diabetes TrialNet Study Group**: Ethnic Differences in Progression of Islet Autoimmunity and Type 1 Diabetes in Relatives at Risk. Diabetologia: 2018 Sep;61(9):2043-2053. doi: 10.1007/s00125-018-4660-9. PMID: 29931415.
493. *Vecchio, F.; Lo Buono, N.; Stabilini, A.; Nigi, L.; Dufort, M.J.; Geyer, S.; Rancoita, P.M.; Cugnata, F.; Mandelli, A.; Valle, A.; Leete, P.; Mancarella, F.; Linsley, P.S.; Krogvold, L.; Herold, K.C.; Elding Larsson, H.; Richardson, S.J.; Morgan, N.G.; Dahl-Jørgensen, K.; Sebastiani, G.; Dotta, F.; Bosi, E.; DRI Biorepository Group; **Type 1 Diabetes TrialNet Study Group**; Battaglia, M.: Abnormal Neutrophil Signature in the Blood and Pancreas of Presymptomatic and Symptomatic Type 1 Diabetes. JCI Insight: 2018 Sep 20;3(18). pii: 122146. doi: 10.1172/jci.insight.122146. PMID: 30232284.
494. *Cabrera, S.M.; Engle, S.; Kaldunski, M.; Jia, S.; Geoffrey, R.; Simpson, P.; Szabo, A.; Speake, C.; Greenbaum, C.J.; **Type 1 Diabetes TrialNet CTLA4-Ig (Abatacept) Study Group**; Chen, Y.G.; Hessner, M.J.: Innate Immune Activity as a Predictor of Persistent Insulin Secretion and Association with Responsiveness to CTLA4-Ig Treatment in Recent-onset Type 1 Diabetes. Diabetologia: 2018 Nov;61(11):2356-2370. doi: 10.1007/s00125-018-4708-x. PMID: 30167736.

495. *Wentworth, J.M.; Bediaga, N.G.; Giles, L.C.; Ehlers, M.; Gitelman, S.E.; Geyer, S.; Evans-Molina, C.; Harrison, L.C.; **Type 1 Diabetes TrialNet Study Group**; Immune Tolerance Network Study Group: Beta Cell Function in Type 1 Diabetes Determined from Clinical and Fasting Biochemical Variables. Diabetologia: 2019 Jan;62(1):33-40. doi: 10.1007/s00125-018-4722-z. PMID: 30167735.
496. *Triolo, T.M.; Fouts, A.; Pyle, L.; Yu, L.; Gottlieb, P.A.; Steck, A.K.; **Type 1 Diabetes TrialNet Study Group**: Identical and Nonidentical Twins: Risk and Factors Involved in Development of Islet Autoimmunity and Type 1 Diabetes. Diabetes Care: 2019 Feb;42(2):192-199. doi: 10.2337/dc18-0288.
497. *Vaitaitis, G.M.; Rihanek, M.; Alkanani, A.K.; Waid, D.M.; Gottlieb, P.A.; Wagner, D.H.; **Type 1 Diabetes TrialNet Study Group**: Biomarker Discovery in Pre-Type 1 Diabetes; Th40 Cells as a Predictive Risk Factor. J Clin Endocrinol Metab: 2019 May 7. pii: jc.2019-00364. doi: 10.1210/jc.2019-00364. PMID: 31063181.
498. *Habib, T.; Long, S.A.; Samuels, P.L.; Brahmandam, A.; Tatum, M.; Funk, A.; Hocking, A.M.; Cerosaletti, K.; Mason, M.T.; Whalen, E.; Rawlings, D.J.; Greenbaum, C.; Buckner, J.H.; **Type 1 Diabetes TrialNet Study Group**: Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression. Diabetes: 2019 Jun;68(6):1240-1250. doi: 10.2337/db18-1081. PMID: 30894366.
499. *Acevedo-Calado, M.J.; Pietropaolo, S.L.; Morran, M.P.; Schnell, S.; Vonberg, A.D.; Verge, C.F.; Gianani, R.; Becker, D.J.; Huang, S.; Greenbaum, C.J.; Yu, L.; Davidson, H.W.; Michels, A.W.; Rich, S.S.; Pietropaolo, M.; **Type 1 Diabetes TrialNet Study Group**: Autoantibodies Directed to a Novel IA-2 Variant Protein Enhance Prediction of Type 1 Diabetes. Diabetes: 2019 Jun 5. pii: db181351. doi: 10.2337/db18-1351. PMID: 31167877.
500. *Herold, K.C.; Bundy, B.N.; Long, S.A.; Bluestone, J.A.; DiMeglio, L.A.; Dufort, M.J.; Gitelman, S.E.; Gottlieb, P.A.; Krischer, J.P.; Linsley, P.S.; Marks, J.B.; Moore, W.; Moran, A.; Rodriguez, H.; Russell, W.E.; Schatz, D.; Skyler, J.S.; Tsalikian, E.; Wherrett, D.K.; Ziegler, A.G.; Greenbaum, C.J.; **Type 1 Diabetes TrialNet Study Group**: An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. The New England Journal of Medicine: 2019 Jun 9. doi: 10.1056/NEJMoa1902226. PMID:31180194.

SUBMITTED OR IN REVISION

501. *Redondo, M. J.; Evans-Molina, C.; Steck, A. K.; **Atkinson, M. A.**; Sosenko, J.: Type 2 Diabetes Factors in the Pathogenesis of Type 1 Diabetes. (submitted).
502. *Mohamed, S. Z.; Lau, K.; Ardisson, A.; Bedoya, S. K.; Collins, E. L.; Wasserfall, C.; **Atkinson, M. A.**; Lorca, G.; Triplett, E. W.; Larkin, J.: Maturation of dendritic cells derived from type 1 diabetes-susceptible NOD mice is differentially regulated by two strains of generally regarded as safe (GRAS) Lactobacillus. (submitted).
503. *de Boer, P.; Pirozzi, N. M.; Wolters, A. H. G.; Kuipers, J.; Kusmartseva, I.; **Atkinson, M. A.**; Campbell-Thompson, M.; Giepmans, B. N. G.: Large-scale open access digital electron microscopy database for human type 1 diabetes. (submitted).
504. *HuBMAP Consortium: Mapping the Human Body at Cellular Resolution — The NIH Common Fund Human BioMolecular Atlas Program. (submitted). Pre-print version available at <https://arxiv.org/abs/1903.07231>.
505. *Zabeen, B.; Govender, D.; Hassan, Z.; Noble, J. A.; Lane, J. A.; Mark, S. J.; **Atkinson, M. A.**; Azad, K.; Wasserfall, C. W.; Ogle, G. D.: Clinical features, biochemistry and HLA-DRB1 status in children and adolescents with diabetes in Dhaka, Bangladesh. (submitted).
506. *Esakov, E.; Nandedkar-Kulkarni, N.; Gregg, B.; Gupta, N. K.; Bretz, J. D.; Balaji, S.; **Atkinson, M. A.**; Rogers, D.; Horner, J. D.; Singer, K.; Lundy, S. K.; McInerney, M. F.: Insulin receptor expressing T cells

appear in individuals at risk for diabetes and can move into the pancreas in C57BL/6 transgenic mice. (submitted).

507. *Russell, J. T.; Roesch, L. F. W.; Ördberg, M.; Ilonen, J.; **Atkinson, M. A.**; Schatz, D. A.; Triplett, E. W.; Ludvigsson, J.: Genetic risk for autoimmunity is associated with distinct changes in the human gut microbiome. (submitted).
508. *Sims, E. K.; Geyer, S.; Johnson, S. B.; Libman, I.; Jacobsen, L. M.; Boulware, D.; Rafkin, L. E.; Mattheson, D.; **Atkinson, M. A.**; Rodriguez, H.; Spain, L.; Spall, M.; Larsson, H. E.; Wherrett, D. K.; Greenbaum, C. J.; Krischer, J.; DiMeglio, L. A.; T1D TrialNet Study Group: Who is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention. (submitted).
509. *Lewis, J. S.; Stewart, J. M.; Marshall, G.P.; Carstens, M. R.; Zhang, Y.; Dolgova, N. V.; Xia, C. Q.; Brusko, T.; Wasserfall, C. H.; Clare-Salzler, M. J.; **Atkinson, M. A.**; Keselowsky B. G.: Dual-sized microparticle system generates suppressive dendritic cells, and prevents and reverses type 1 diabetes in the non-obese diabetic mouse. (submitted).
510. *Shapiro, M. R.; Wasserfall, C. H.; McGrail, S. M.; Posgai, A. L.; Muir, A.; Haller, M. J.; Schatz, D. A.; **Atkinson, M. A.**; Brusko, T. M.: Reduced Insulin-Like Growth Factors and Differential Modulation of Their Binding Proteins in Pre-Type 1 Diabetes. (submitted).
511. *Gier, B.; Matveyenko, A.V.; Kirakossian, D.; Parik, J.; **Atkinson, M.**; Butler, P.C.: Recovery of High Quality RNA From Laser Capture Microdissected Human and Rodent Pancreas. (submitted).
512. *Gagliani, N.; Jofra, T.; Valle, A.; Stabilini, A.; Gregori, S.; Deng, S.; Rothstein, D.M.; **Atkinson, M.**; Kamanaka, M.; Flavell, R.A.; Roncarolo, M.G.; Battaglia, M.: Murine Foxp3+ Treg and Tr1 Cells Split Their Responsibility for the Induction and Maintenance of Tolerance. (submitted).
513. *Gregori, S.; Gagliani, N.; Migliavacca, B.; Jofra, T.; Carballido, J.; Sanvito, F.; Olivieri, S.; Doglioni, C.; **Atkinson, M.**; Vries, J.; Korthauer, U.; Roncarolo, M.G.: In Vivo Mode of Action of Anti-Human CD45RO/RB Monoclonal Antibody in Humanized Model of Islet Transplantation. (submitted).
514. *Zhang, B.; Xia, S.L.; Pileggi, A.; **Atkinson, M.**; Song, S.: Human Alpha 1 Antitrypsin Increases Cellular cAMP and Calcium Levels and Enhances Insulin Secretion in Mouse Pancreatic Beta Cells. (submitted).
515. *Michels, A.W.; Michels, N.M.; Gottlieb, P.A.; Peters, B.; Sidney, J.; **Atkinson, M.A.**; Ostrov, D.A.: Peptides Corresponding to HLA-DQB10302 Stimulate IFN- γ Responses in HLA-DRB1*04-DQB1*0302 Diabetic Patients. (submitted).
516. ***Atkinson, M.A.**; Benton, T.; Meurer, D.: Medical Missions Travel for Healthcare Professionals – Lessons on The Law of Unintended Consequences. (submitted).
517. *Wasserfall, C.H.; Posgai, A.; Li, X.; **Atkinson, M.A.**: Translational Efforts in Type 1 Diabetes – Listening to the Coal Miner's Canary. (submitted).
518. *Ardissone, A.; Davis-Richardson, A.; Simell, V.; Kemppainen, K.; Schatz, D.; **Atkinson, M.**; Nurminen, N.; Mykkanen, J.; Ilonen, J.; Knip, M.; Toppari, J.; Hyoty, H.; Veijola, R.; Simell, T.; Simell, O.; Triplett, E.: Significant Gut Bacteria Associations with Autoimmunity for Type 1 Diabetes in a Large Pediatric Cohort. (submitted).
519. *Perry, D. J.; Saikumar Lakshmi, P.; Zhang, L.; Han, Z.; Mathews, C. E.; Wasserfall, C. W.; **Atkinson, M. A.**; Brusko, T. M.: Ectopic expression of the PTPN22 Autoimmune Risk Variant LYP-620W Fails to Restrain Human CD4+ T cell Activation. (submitted).
520. *Redondo, M. J.; Sosenko, J.; Libman, I.; McVean, J.; Tosur, M.; **Atkinson, M.**; Becker, D.; Geyer, S.; Type 1 Diabetes TrialNet Study Group: Differential Characteristics at Type 1 Diabetes Diagnosis by Number of

Positive Islet Autoantibodies. (submitted).

521. *Redondo, M.J.; Sosenko, J.; Libman, I.; McVean, J.; Tosur, M.; **Atkinson, M.A.**; Becker, D.; Geyer, S.; Type 1 Diabetes TrialNet Study Group: Single Islet Autoantibody Positivity at Type 1 Diabetes Diagnosis Associated with Older Age and Insulin Resistance at Onset. (submitted).
522. *Walejko, B.S.; Chelliah, A.; Keller-Wood, M.; Wasserfall, C.; **Atkinson, M.**; Gregg, A.; Edison, A.S.: Diabetes Leads to Alterations in Normal Metabolic Transitions of Pregnancy as Revealed by Time-Course Metabolomics. (submitted).
523. *Jacobsen, L.M.; Bundy, B.N.; Greco, M.N.; Schatz, D.A.; **Atkinson, M.A.**; Brusko, T.M.; Mathews, C.E.; Herold, K.C.; Gitelman, S.E.; Krischer, J.P.; Haller, M.J.: Comparison of Type 1 Diabetes Recent-Onset Intervention Trial Efficacy. (submitted).
524. *Qadir, M.M.F.; Weitz, J.; Cechin, S.; Álvarez-Cubela, S.; Tamayo, A.; Almaca, J.; Klein, D.; Hiller, H.; Beery, M.; Panzer, J.K.; Kusmartseva, I.; **Atkinson, M.**; Speier, S.; Ricordi, C.; Pugliese, A.; Caicedo, A.; Fraker, C.A.; Luis Pastori, R.L.; Domínguez-Bendala, J.: Long-term Culture of Human Pancreatic Slices as a Model to Study Real-time Islet Regeneration. (submitted).
525. *Walejko, J.; Chelliah, A.; Keller-Wood, M.; Wasserfall, C.; **Atkinson, M.**; Gregg, A.; Edison, A.S.: Diabetes Leads to Alterations in Normal Metabolic Transitions of Pregnancy as Revealed by Time-Course Metabolomics. (submitted).
526. *Qadir, M.; Weitz, J.; Cechin, S.; Alvarez-Cubela, S.; Tamayo, A.; Almaca, J.; Klein, D.; Hiller, H.; Beery, M.; Panzer, J.; Kusmartseva, I.; **Atkinson, M.**; Stephan, S.; Ricordi, C.; Pugliese, A.; Caicedo, A.; Fraker, C.; Pastori, R.; Dominguez-Bendala, J.: Long-term Culture of Human Pancreatic Slices as a Model to Study Tissue Regeneration in Real Time. (submitted).
527. *Cook, D. P.; Cunha, J. P. M. C. M.; Mancarella, F.; Ventriglia, G.; Sebastiani, G.; Vanherwegen, A.; **Atkinson, M.A.**; Van Huynegem, K.; Steidler, L.; Caluwaerts, S.; Rottiers, P.; Dotta, F.; Gysemans, C.; Mathieu, C.: Intestinal delivery of proinsulin and IL-10 via Lactococcus lactis combined with low-dose anti-CD3 restores tolerance outside the window of acute type 1 diabetes diagnosis. (submitted).
528. *Panzer, J.K.; Hiller, H.; Cohrs, C.M.; Almaca, J.; Enos, S.J.; Beery, M.; Cechin, S.; Drotar, D.M.; Weitz, J.R.; Santini, J.; Huber, M.K.; Qadir, M.M.F.; Pastori, R.L.; Domínguez-Bendala, J.; Phelps, E.A.; **Atkinson, M.A.**; Pugliese, A.; Caicedo, A.; Kusmartseva, I.; Speier, S.: Pancreas Tissue Slices from Organ Donors Enable In Situ Analysis of Type 1 Diabetes Pathogenesis. (submitted).
529. *Garrett, T.J.; Atkinson, P.; Quinlivan, E.Q.; Ang, L.; Hirsch, I.B.; Laffel, L.; Pietropaolo, M.; Haller, M.J.; **Atkinson, M.A.**: Commercially Available Human Insulin Products Demonstrate Stability Throughout the Cold Supply Chain across the United States. (submitted).
530. *Carr, A.L.J.; Perry, D.J.; Lynam, A.L.; Chamala, S.; Flaxman, C.S.; Sharp, S.A.; Ferrat, L.A.; Jones, A.G.; Beery, M.L.; Jacobsen, L.M.; Wasserfall, C.H.; Campbell-Thompson, M.L.; Kusmartseva, I.; Posgai, A.; Schatz, D.A.; **Atkinson, M.A.**; Brusko, T.M.; Richardson, S.J.; Shields, B.M.; Oram, R.A.: Histological Validation of a Type 1 Diabetes Clinical Diagnostic Model for Classification of Diabetes. (submitted).
531. *Renard, E.; Majidi, S.; Breton, M.; Akturk, H.; Courtet, P.; Olie, E.; Lal, R.; Naranjo, D.; Johnson, N.; **Atkinson, M.**; Barnard, K.: An Intolerable Burden – Suicide, Self-inflicted Injury, and Diabetes. (submitted).
532. *Neiman, D.; Gillis, D.; Pyanzin, S.; Cohen, D.; Fridlich, O.; Glasberg, S.; Avniel-Polak, S.; Zick, A.; Oron, J.T.; Korsgren, O.; Levy-Khademi, F.; Shapiro, A.M.J.; Greenbaum, C.; Hosford, J.; Posgai, A.; **Atkinson, M.A.**; Glaser, B.; Schatz, D.A.; Shemer, R.; Yuval Dor, Y.: Multiplexing DNA methylation markers to interrogate circulating cell-free DNA derived from human pancreatic beta-cells. (submitted).
533. *Redondo, M.J.; Sosenko, J.; Libman, I.; McVean, J.J.F.; Tosur, M.; Atkinson, M.A.; Becker, D.; Geyer, S.;

Type 1 Diabetes TrialNet Study Group: Single Islet Autoantibody at Diagnosis of Clinical Type 1 Diabetes is Associated with Older Age and Insulin Resistance. (submitted).

534. Sims, E.K.; Ismail, H.; Nathan, B.M.; Jacobsen, L.; Paprocki, E.; Palmer, J.; **Atkinson, M.**; Evans-Molina, C.; Skyler, J.; Sosenko, J.M.: Slower Progression to T1D in the Diabetes Prevention Trial-Type 1 (DPT-1) is Associated with Persistent β -cell Responsiveness in Children at High Risk for Type 1 Diabetes. (submitted).

* Peer reviewed.

BOOKS AND CHAPTERS IN BOOKS:

1. Excerpta Medica International Congress Series, The Immunology of Diabetes Mellitus, Scordis, N.; **Atkinson, M.A.**; Winter, W.E.; Beppu, H.; Riley, W.J.; and Maclaren, N.K.: The Effect of Diet on Incidence and Onset of Insulin Dependent Diabetes Mellitus. In: M.A. Jaworski et al (eds.): Elsevier Science, 1986, 319-324.
2. Molecular and Cellular Biology of Diabetes Mellitus, **Atkinson, M.A.**; and Maclaren, N.K.: Genetics of the Immune Response to Insulin. In: B. Draznin, S. Melmed, and D. LeRoith (ed.): Alan R. Liss, New York, New York, 183-192.
3. Prediabetes. Riley, W.J.; **Atkinson, M.A.**; and Maclaren, N.K.: Insulin autoantibodies in prediabetes. In: R.A. Camerini-Davalos and H.S. Cole (ed.) Plenum Press, New York, New York, 1989, 45-52.
4. Immunotherapy of Type 1 Diabetes. Maclaren, N.; Riley, W.; Silverstein, J.; Schatz, D.; **Atkinson, M.**: Progress Towards the Prevention of Insulin Dependent Diabetes. The Gainesville Studies. In: D. Andreani, H. Kolb, P. Pozzilli (eds): John Wiley and Sons Ltd, 1989, 147-154.
5. Immunosuppressive and Anti-inflammatory Drugs. Maclaren, N.; Muir, A.; Silverstein, J.; Song, Y.H.; She, X.I.; Krischer, J.; **Atkinson, M.**; and Schatz, D.: Early Diagnosis and Specific Treatment of Insulin-Dependent Diabetes. The Gainesville Studies. In: A.C. Allison, K.J. Lafferty, H. Fliri. (eds): The New York Academy of Sciences, New York, New York, 696: 1993, 147-154.
6. Prediction, Prevention, and Genetic Counseling in IDDM. **Atkinson, M.A.**: T Cell Markers. In: Palmer, J.P. (ed): John Wiley and Sons Ltd, 1996, 109-128.
7. NOD Mice and Related Strains: Research Applications in Diabetes, AIDS, Cancer and Other Diseases. E. Leiter, **M.A. Atkinson** (ed): R.G. Landes, Dallas 1998, 1-203.
8. NOD Mice and Related Strains: Research Applications in Diabetes, AIDS, Cancer and Other Diseases. M.A. Atkinson. NOD Mice as a Model for Therapeutic Interventions in Human Insulin Dependent Diabetes Mellitus. In: E. Leiter, **M.A. Atkinson** (ed): R.G. Landes, Dallas 1998, 145-162.
9. Atlas of Clinical Endocrinology. **M.A. Atkinson**. Type 1 Diabetes: Genetics, Epidemiology, and Pathogenesis. In: C.R. Kahn (vol. ed), S.G. Korenman (ser. Ed.): Current Medicine, Blackwell Science, Philadelphia 1999, 45-59.
10. Molecular Diagnosis of Infectious Diseases, Specifications for Immunological Testing for Infectious Diseases: Approved Guideline—Second Edition. Hannon, W.H.; Goldsmith, M.L.; **Atkinson, M.A.**; Ball, D.J.; Mattson, P.N.J., Whitley, R.J., NCCLS. 2001, 1-46.
11. Oxford Textbook of Endocrinology. **M.A. Atkinson**. The Immunology of Type 1 Diabetes. In: Shalet and Wass (chief ed), Gale (section ed): Oxford University Press, 2002, 1659-1670.
12. Atlas of Diabetes. **M.A. Atkinson**. Type 1 Diabetes. In: J. Skyler (vol. ed), A. Mirra (devp ed): Current Medicine, Philadelphia, Third Edition 2006, 57-76.
13. How Do We Best Employ Animal Models for Type 1 Diabetes and Multiple Sclerosis (Annals of the New

13. How Do We Best Employ Animal Models for Type 1 Diabetes and Multiple Sclerosis (Annals of the New York Academy of Sciences). von Herrath, M.; **Atkinson, M.**; Hafler, D.A.; Roep, B.O. (ed): Wiley-Blackwell, New Jersey 2007, 1-300.
14. Annals of the New York Academy of Sciences: Immunology of Diabetes V: From Bench to Bedside. Sanjeevi, C.B.; Schatz, D.A.; **Atkinson, M.A.** (ed): Wiley-Blackwell, New Jersey 2009, 1-352.
15. Type 1 Diabetes, An Issue of Endocrinology and Metabolism Clinics of North America. Schatz, D.A.; Haller, M.; **Atkinson, M.A.**: Saunders, Philadelphia 2010.
16. Type 1 Diabetes (Cold Spring Harbor Perspectives in Medicine). Bluestone, J.A.; **Atkinson, M.A.**; Arvan, P. (ed): Cold Spring Harbor Laboratory Press, New York 2012, 1-305.
17. Atlas of Clinical Endocrinology. **M.A. Atkinson**. Type 1 Diabetes: Genetics, Epidemiology, and Pathogenesis. In: J. Skyler (vol. ed), S.G. Korenman (ser. Ed.): Current Medicine, Blackwell Science, Philadelphia, volume II. (In Press).
18. Adeno-Associate Virus and Adeno-Associated Virus-based Vector Systems. Zhang, C.; Powers, M.; **Atkinson, M.A.**; Flotte, T.R.: Measurement of Humoral and Cell-Mediated Immune Responses to AAV Vector Administration. Humana Press. (In Press).
19. Adeno-Associated Viral Vectors for Gene Therapy. Laboratory Techniques in Biochemistry and Molecular Biology, Volume 31. Kapturczak, M.; Burkhardt, B.; **Atkinson, M.A.** Gene Therapy for Prevention and Treatment of Type 1 Diabetes. In: Flotte, T.R. and Berns, K.I. (ed), Elsevier 2005, 125-159.
20. The pancreas in human type 1 diabetes. Rowe, P.; Campbell-Thompson, M.; Schatz, D.; **Atkinson, M.A.** (Submitted)
21. Diabetes and Viruses. Pugliese, A.; Campbell-Thompson, M.; **Atkinson, M.A.** JDRF nPOD: a novel resource and study approach in type 1 diabetes research. (Submitted).
22. Williams Textbook of Endocrinology. **Atkinson, M.A.** Type 1 Diabetes. In: Melmed, S.; Polonsky, K.S.; Larsen, R.; Kronenberg, H.M (ed), Elsevier Health Sciences 2015, 1451-1483.

ABSTRACTS:

1. **Atkinson, M.A.**; Maclaren, N.K.; Riley, W.J.; Fisk, D.D.; Spillar, R.P.: Are Insulin Auto Antibodies, Markers For Insulin-Dependent Diabetes Mellitus? Int. Meet. Immunogenetics of Endo. Disorders, St. John's, Newfoundland, Canada, 1985.
2. Maclaren, N.K.; Riley, W.J.; **Atkinson, M.A.**: Inherited Susceptibility To Autoimmune Addison's Disease Is Linked To HLA-DR3 And/Or DR4, Except When Part Of Type 1 Autoimmune Polyglandular Syndrome. Int. Meet. Immunogenetics of Endo. Disorders. St. John's, Newfoundland, Canada, 1985.
3. **Atkinson, M.A.**; Fisk, D.D.; Spillar, R.P.: Insulin Autoantibodies as markers for Insulin Dependent Diabetes Mellitus. Diabetes 35; 346 (Suppl 1), 1986.
4. Beppu, H.; Winter, W.E; **Atkinson, M.A.**; Fujita, K.; Takahashi, H.: Immune Response to Bovine Serum Albumin (BSA) in NOD mice: Possible Relevance to Diabetes. Diabetes 35; 705 (Suppl 1), 1986.
5. **Atkinson, M.A.**; Winter, W.E; Beppu, H.; Riley, W.J.; Maclaren, N.K.: The Effect of Diet on Incidence and Time of Onset of Insulin Dependent Diabetes (IDD) in the BB Rat. Immunology of Diabetes, 6th Int. Imm. Conf. S 28. Edmonton, Alberta, Canada, 1986.
6. **Atkinson, M.A.**; Riley, W.J.; Gerling, I.; Baekkeskov, S.; Maclaren, N.K.; Lernmark, A.: Autoantibodies to an Immunoprecipitable 20 K Antigen in Addison's Disease. 4th Int Symp On Immunobiology of Proteins and Peptides. Las Vegas, Nevada, 1986.
7. **Atkinson, M.A.**; Riley, W.J.; Lernmark, A.; Gerling, I.; Maclaren, N.K.: Adrenal Cell Surface Autoantibodies in Addison's Disease Detected on a Murine Adrenocortical Cell Line. The Endocrine Society 69th Annual Meeting Indianapolis Indiana 1987

8. **Atkinson, M.A.**; Maclaren, N.K.; Klein, P.A.; Gerling, I.; Riser, M.E.; Lernmark, A.: Islet Cell Surface Autoantibodies (ICSA) Detected using Human Insulinoma Somatic Cell Hybrids: Evidence that Chromosomes 15, 17, and/or 20 are Required for Antigen Expression. Diabetes 36; 255 (Suppl 1), 1987.
9. **Atkinson, M.A.**; Riley, W.J.; Holmes, L.A.; Lernmark, A.; Maclaren, N.K.: Disease and Tissue Specificities for Immunoprecipitable Autoantibodies in IDD and Addison's Disease. Diabetes 37; 31A, 1988.
10. Maclaren, N.; Fisk, D.; Decker, P.; **Atkinson, M.**; Riley, W.: Optimized Insulin Radioligand to Detect Insulin Autoantibodies. Immunology and Diabetes Workshops. New York, New York, 1987.
11. **Atkinson, M.A.**; Maclaren, N.K.; Riley, W.J.; Scharp, D.W.; Holmes, L.: Mr 64,000 Autoantibodies (64KA) Predict Insulin Dependent Diabetes (IDD). Diabetes 37; 98A (Suppl 1), 1988.
12. Maclaren, N.K.; **Atkinson, M.A.**; Decker, P.; Fisk, D.D.: Insulin Autoantibodies (IAA) are Markers for Impending Insulin Dependent Diabetes (IDD). Diabetes 37; 98A (Suppl 1), 1988.
13. **Atkinson, M.A.**; Maclaren, N.K.; Luchetta, R.; Burr, I.: Prophylactic insulin therapy prevents Insulinitis and Insulin Dependent Diabetes (IDD) in Non-Obese Diabetic Mice. Diabetes 38:64A (Suppl 1), 1989.
14. **Atkinson, M.A.**; Luchetta, R.; Maclaren, N.K.; Scott, F.W.: Beta Cell Rest and Amelioration of Diabetes in NOD Mice. Symposia on Diet and IDDM. Canadian Health and Welfare Society. Ottawa, Canada, September, 1989.
15. **Atkinson, M.A.**; Maclaren, N.K.: Autoantibodies in Non-Obese Diabetic Mice Immunoprecipitate and Mr 64,000 Islet Cell Antigen. IX International Workshop on the Immunology of Diabetes, Satellite Symposium of the International Diabetes Federation. The Journal of Autoimmunity 3; 43, 1990.
16. **Atkinson, M.A.**; Maclaren, N.K.; Riley, W.J.; Scharp, D.W.; Holmes, L.: The Natural History and Predictive Value of Mr 64,000 Autoantibodies (64KA) for Insulin Dependent Diabetes (IDD). IX International Workshop on the Immunology of Diabetes, Satellite Symposium of the International Diabetes Federation. The Journal of Autoimmunity 3; 43, 1990.
17. Riley, W.J.; Maclaren, N.K.; **Atkinson, M.A.**; Scharp, D.; Lacy, P.: Islet Autoantibodies in "Prediabetes". IX International Workshop on the Immunology of Diabetes, Satellite Symposium on Beta Cell Destruction and Restoration in Type 1 Diabetes. The Journal of Autoimmunity 3; 87, 1990.
18. Maclaren, N.; Riley, W.; Krischer, J.; **Atkinson, M.**; Spillar, R.: Autoantibody prediction of Insulin Dependent Diabetes in Non-Diabetic Relatives with an Affected Proband. 10th International Diabetes Workshop, Immunology of Diabetes. March, 1989, Jerusalem, Israel.
19. **Atkinson, M.A.**; Holmes, L.A.; Laskowska, D.; Kastern, W.A.; Lang, F.P.; Maclaren, N.K.: ATP Specific-Serine Phosphorylation of the Mr 64,000 (64K) Islet Cell Autoantigen in Insulin Dependent Diabetes (IDD). Diabetes 39:70A (Suppl 1), 1990.
20. Holmes, L.; Laskowska, D.; **Atkinson, M.A.**: Biochemical Characterization of the Mr 64,000 (64K) Islet Cell Autoantigen in Insulin Dependent Diabetes (IDD). Diabetes 39:70A (Suppl 1), 1990.
21. **Atkinson, M.A.**; Holmes, L.A.; Laskowska, D.; Kastern, W.K.; Lang, F.P.; Scharp, D.W.; Lacy, P.E.; Maclaren, N.K.: Biochemical Characterization of the Mr 64,000 (64K) Islet Cell Autoantigen in Insulin Dependent Diabetes (IDD). Third International Meeting of the National Diabetes Research Interchange. September, 1989. Washington, DC.
22. Alsaeid, K.; Schiffenbauer, J.; **Atkinson, M.A.**; Ayoub, E.A.: Association of HLA-DR 4 Subtype Dw10 with Rheumatic Fever. The American Pediatric Society/Society for Pediatric Research Annual Meeting. May, 1991.
23. Tobin, A.J.; **Atkinson, M.A.**; BU, D.F.; Clare-Salzler, M.; Erlander, M.G.; Feldblum, S.; Houser, C.; Kaufman, D.F.; Maclaren, N.K.; Patel, N.; Pinal, C.; Tillakartne, N.J.K.: Autoantibodies in Insulin-Dependent Diabetes Recognize Two Form of Glutamate Decarboxylase, Which Derive From Two Genes. Diabetes 40:6A (Suppl 1), 1991.

24. Kaufman, D.L.; **Atkinson, M.A.**; Erlander, M.G.; Maclaren, N.K.; Tobin, A.J.: Glutamate Decarboxylase Autoantibodies in Insulin Dependent Diabetes Mellitus. Diabetes 40:7A (Suppl 1), 1991.
25. Jing, D.; Schatz, D.; Muir, A.; Luchetta, R.; Hao, W.; **Atkinson, M.**; Maclaren, N.: Insulin Autoantibodies Predict time of Onset of Diabetes in NOD Mice. The 11th International Immunology and Diabetes Workshop. November, 1991, Nagasaki, Japan.
26. Jing, D.; Muir, A.; Schatz, D.; Luchetta, R.; Hao, W.; **Atkinson, M.**; Maclaren, N.: Oral Administration of Insulin Prevents Diabetes in NOD mice. The 11th International Immunology and Diabetes Workshop. November, 1991, Nagasaki, Japan.
27. **Atkinson, M.A.**; Kaufman, D.L.; Campbell, L.; Gibbs, K.A.; Shah, S.C.; Bu, D.F.; Erlander, M.G.; Tobin, A.J.; Maclaren, N.K.: Peripheral Blood Mononuclear Cells Respond to Glutamate Decarboxylase in Insulin Dependent Diabetes. Diabetes 40: 39A (Suppl 1), 1992.
28. **Atkinson, M.**; Kaufman, D.; Erlander, M.; Tobin, A.; Brown, L.; Maclaren, N.: Identification of Islet Cell Cytoplasmic Autoantibodies in Insulin Dependent Diabetes are not Reactive to Glutamate Decarboxylase 65 or 67. Diabetes 40: 38A (Suppl 1), 1992.
29. Kaufman, D.L.; **Atkinson, M.A.**; Ting, J.; Robinson, P.; Tian, J.D.; Newman, D.; Erlander, M.G.; Kim, N.; Phan, T.; Maclaren, N.K.; Tobin, A.J.; Clare-Salzler, M.C.: Autoimmunity to Glutamate Decarboxylases GAD65 and GAD67. The Society for Neuroscience, 18:520.7 (Suppl 2), 1992.
30. **Atkinson, M.A.**; Campbell, L.; Kaufman, D.L.; Tian, J.D.; Maclaren, N.K.: Conformational Epitope Dependency for Islet Cell Autoantibodies Reactive to Glutamate Decarboxylase in Insulin Dependent Diabetes. The International Diabetes Federation-Immunology of Diabetes Symposia. 1993: Autoimmunity.
31. Huang, L.; **Atkinson, M.A.**; Dush, P.; Kennedy, R.T.: Electrochemical Monitoring of Individual Exocytosis Events in Pancreatic Beta Cells. Diabetes 42:77A (Suppl 1), 1993.
32. **Atkinson, M.A.**; Campbell, L.; Kaufman, D.L.; Tian, J.D.; Maclaren, N.K.: Conformational Epitope Dependency for Islet Cell Autoantibodies Reactive to Glutamate Decarboxylase in Insulin Dependent Diabetes. Diabetes 42:114A (Suppl 1) 1993.
33. Tian, J.; Lehmann, P.V.; Forsthuber, T.; Ting, G.S.P.; Newman, D.; **Atkinson, M.A.**; Sercarz, E.E.; Tobin, A.J.; Clare-Salzler, M.; Kaufman, D.L.: Spontaneous Loss of T Cell Self Tolerance to Glutamate Decarboxylase is a Key Event in the Pathogenesis of Murine Insulin-Dependent Diabetes. Society for Neuroscience Annual Meeting. November, 1993.
34. Kaufman, D.L.; Tian, J.; Lehmann, P.V.; Forsthuber, T.; Newman, D.; **Atkinson, M.**; Sercarz, E.E.; Tobin, A.J.; Clare-Salzler, M.: Induced Tolerance to Peptides of Glutamate Decarboxylase Prevents Murine Insulin Dependent Diabetes. Society for Experimental Biology Annual Meeting. April, 1994.
35. Gerling, I.C.; **Atkinson, M.A.**; Peck, A.B.; Cornelius, J.G.; Leiter, E.H.: Intrathymic (IT) Injection of a Glutamic Acid Decarboxylase Derived Peptide Accelerates Diabetes Onset in NOD/Lt Females. 13th International Immunology and Diabetes Workshop. May, 1994.
36. **Atkinson, M.**; Bowman, M.; Darrow, B.; Kaufman, D.; Maclaren, N.: Cellular Immunity to an Epitope Common to Glutamate Decarboxylase and Coxsackie Virus in Insulin Dependent Diabetes. 13th International Immunology and Diabetes Workshop. May, 1994.
37. Bowman, M.; Simmel, O.; Look, Z.; Luchetta, R.; **Atkinson, M.**: Pharmacokinetic and Therapeutic Analysis of Aminoguanidine in Non-Obese Diabetic Mice. 13th International Immunology and Diabetes Workshop. May, 1994.
38. Tian, J.; Kamarzarian, A.; Lehmann, P.V.; **Atkinson, M.**; Clare-Salzler, M.; Kaufman, D.: Induced Tolerance to Peptides of Glutamate Decarboxylase Prevents Murine IDDM. 13th International Immunology and Diabetes Workshop. May, 1994.
39. Daw, K.H.; Ujihara, N.; **Atkinson, M.**; Powers, A.C.: Epitope Mapping of GAD Antibodies in Individuals with

and without Diabetes. 13th International Immunology and Diabetes Workshop. May, 1994.

40. Maclaren, N.; Schatz, D.; Schott, M.; Wei, H.; Xiong She, J.; Pusateri, A.; Maclaren, S.; **Atkinson, M.**; Krischer, J.: The Predictability and Possible Prevention of Insulin Dependent Diabetes (IDD). 20th Annual Meeting of the International Society for Pediatric and Adolescent Diabetes. November, 1994.
41. **Atkinson, M.**; Bowman, M.; Darrow, B.; Kaufman, D.; Maclaren, N.: Cellular Immunity to an Epitope Common to Glutamate Decarboxylase and Coxsackie Virus in Insulin Dependent Diabetes. Diabetes 43:93A (Suppl 1), 1994.
42. Bowman, M.; Simmel, O.; Look, Z.; Luchetta, R.; **Atkinson, M.**: Pharmacokinetic and Therapeutic Analysis of Aminoguanidine in Non-Obese Diabetic Mice. Diabetes 43:235A (Suppl 1), 1994.
43. Tian, J.; Kamarzarian, A.; Lehmann, P.V.; **Atkinson, M.**; Clare-Salzler, M.; Kaufman, D.: Induced Tolerance to Peptides of Glutamate Decarboxylase Prevents Murine IDDM. Diabetes 43:93A (Suppl 1), 1994.
44. **Atkinson, M.**: Cellular and humoral immune responses to islet cell autoantigens in human IDDM. International Symposium of Type 1 (Insulin-Dependent) Diabetes, 1994.
45. Ellis, T.; Hanninen, A.; Simell, O.; **Atkinson, M.**: Cross-Fostering Influences the Progression of Insulinitis and Insulin Dependent Diabetes (IDD) in NOD Mice. Diabetes 43: A241 (Suppl 1), 1995
46. Ellis, T.; Darrow, B.; Campbell, L.; **Atkinson, M.**: Inverse relationship between Humoral and Cellular Immune Responses to Glutamate Decarboxylase 65 (GAD) and Insulin in IDD. Diabetes 43: A52 (Suppl 1), 1995.
47. Bowman, M.; Campbell, L.; Ellis, T.; Darrow, B.; Suresh, A.; Clare-Salzler, M.; **Atkinson, M.**: Immunologic and Metabolic Effects of Prophylactic Insulin Therapy in IDD. Diabetes A137 (Suppl 1).1995
48. Tian, J.; **Atkinson, M.**; Clare-Salzler, M.; Herschenfeld, A.; Middleton, B.; Kerfoot, C.; Chau, C.; Khadavi, M.; Kariya, E.; Chang, M.; Forsthuber, T.; Evans, C.; Lehmann, P.; Kaufman, D.: GAD Based Immunotherapies for Murine IDDM. Autoimmunity 21:A260, 1995.
49. Hansen, M.S.; Serreze, D.V.; **Atkinson, M.A.**; Singh, B.; Leiter, E.H.: Clonal Diversion of T Cell Responses from TH1 to TH2: A Possible Mechanism of Diabetes Resistance in NOD-Ea^d Transgenic Mice. Autoimmunity 21:A199, 1995.
50. Tian, J.; Herschenfeld, A.; **Atkinson, M.A.**; Clare-Salzler, M.; Middleton, B.; Chang, M.; Chau, C.; Kariya, E.; Mehrak, K.; Chau, H.; Pham, T.; Nisenberg, O.; Mullen, Y.; Lehmann, P.V.; Kaufman, D.L.: Autoimmunity to Glutamic Acid Decarboxylase (GAD) in Insulin Dependent Diabetes Mellitus. UCLA Symposium on Pancreatic Islet Cell Transplantation. December, 1996.
51. Aanstoot, H.J.; Kang, S.M.; Kim, J.; Knip, M.; **Atkinson, M.**; Ludvigsson, J.; Landin, M.; Bruining, J.; Maclaren, N.; Akerblom, H.K.; Baekkeskov, S.: Identification and Characterization of a 38kD with GAD65 and IA2 Marks the Early Phases of Autoimmune Response in Type 1 Diabetes. Diabetes 44: A81, 1996.
52. Roll, U.; Aanstoot, H.J.; Kang, S.M.; Knip, M.; **Atkinson, M.**; MoseLarsen, P.; Landin, M.; Bruining, J.; Maclaren, N.; Akerblom, H.K.; Baekkeskov S.: Identification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD(65) and IA2 marks the early phases of autoimmune response in type 1 diabetes. Molecular Biology of the Cell 7: 3468-3468, 1996.
53. **Atkinson, M.**; Gendreau, P.; Ellis, T.; Petitto, J.: NOD mice as a model for inherited deafness. Diabetologia 40: 868, 1997.
54. Ellis, T.M.; Schatz, D.; Ottendorfer, E.; Wasserfall, C.; Maclaren, N.K.; **Atkinson, M.A.**: Cellular Immune Reactivities Against Proinsulin in Insulin Dependent Diabetes. Diabetes 45: A195 (Suppl 1), 1997.
55. Ellis, T.; Schatz, D.; Lan, M.; Ottendorfer, E.; Wasserfall, C.; Notkins, A.; Maclaren, N.; **Atkinson, M.**: Relationship Between Humoral and Cellular Immunity to IA-2 in Insulin Dependent Diabetes. Diabetes 45:

55. Ellis, T.; Schatz, D.; Lan, M.; Ottendorfer, E.; Wasserfall, C.; Notkins, A.; Maclaren, N.; **Atkinson, M.**: Relationship Between Humoral and Cellular Immunity to IA-2 in Insulin Dependent Diabetes. Diabetes 45: A 347 (Suppl 1), 1997.
56. Ellis, T.M.; Schatz, D.; Lan, M.S.; Ottendorfer, E.; Wasserfall, C.; Notkins, A.L.; Maclaren, N.K.; **Atkinson, M.A.**: Relationship Between Humoral and Cellular Immunity to IA-2 in Insulin Dependent Diabetes. 16th International Diabetes Federation Congress, 1997.
57. Ellis, T.M.; Schatz, D.; Ottendorfer, E.; Wasserfall, C.; Maclaren, N.K.; **Atkinson, M.A.**: Cellular Immune Reactivities Against Proinsulin in Insulin Dependent Diabetes. 16th International Diabetes Federation Congress, 1997.
58. Schiffenbauer, J.; Xie, T.; Clare-Salzler, M.; **Atkinson, M.A.**: The Effect of Superantigen Administration on the Natural History of IDD in NOD Mice. 16th International Diabetes Federation Congress, 1997.
59. **Atkinson, M.**; Ellis, T.; Ottendorfer, E.; Jodoin, E.; Schatz, D.: Cellular and Humoral Immune Responses to Islet Cell Autoantigens in Individuals Undergoing Prophylactic Insulin Therapy for the Prevention of Diabetes. Diabetes, 47:A33, 1998.
60. Jodoin, E.; Ellis, T.; Ottendorfer, E.; Salisbury, P.; She, J.X.; Schatz, D.; **Atkinson, M.**: Cellular Immune Responses against β Casein: Elevated in but not Specific for Individuals with IDDM. Diabetes 47:A216, 1998.
61. Wasserfall, E.; Wilson, B.; Kent, S.; Hafler, D.; Strominger, J.; She, J.X.; Schatz, D.; **Atkinson, M.**; Ellis, T.: Increased Serum Interleukin-4 (IL-4) in IDDM: Evidence for Inheritance in Multiplex Families of a Trait Associated with Protection from Disease. Diabetes, 47:A217, 1998.
62. Sirninger, J.; Constadine, P.; Ottendorfer, E.; Tian, J.; Kaufman, D.; **Atkinson, M.**; Ellis, T.: No Acceleration or Attenuation of IDDM through Early Stimulation of Anti-Proinsulin Immunity in NOD Mice. Diabetes, 47:A216, 1998.
63. **Atkinson, M.**; Ellis, T.; Ottendorfer, E.; Jodoin, E.; Schatz, D.: Cellular and Humoral Immune Responses to Islet Cell Autoantigens in Individuals Undergoing Prophylactic Insulin Therapy for the Prevention of Diabetes. 3rd Meeting, International Diabetes Society, 1998.
64. Jodoin, E.; Ellis, T.; Ottendorfer, E.; Salisbury, P.; She, J.X.; Schatz, D.; **Atkinson, M.**: Cellular Immune Responses against β Casein: Elevated in but not Specific for Individuals with IDDM. 3rd Meeting, International Diabetes Society, 1998.
65. Wasserfall, E.; Wilson, B.; Kent, S.; Hafler, D.; Strominger, J.; She, J.X.; Schatz, D.; **Atkinson, M.**; Ellis, T.: Increased Serum Interleukin-4 (IL-4) in IDDM: Evidence for Inheritance in Multiplex Families of a Trait Associated with Protection from Disease. 3rd Meeting, International Diabetes Society, 1998.
66. Sirninger, J.; Constadine, P.; Ottendorfer, E.; Tian, J.; Kaufman, D.; **Atkinson, M.**; Ellis, T.: No Acceleration or Attenuation of IDDM through Early Stimulation of Anti-Proinsulin Immunity in NOD Mice. 3rd Meeting, International Diabetes Society, 1998.
67. Song, S.; Morgan, M.; Ellis, T.; Poirier, A.; Chesnut, K.; Wang, J.; Brantley, M.; **Atkinson, M.**; Byrne, B.; Flotte, T.: Sustained Secretion of Human Alpha-1-Antitrypsin from Murine Muscle Transduced with Adeno-Associated Virus Vectors. American Society of Gene Therapy, May 1998.
68. Ellis, T.M.; Wilson, S.B.; Wasserfall, C.; Kent, S.; Strominger, J.L.; Hafler, D.; **Atkinson, M.A.**: Potential Heterophilic Antibodies as a Confounding Variable to Measurement of Serum Interleukin-4 (IL-4). Diabetes 48:A210, 1999.
69. Ottendorfer, E.; Bahjat, K.; Clare-Salzler, M.; **Atkinson, M.A.**; Ellis, T.M.: No Alteration in T Lymphocyte Expression of CD40 Ligand (CD154) in Individuals with or at Increased Risk for Insulin-Dependent Diabetes Mellitus. Diabetes 48: A213, 1999.
70. Serreze, D.; Ottendorfer, E.; Gauntt, C.; Ellis, T.M.; **Atkinson, M.A.**: Acceleration of Insulin Dependent diabetes Mellitus by a Coxsackievirus Infection Requires a Preexisting Critical Mass of Autoreactive T cells

71. Qin, H.; Mahon, J.L.; Chaturvedi, P.; Ellis, T.M.; Wasserfall, C.; **Atkinson, M.A.**; Elliott, J.F.; Singh, B.: Glucose Regulated Protein (GRP94/HSP90a) Autoantibodies Correlate with Anti-GAD65 and ICA in Type 1 Diabetes. 4th Meeting, International Diabetes Society, 1999.
72. Marchase, R.B.; Chen, P.Y.; Su, Z.; Bounelis, P.; Ottendorfer, E.; Ellis, T.; Strominger, J.L.; Wilson, S.B.; **Atkinson, M.A.**; Blalock, J.E.: Lymphocytes from Subjects with Type 1 Diabetes Are Deficient in Capacitative Calcium Entry: Implications to Immune Function, Cytokine Production, and T cell subset representation. 4th Meeting, International Diabetes Society, 1999.
73. Falcone, M.; Wasserfall, C.; Jodoin, E.; Schatz, D.; Ellis, T.; **Atkinson, M.**: Cytokine Elaboration from Peripheral Blood Mononuclear Cells of Persons Participating in the Diabetes Prevention Trial-Type 1 (DPT-1). 4th Meeting, International Diabetes Society, 1999.
74. Serreze, D.; Ottendorfer, E.; Falcone, M.; Gauntt, C.; Ellis, T.; **Atkinson, M.**: Acceleration of Type 1 Diabetes by Coxsackieviral Infection requires a Pre-existing Critical Mass of Autoreactive T cells in Pancreatic Islets. 4th Meeting, International Diabetes Society, 1999.
75. Wasserfall, C; **Atkinson, M.**; Jodoin, E.; Schatz, D.; She, J.X., Ellis, T.: Glutamic Acid Decarboxylase (GAD) and IA-2 Autoantibodies in Type 1 Diabetes; Comparing Samples Substrates for Autoantibody determination. 4th Meeting, International Diabetes Society, 1999.
76. Song, S.; Wang, J.; Morgan, M.; Rhodin, N.; Ellis, T.; Flotte, T.; **Atkinson, M.**: Regulated High-Level Expression of Cytokines Interleukin-4 (IL-4) and IL-10 from Murine Muscle Transduced with Recombinant Adeno-Associated Virus (rAAV) Vectors. 4th Meeting, International Diabetes Society, 1999.
77. Aptsiauri, N.; Ellis, T.; Wasserfall, C.; Guy, J.; Heklenlively, J.; **Atkinson, M.**; Jodoin, E.: Glutamic Acid Decarboxylase (GAD) Autoantibodies in Patients with Autoimmune Retinopathies: CAR-Syndrome, Diabetic Retinopathy, and Retinitis Pigmentosa (RP) with Cystoid Macular Edema (CME). 4th Meeting, International Diabetes Society, 1999.
78. Wang, J.; Song, S.; Chesnut, K.; Ellis, T.; **Atkinson, M.**; Flotte, T.: Ex Vivo Transduction of Human Pancreatic Islet Cells With Recombinant Adeno-Associated Virus Vectors. Diabetes (Supplement 1) 49: A339, 2000.
79. Henderson, O.; **Atkinson, M.**; Bingley, P.; Bonifacio, E.; Bosi, E.; Ellis, T.; Eisenbarth, G.; Hagopian, W.; Hannu, W.H.; Jackson, R.; Lernmark, A.; Lou, D.; Mei, J.; Orban, T.; Smith, S.J.; Vogt, R.; Wasserfall, C.; Williams, A.; Yu, L.; and the DBSTAR workgroup. Dried Blood-Spots as a Matrix for Type-1 Diabetes Autoantibody Detection. Diabetes (Supplement 1) 49: A36, 2000.
80. Schatz, D.; Muir, A.; Fuller, K.; **Atkinson, M.**; Crockett, S.; Hsiang, H.; Winter, B.; Ellis, T.; Taylor, K.; Saites, C.; Dukes, M.; Fang, Q.; Clare-Salzler, M.; She, J-X.: Prospective Assessment in Newborns for Diabetes Autoimmunity (PANDA): A Newborn Diabetes Screening Program in the General Population of Florida. Diabetes (Supplement 1) 49: A67, 2000.
81. Ottendorfer, E.W.; Ellis, T.M.; **Atkinson, M.A.**; Serreze, D.V.: Diabetes Acceleration or Prevention by Coxsackie Virus Infection: Potential for Paradoxical Effects of Th1 and Th2 Cytokines. The NOD Mouse: Applications for Human Type 1 Diabetes. Winter Park, Colorado, 2000.
82. Bonifacio, E.; **Atkinson, M.A.**; Eisenbarth, G.S.; Kay, T.W.H.; Serreze, D.V.; Chan, E.L.; Singh, B.L.: Prevalence of Autoantibodies in NOD Mice Correlate with Age and Disease Status: Report of the First NOD Autoantibody Workshop. The NOD Mouse: Applications for Human Type 1 Diabetes. Winter Park, Colorado, 2000.
83. Peakman, M.; **Atkinson, M.**; Roep, B.; Honeyman, M.: The Second IDS Human T Cell Workshop – Phase II: Distribution of high quality islet autoantigen preparations for novel T cell assays. Diabetes Metabolism Research and Reviews 17 (Suppl. 1), S12, 2001.
84. Bonifacio, E.; **Atkinson, M.A.**; Eisenbarth, G.S.; Kay, T.W.H.; Serreze, D.V.; Chan, E.L.; Singh, B.L.: Prevalence of Autoantibodies in NOD Mice Correlate with Age and Disease Status: Report of the First

NOD Autoantibody Workshop. Diabetes Metabolism Research and Reviews 17 (Suppl. 1), S12, 2001.

85. Bonifacio, E.; Scirpoli, M.; **Atkinson, M.**; Eisenbarth, G.S.; Hagopian, W.; Harrison, L.; Knip, M.; Leslie, R.D.G.; Ziegler, A.; Workshop on GAD Antibody Isotypes and IgG Subclass Measurements. Diabetes Metabolism Research and Reviews 17 (Suppl. 1), S12 2001.
86. Kapturczak, M.; Zolotukhin, S.; Flotte, T.; Nick, H.; **Atkinson, M.**; Agarwal, A.: Transduction of Human and Murine Pancreatic Islet Cells Using a Bicistronic Recombinant Adeno-Associated Viral (rAAV) Vector. American Society for Gene Therapy, 2001.
87. Loiler, S.A.; Wang, J.; **Atkinson, M.**; Flotte, T.: Optimizing Promoter Expression and Transduction Efficiency of Human Islet Cells for the Treatment of Type I Diabetes. American Society for Gene Therapy, 2001.
88. Kapturczak, M.H.; Zolotukhin, S.; Flotte, T.; Nick, H.; **Atkinson, M.**; Agarwal, A.: Transduction of Human and Murine Pancreatic Islet Cells Using a Bicistronic Recombinant Adeno-Associated Viral (rAAV) Vector. American Diabetes Association, 61st Scientific Sessions, 2001.
89. Morales, A.; Anderson, J.; Jodoin, E.; Novak, D.; Schatz, D.; **Atkinson, M.**; Ellis, T.; Wasserfall, C.: Age Related Association of Autoantibodies to Tissue Transglutaminase in a US Population of Children and Persons with Type 1 Diabetes. American Diabetes Association, 61st Scientific Sessions, 2001.
90. Ottendorfer, E.W.; Ellis, T.M.; **Atkinson, M.A.**; Serreze, D.V.: Diabetes Acceleration or Prevention by Coxsackie Virus Infection: Potential for Paradoxical Effects of Th1 and Th2 Cytokines. American Diabetes Association, 61st Scientific Sessions, 2001.
91. Goudy, K.; Ellis, T.; Ottendorfer, E.; Song, S.; Wasserfall, C.; Flotte, T.; **Atkinson, M.**: Interleukin-10 Gene Therapy Utilizing Adeno-Associated Virus Vectors Prevents Type 1 Diabetes in NOD Mice. American Diabetes Association, 61st Scientific Sessions, 2001.
92. Wilson, S.B.; Ottendorfer, E.W.; Strominger, J.L.; Ellis, T.M.; **Atkinson, M.A.**: Development of Monoclonal Antibodies to V α 24J α Q T cells Detects Alterations in Cell Frequency in New-Onset Type 1 Diabetes Patients. American Diabetes Association, 61st Scientific Sessions, 2001.
93. Zhang, Y.C.; Molano, R.D.; Pileggi, A.; Powers, M.; Wasserfall, C.; Brusko, T.; Flotte, T.; Ellis, T.M.; Ricordi, C.; **Atkinson, M.A.**; Inverardi, L.: Adeno-Associated Virus Mediated Interleukin-10 Gene Therapy Inhibits Autoimmune Diabetes Recurrence in Syngeneic Islet Transplanted NOD Mice. American Diabetes Association, 62nd Scientific Sessions, 2002.
94. Zhang, Y.C.; Molano, R.D.; Pileggi, A.; Powers, M.; Wasserfall, C.; Brusko, T.; Flotte, T.; Ellis, T.M.; Ricordi, C.; Inverardi, L.; **Atkinson, M.A.**: Adeno-Associated Virus Mediated Interleukin-4 Gene Therapy Fails to Enhance Recurrence to Normoglycemia in Syngeneic Marginal Mass Islet Transplants. American Diabetes Association, 62nd Scientific Sessions, 2002.
95. Loiler, S.; Song, S.; **Atkinson, M.**; Muzyczka, N.; Flotte, T.R.: Enhanced Transduction of Pancreatic Islet Cells with Targeted Recombinant Adeno-Associated Virus Vectors. American Society for Gene Therapy, 2002.
96. Zhang, Y.C.; Molano, R.D.; Pileggi, A.; Powers, M.; Wasserfall, C.; Brusko, T.; Flotte, T.; Ellis, T.M.; Ricordi, C.; Inverardi, L.; **Atkinson, M.A.**: Adeno-Associated Virus Mediated Interleukin-10 Gene Therapy Inhibits Autoimmune Diabetes Recurrence in Syngeneic Islet Transplanted NOD Mice. American Society for Gene Therapy, 2002.
97. Zhang, Y.C.; Molano, R.D.; Pileggi, A.; Powers, M.; Wasserfall, C.; Brusko, T.; Flotte, T.; Ellis, T.M.; Ricordi, C.; Inverardi, L.; **Atkinson, M.A.**: Adeno-Associated Virus Mediated Interleukin-4 Gene Therapy Fails to Enhance Recurrence to Normoglycemia in Syngeneic Marginal Mass Islet Transplants. American Society for Gene Therapy, 2002.
98. Zhang, Y.C.; Molano, R.D.; Pileggi, A.; Powers, M.; Wasserfall, C.; Brusko, T.; Flotte, T.; Ellis, T.M.; Ricordi, C.; **Atkinson, M.A.**; Inverardi, L.: Adeno-Associated Virus Mediated Interleukin-10 Gene Therapy Inhibits Autoimmune Diabetes Recurrence in Syngeneic Islet Transplanted NOD Mice. American Society

for Transplantation, 2002.

99. Song, S.; Goudy, K.; Campbell-Thompson, M.; Wasserfall, C.; Scott-Jorgensen, M.; Wang, J.; Tang, Q., Crawford, J.M.; **Atkinson, M.A.**; Flotte, T.: Recombinant AAV Mediated Alpha 1 Antitrypsin Gene Therapy Prevents Type 1 Diabetes in NOD Mice. American Society for Gene Therapy, 2002.
100. Zhang, Y.C.; Molano, R.D.; Pileggi, A.; Powers, M.; Wasserfall, C.; Brusko, T.; Flotte, T.; Ellis, T.M.; Ricordi, C.; **Atkinson, M.A.**; Inverardi, L.: Adeno-Associated Virus Mediated Interleukin-4 Gene Therapy Fails to Enhance Recurrence to Normoglycemia in Syngeneic Marginal Mass Islet Transplants. American Society for Transplantation, 2002.
101. Chen, S.; Agarwal, A.; Glushakova, O.; Salgar, S.; Croker, B.; Madsen, K.M.; **Atkinson, M.A.**; Hauswirth, W.; Berns, K.I.; Tisher, C.C.: Gene Delivery in the Kidney using Recombinant Adeno-Associated Viral Vectors. American Society for Transplantation, 2002.
102. Womer, K.L.; Song, S.; Loiler, S.A.; Li, C.; **Atkinson, M.A.**; Flotte, T.R.; Clare-Salzler, M.: Murine Dendritic Cells Are More Efficiently Transduced by AAV Serotype 1 Vectors Compared With Other Serotypes. American Society for Transplantation, 2002.
103. Womer, K.L.; Song, S.; Loiler, S.A.; Li, C.; **Atkinson, M.A.**; Flotte, T.R.; Clare-Salzler, M.: Murine Dendritic Cells Are Transduced More Efficiently by rAAV Serotype 1 Vectors Compared With Other Serotypes. International Congress for Transplantation, 2002.
104. Flotte, T.R.; Loiler, S.; Conlon, T.J.; Song, S.; Wital, R.; Li, C.; Warrington, K.; **Atkinson, M.**; Petersen, B.; Muzyczka, N.: Capsid modifications enhance the efficiency of recombinant AAV-mediated gene transfer to liver stem cells (*ex vivo*) and mature hepatocytes (*in vivo*). Stem Cell Workshop for Alpha-One Antitrypsin Disease, 2002.
105. Chen, S.; Agarwal, A.; Glushakova, O.; Salgar, S.; Croker, B.P.; Madsen, K.M.; **Atkinson, M.A.**; Hauswirth, W.W.; Berns, K.I.; Tisher, C.C.: Gene Delivery in Renal Tubular Epithelial Cells Using Recombinant Adeno-Associated Viral Vectors. American Society of Nephrology 35th Annual Meeting & Scientific Exposition, 2002.
106. Chen, S.; Kapturczak, M.; Loiler, S.A.; Glushakova, O.; Li, C.; Hauswirth, W.W.; Berns, K.I.; Madsen, K.M.; Samulski, R.J.; Flotte, T.R.; **Atkinson, M.A.**; Tisher, C.C.; Agarwal, A.A.: Transduction of Human Aortic Endothelial and Smooth Muscle Cells with Recombinant Adeno-Associated Viral Vectors. American Society of Nephrology 35th Annual Meeting & Scientific Exposition, 2002.
107. Burkhardt, B.R.; Loiler, S.A.; Kilberg, M.S.; Crawford, J.M.; Flotte, T.R.; Goudy, K.; Ellis, T.M.; **Atkinson, M.A.**: Glucose-Responsive Expression of the Human Insulin Promoter In HEP-G2 Human Hepatoma Cells. 6th Annual Meeting of the Immunology of Diabetes Society, 2002.
108. Zhang, Y.C.; Pileggi, A.; Molano, R.D.; Zahr, E.; Poggioli, R.; Powers, M.; Wasserfall, C.; Brusko, T.; Jorgensen, M.S.; Thompson, M.C.; Crawford, J.M.; Flotte, T.; Ellis, T.M.; Ricordi, C.; **Atkinson, M.A.**; Inverardi, L.: Adeno-Associated Virus Medicated Interleukin-10 Gene Therapy Inhibits Autoimmune Diabetes Recurrence in Syngeneic Islet Transplanted NOD Mice. 6th Annual Meeting of the Immunology of Diabetes Society, 2002.
109. Y.C. Zhang, R.D. Molano, A. Pileggi, J. Cross, M. Powers, C. Wasserfall, M.S. Jorgensen, M.C. Thompson, J.M. Crawford, T. Flotte, T.M. Ellis, C. Ricordi, **M.A. Atkinson**, L. Inverardi, IL-4 Expressed from AAV Transduced Islet Grafts Fails to Improve the Reversal of Hyperglycemia in Syngeneic and Allogeneic Islet Transplantation Models. 6th Annual Meeting of the Immunology of Diabetes Society, 2002.
110. C. Wasserfall, J. Cross, K. Goudy, M. Kapturczak, M. Powers, T.M. Ellis, **M.A. Atkinson**. Anti-Insulin Immunity in NOD Mice, as Assessed by Insulin Autoantibodies, Associates with the Efficacy of Adoptive Transfer of Diabetes. 6th Annual Meeting of the Immunology of Diabetes Society, 2002.
111. K. Goudy, C. Wasserfall, B. Burkhardt, T. Brusko, E. Sobel, S. Song, T. Ellis, T. Flotte, **M. Atkinson**. Gene Therapy Using AAV-IL-10 Prevents Diabetes IN NOD MICE in a Dose and Time Dependent Fashion Through Immunoregulatory Enhancement. 6th Annual Meeting of the Immunology of Diabetes Society,

111. K. Goudy, C. Wasserfall, B. Burkhardt, T. Brusko, E. Sobel, S. Song, T. Ellis, T. Flotte, **M. Atkinson**. Gene Therapy Using AAV-IL-10 Prevents Diabetes IN NOD MICE in a Dose and Time Dependent Fashion Through Immunoregulatory Enhancement. 6th Annual Meeting of the Immunology of Diabetes Society, 2002.
112. Goudy, K.; Wasserfal, C.; Burkhardt, BA.; Brusko, T.; Song, S.; Ellis, T.; Flotte, T.; **Atkinson M.** Evaluation of mechanism, dose, and time, dependency for AAV-IL-10 gene therapy in NOD mice. *Diabetes* 51: 1159, 2002.
113. S.A. Loiler, T.J. Conlon, S. Song, K.H. Warrington, A. Agarwal, M. Kapturczak, C. Ricordi, **M. Atkinson**, N. Muzyczka, T.R. Flotte Targeting Adeno-Associated Virus (AAV) Vectors to Enhance Gene Therapy for Type I Diabetes. 6th Annual Meeting of the Immunology of Diabetes Society, 2002.
114. S. Song, K. Goudy, M. Campbell-Thompson, C. Wasserfall, M. Scott-Jorgensen, J. Wang, Q. Tang, J.M. Crawford, **M.A. Atkinson**, T.R. Flotte, Recombinant AAV Mediated Alpha-1 Antitrypsin Gene Therapy Prevents Type 1 Diabetes in NOD Mice. 6th Annual Meeting of the Immunology of Diabetes Society, 2002.
115. Loiler, S.A., Song, S., Warrington, K.H., Agarwal, A.; Kapturczak, M., **Atkinson, M.A.**, Muzyczka, N.; Flotte, T.R: Targeting Adeno-Associated Virus (AAV) Vectors to Enhance Gene Transfer. American Society for Microbiology, Banff, Alberta Canada, 2003.
116. Lu, Y.; Dang, H.; Middleton, B.; Zhang, Z.; Hanssen' L.; Campbell' M.; **Atkinson, M.**; Gambhir, S.; Tian, J.; Kaufman, D.: Repetitive microPET imaging of implanted human islets in mice. NIH Conference on Islet Imaging, 2003.
117. Loiler, S.A., Song, S., Warrington, K.H., Agarwal, A.; Kapturczak, M., **Atkinson, M.A.**, Muzyczka, N.; Flotte, T.R: Targeting Adeno-Associated Virus Vectors to Enhance Gene Transfer. Pediatric Academic Societies, 2003
118. Lernmark, A., Abdulahi, P.; Agardh, C.; **Atkinson, M.**; Cilio, C.; Essen-Moller, A.; Harris, R.A.; Hawa, M.; Kaufman, D.L.; Klareskog, L.; Leslie, D.R.; Letthagen, A.; Londei, M.; Lynch, K.; Palmer, M.; Robertson, J.A.; Tobin, A.J.: Phase II Clinical Trial Involving Alum-Formulated GAD65 Vaccination of GAD65-Autoantibody Positive Adult Diabetes Patients. American Diabetes Association, 63rd Scientific Sessions, 2003.
119. Tang, D.; Cao, L.; Burkhardt, B.; **Atkinson, M.**; Yang, L.: Derivation and Characterization of Functional Insulin-Producing Cells from Human and Mouse Bone Marrow-Derived Stem Cells. American Diabetes Association, 63rd Scientific Sessions, 2003.
120. Pearce, David A.; Wasserfall,, Clive H; Pritchard, Lane; Ellis, Tamir M.; Chattopadhyay, Subrata; **Atkinson, Mark A.**. Humoral Immune Markers of Type 1 Diabetes in the Patients with the Neurodegenerative Disorder Batten's Disease. American Diabetes Association, 63rd Scientific Sessions, 2003.
121. Chen, Sifeng; Kapturczak, Matthias; Loiler, Scott A.; Song, Sihong; Glushakova, Olena Y.; Li, Chengwen; Hauswirth, William W.; Berns, Kenneth I.; Madsen, Kirsten M.; Samulski, Richard J.; Flotte, Terence R.; **Atkinson, Mark A.**; Tisher, Craig C.; Agarwal, Anupam: Endothelial Cell Transduction with Recombinant Adeno-Associated Viral (AAV) Serotypes: Implications for Gene Therapy in Diabetic Macrovascular Complications. American Diabetes Association, 63rd Scientific Sessions, 2003.
122. Kapturczak, Matthias H.; Wasserfall, Clive H.; Loiler, Scott; Campbell-Thompson, Martha; Scott-Jorgensen, Marda; Cross, Jeff; Crawford, James M.; Ellis, Tamir M.; Flotte, Terence; **Atkinson, Mark A.**: Systemic Gene Therapy with Interleukin-10 (IL-10) for Prevention of Type 1 Diabetes in NOD Mice: Comparison of Mutant (I87A Substitution) to Recombinant Murine IL-10. American Diabetes Association, 63rd Scientific Sessions, 2003.
123. Wilson, S. Brian; Pritchard, Lane; Wasserfall, Clive; Clare-Salzer, Michael; **Atkinson Mark**: Temporal Alterations in the Frequency of VaJaQ T Cells in Type 1 Diabetes. American Diabetes Association, 63rd Scientific Sessions, 2003.

125. Goudy, Kevin; Burkhardt, Brant; Wasserfall, Clive; Sobel, Eric; Song, Sihong; Tamir, Ellis; Clare-Salzler, Michael; Flotte, Terence; **Atkinson, Mark**: Immunomodulation of Antigen Presenting Cells and Induction of Regulatory T Cells Prevents Type 1 Diabetes in NOD Mice Using AAV-IL10 Gene Therapy. American Diabetes Association, 63rd Scientific Sessions, 2003.
126. Burkhardt, Brant R.; Zhang, Y. C.; Anderson, Jo Ann; Loiler, Scott A.; Crawford, James M.; Flotte, Terence R.; Ellis, Tamir M.; **Atkinson, Mark A.**: Insulin Regulated Transgene Expression via Human Insulin Promoter Driven Recombinant Adeno-Associated Virus. American Diabetes Association, 63rd Scientific Sessions, 2003.
127. Morales, Alba E.; Wasserfall, Clive; Ellis, Tamir; **Atkinson, Mark**; Silverstein, Janet: Adiponectin and Cytokine Levels in Children with Diabetes. American Diabetes Association, 63rd Scientific Sessions, 2003.
128. Pileggi, A.; Molano, D.; Zhang, N.; Jorgensen, M.; **Atkinson, M.**; Inverardi, L.; Ricordi, C.; Agarwal, A.; Nick, H.: Recombinant Adeno-Associated Virus-Mediated Manganese Superoxide Dismutase Gene Delivery in Syngeneic Islet Transplantation. American Diabetes Association, 63rd Scientific Sessions, 2003.
129. Chen, S.; Kapturczak, M.; Wasserfall, C.; Glushakova, O.Y.; Zhang, L.; Cruz, P.; Campbell-Thompson, M.; Hauswirth, W.; Berns, K.; Madsen, K.M.; Croker, B.P.; **Atkinson, M.**; Flotte, T. R.; Tisher, C.; Agarwal, A.; Adeno-Associated Virus (type 1) Vector-Mediated Interleukin-10 Gene Delivery Attenuates Neointimal Proliferation in Rat Aortic Allografts. American Society of Nephrology 36th Annual Meeting and Scientific Exposition, 2003.
130. Kapturczak, M.; Wasserfall, C.; Ellis, T.; **Atkinson, M.**; Agarwal, A.; Heme Oxygenase-1 (HO-1) Modulates Early Inflammatory Responses: Evidence from the HO-1 Deficient Mouse. American Society of Nephrology 36th Annual Meeting and Scientific Exposition, 2003.
131. Zhang, Y.C.; **Atkinson, M.A.**: siRNA silencing of Fas on pancreatic islet cells for improving islet transplantation in diabetes. *Molecular Therapy* 7: 361, 2003.
132. Davoodi-Semiromi, A.; Litterland, S.; **Atkinson, M.**; She, JX.; Clare-Sazler, M.: Evaluation of Stat5b target genes in non-obese diabetic (NOD) mice by northern blot analysis and DNA microarray. *American Journal of Human Genetics* 73: 1041, 2003.
133. Cushman, J. D.; Wasserfall, C.; Huang, Z.; Ha, G.; Kapturczak, M.; Ellis, T.; **Atkinson, M.**; Petitto, J.; Immune reconstitution restores components of neurobehavioral performance in Recombinase Activation Gene-1 Knockout mice. Society for Neuroscience Meeting, 2003.
134. Zhnag, Y.C.; Pileggi, A.; Molano, R.D.; Wasserfall, C.; Campbell-Thompson, M.; Zahr, E.; Poggioli, R.; Brusko, T.; Flotte, T.; Ricordi, C.; **Atkinson, M.**; Inverardi, L.: Adeno-Associated Virus Mediated Interleukin-10 Gene Therapy Markedly Inhibits Islet Allograft Rejection in NOD Mice. American Diabetes Association, 64th Scientific Sessions, 2004.
135. Yang, L.; Tang, d.; Burkhardt, B.; Cao, L.; Litherland, S.; **Atkinson, M.**: Derivation of Functional Insulin Producing Cells from Mouse and Human Bone Marrow-Derived Stem Cells. American Diabetes Association, 64th Scientific Sessions, 2004.
136. Simon, GG.; Byrne, BJ.; **Atkinson, M.A.**: Modulation of the acute phase response by recombinant adeno-associated viral expression of the IL-1 type 1 soluble receptor. *Molecular Therapy* 9: S213, 2004.
137. Lu, Y.; Tang, M.; Wasserfall, C.; Choi, Y.; Gardmann, T.; Campbell-Thompson, M.; Ellis, T.; **Atkinson, M.**; Song, S.: Prevention of Type 1 Diabetes by Alpha 1 Antitrypsin Gene Therapy. American Diabetes Association, 64th Scientific Sessions, 2004.
138. Zhang, Y.C.; Burkhardt, B.R.; **Atkinson, M.A.**; Tang, Y.; Qian, K.; Shen, L.: Small Interference RNA Silencing of Fas on Cytokine-Stimulated Pancreatic Islet Cells for Improving Islet Transplantation and Preventing Islet Cell Loss. American Diabetes Association, 64th Scientific Sessions, 2004.
139. Wasserfall, C.H.; Huppmann, M.; Ziegler, A.G.; Schwartz, R.F.; Ellis, T.M.; **Atkinson, M.A.**; Bonifacio, E.:

Leptin Concentration and Body Mass Index are Increased at a Very Early Age in Obese Children. American Diabetes Association, 64th Scientific Sessions, 2004.

140. Loiler, S.A.; Tang, Q.; Perret-Gentil, M.; **Atkinson, M.A.**; Flotte, T.R.: Intrapancreatic Injections of Adeno-Associated Virus Vectors for Local Gene Expression. American Society of Gene Therapy, 2004.
141. Lu, YQ.; Tang, M.; Wasserfall, C.; Choi, YK.; Gardmann, T.; Campbell-Thompson, M.; Atkinson, MA.; Song, SH.: Alpha 1 antitrypsin gene delivery for preventing type 1 diabetes in NOD mice. Molecular Therapy 9: S164, 2004.
142. Lu, Y.; Dang, H.; Middleton, B.; Campbell-Thompson, M.; Ngo, D.; Slack, S.; Liang, C.; Khankan, R.; **Atkinson, M.A.**; Gambhir, S.S.; Tian, J.; Kaufman, D.; Noninvasive PET Imaging of Islets Implanted Into the Mouse Liver. Levine Symposium, 2004.
143. Guleria, I.; Eckenrode, S.; Ansari, M. J.; Azuma, M.; **Atkinson, M.A.**; She, J.X.; Sayegh, M.; PDL1 Regulates Autoimmunity by Limiting Expansion of Autoreactive Th1 Cells and Mediates Resistance to Diabetes in NOD Mice. FOCIS, 2005.
144. Caicedo, R.A.; Liboni, K.C.; Neu, M.; Li, N.; **Atkinson, M.A.**; Schatz, D.; Neu, J.; Intestinal Barrier Function and Inflammation in a Rodent Model of Type 1 Diabetes. Society for Pediatric Research, 2005.
145. Brusko, T.M.; Wasserfall, C.W.; **Atkinson, M.A.**; Dynamics of CD4+CD25+ T Cells and Soluble CD25 in Type 1 Diabetes. American Diabetes Association, 65th Scientific Sessions, 2005.
146. Loiler, S.A.; Tang, Q.; Clarke, T.; Campbell-Thompson, M.L.; Chiodo, V.; Hauswirth, W.; **Atkinson, M.A.**; Flotte, T.R.; Ramiya, V.K.: Intra-Pancreatic Gene Delivery to Induce Islet Regeneration Using Adeno-Associated Virus Vector Encoding Glucagon-Like Peptide-1. American Diabetes Association, 65th Scientific Sessions, 2005.
147. Young, D.L.; Chung, C.D.; Kreuwel, H.; Ramanujan, S.; **Atkinson, M.A.**; Bluestone, J.A.; Eisenbarth, G.S.; Mathis, D.; Rossini, A.A.; Shoda, L.: Comprehensive Analysis of Time-Dependent Effects for Treatment Outcomes in the NOD Mouse. American Diabetes Association, 65th Scientific Sessions, 2005.
148. Chung, C.D.; Shoda, L.; Kreuwel, H.; Ramanujan, S.; **Atkinson, M.A.**; Bluestone, J.A.; Eisenbarth, G.S.; Mathis, D.; Rossini, A.A.; Young, D.L.: A Comprehensive Analysis of Therapeutic Interventions in the NOD Mouse. American Diabetes Association, 65th Scientific Sessions, 2005.
149. Haller, M.; Cooper, S. Putnam, A.; Frees, B.; Brusko, T.; **Atkinson, M.A.**; Chase, P.; Schatz, D.; Autologous Cord Blood Transfusion Associated with Prolonged Honeymoon and Preserved C-Peptide in a Child with Type 1 Diabetes (T1D). American Diabetes Association, 65th Scientific Sessions, 2005.
150. Hubb, T.C.; Shoda, L.; Young, D.L.; Chung, C.D.; **Atkinson, M.A.**; Bluestone, J.A.; Eisenbarth, G.S.; Mathis, D.; Rossini, A.A.; Ramanujan, S.: Comparative Analysis of Therapies Tested in Animal Models of T1D and Human Clinical Trials. American Diabetes Association, 65th Scientific Sessions, 2005.
151. Stalvey, M.; Wasserfall, C.; Brusko, T.; Flotte, T.R.; Schatz, D.; **Atkinson, M.A.**: A Pro-Inflammatory State and Hyperglycemia are Associated with a Cystic Fibrosis Related Diabetes Mouse Model. American Diabetes Association, 65th Scientific Sessions, 2005.
152. Ramiya, V.K.; Viener, H.L.; Haller, M.J.; Liu, B.; **Atkinson, M.A.**; Schatz, D.A.: Differentiation of a Human Exocrine Pancreatic Duct-Derived Cell Line into Insulin-Expressing Cells. American Diabetes Association, 65th Scientific Sessions, 2005.
153. Stalvey, M.; Wasserfall, C.; Brusko, T.; Schatz, D.; **Atkinson, M.A.**; Flotte, T.R.; A Pro-Inflammatory State is Associated with Streptozotocin-Induced Hyperglycemia in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Knockout Mice. Lawson Wilkins Pediatric Endocrine Society, 2005.
154. Stalvey, M.; Muller, C.; Wasserfall, C.; Brusko, T.; Schatz, D.; **Atkinson, M.**; Flotte, T.; Modeling Cystic Fibrosis Related Diabetes in CFTR-Deficient Mice: Effects of CFTR Genotype on Glycemic Control After Sub-Lethal Beta Cell Injury or Pulmonary Sensitization and Challenge. Society for Pediatric Research,

2005.

155. Brusko, T.M.; Wasserfall, C.H.; Clare-Salzler, M.J.; Schatz, D.A.; **Atkinson, M.A.**: Functional defects and the influence of age on the frequency of CD4(+)CD25(+) T cells in type 1 diabetes. American Diabetes Association, 65th Scientific Sessions, 2005.
156. Tang, M.; Lu, Y.; Brusko, T.; Wasserfall, C.; Zhang, B.; Campbell-Thompson, M.; **Atkinson, M.A.**; Song, S.: Prevention of type 1 diabetes by AAT gene therapy is dose and time dependent. American Diabetes Association, 65th Scientific Sessions, 2005.
157. Campbell-Thompson, M.; Lee, C.H.; Wasserfall, C.H.; Reifsnyder, P.C.; Tenace, L.M.; Chen, J.; **Atkinson, M.A.**; Leiter, E.H.: Obesity and beta-cell regeneration in spontaneous leptin receptor mutation NOD/LtJ mice. American Diabetes Association, 65th Scientific Sessions, 2005.
158. Wasserfall, C.; Schwartz, R.F.; Simon, G.; Binns, S.; Brusko, T.; Stalvey, M.; Clare-Salzler, M.; Song, S.; Campbell-Thompson, M.; Flotte, T.; **Atkinson, A.**: Dichotomous Role for Interleukin-10 in the Pathogenesis of Type 1 Diabetes. American Diabetes Association, 65th Scientific Sessions, 2005.
159. Stalvey, M.; Muller, C.; Wasserfall, C.; Brusko, T.; Schatz, D.; **Atkinson, M.**; Flotte, T.R.: Modeling Cystic Fibrosis Related Diabetes In Cftr-Deficient Mice: Effects Of Cftr Genotype On Glycemic Control After Sub-Lethal Beta Cell Injury Or Pulmonary Sensitization And Challenge. North American Cystic Fibrosis Conference, 2005.
160. Kreuwel, H.T.C.; Shoda, L.K.M.; Young, D.L.; Chung, C.D.; **Atkinson, M.A.**; Stone, J.A.B.; Mathis, D.; Rossini, A.A.; Ramanujan, S.: Comparative analysis of therapies tested in animal models of type 1 diabetes and human clinical trials. American Diabetes Association's 65th Scientific Session, Diabetes 54: A26, 2005.
161. Simon, G.; Wasserfall, C.; Byrne, B.; **Atkinson, M.**: Adeno-Associated Viral Gene Therapy for the Prevention of Type 1 Diabetes in the NOD Mouse. 8th Annual Meeting of the Immunology of Diabetes Society, 2005. Japan.
162. Lee, C.H.; Chen, Y.G.; Chen, J.; Reifsnyder, P.C.; Serreze, D.V.; Clare-Salzler, M.; Rodriguez, M.; Wasserfall, C.; **Atkinson, M.A.**; Leiter, E.H.: Suppressed Autoimmunity in Leptin Receptor Mutated NOD-Lepr^{db-5j}/Lt Mice. 8th Annual Meeting of the Immunology of Diabetes Society, 2005. Japan.
163. Huerta, M.; Jaques, C.; Mendosa, P.; Schwartz, R.F.; Wasserfall, C.; Nadler, J.; **Atkinson, M.**: Decreased Adiponectin/Leptin ratio is Associated with Inflammation, Insulin Resistance and Endothelial and Monocyte Activation in Obese Children. American Diabetes Association, 66th Scientific Sessions, 2006.
164. Brusko, T.; Wasserfall, C.; **Atkinson, M.**: CD25 Stability Controls the In Vitro Suppressive Capacity of CD4+CD25+ Regulatory T Cells. American Diabetes Association, 66th Scientific Sessions, 2006.
165. Stalvey, M.; Schwartz, F.; Muller, C.; Brusko, T.; Wasserfall, C.; Schatz, D.; Flotte, T.; and **Atkinson, M.**: Increased Inflammatory Reactivity of Cystic Fibrosis Transmembrane Conductance Regulator Deficient (CFTR-/-) Mice Is Not Associated with Insulin Resistance. American Diabetes Association, 66th Scientific Sessions, 2006.
166. Zhang, B.; Lu, Y.; Campbell-Thompson, M.; Wasserfall, C.; **Atkinson, M.**; Song, S.: Alpha 1 antitrypsin protects against islet cell apoptosis. American Diabetes Association, 66th Scientific Sessions, 2006.
167. Guleria, I.; Dada, S.; Eckenrode, S.; Bupp, M.G.; Ansari, M.; Vadive, I.N.; Trikudanathan, S.; Fiorina, P.; Khosroshahi, A.; Yagita, H.; Azuma, M.; **Atkinson, M.**; She, J.X.; Bluestone, J.; Sayegh, M.: PDL1 regulates autoimmunity by limiting expansion of autoreactive Th1 cells and mediates resistance to diabetes in NOD mice. Clinical Immunology 119: S168, 2006.
168. Stalvey, M.; Pashuck, T.; Wasserfall, C.; **Atkinson, M.A.**; Flotte, T.R.: Cystic Fibrosis Related Diabetes Mouse Model Resembles Clinical Disease. North American Cystic Fibrosis Conference, 2006.
169. Stalvey, M.; Brusko, T.; Muller, C.; Schwartz, F.; Wasserfall, C.; Schatz, D.; **Atkinson, M.**; Flotte, T.: Increased Immune Responsiveness Following Streptozotocin induced Hyperglycemia In CFTR Knockout

169. Stalvey, M.; Brusko, T.; Muller, C.; Schwartz, F.; Wasserfall, C.; Schatz, D.; **Atkinson, M.**; Flotte, T.: Increased Immune Responsiveness Following Streptozotocin induced Hyperglycemia In CFTR Knockout Mice. Pediatric Academic Societies Meeting,
170. M Huerta, A. Weltman, C J, P Mendosa, S Street, HL Viener, G Francois, C Wasserfall, **M Atkinson**, J Silverstein, J Nadler: Role of Adipokines and Inflammation in the Development of Type 2 Diabetes in Adolescents. PAS meeting, 2007.
171. M Escobar-Douglas, **M Atkinson**, C Wasserfall, N Li, R Caicedo, J Neu, DA. Schatz: Sodium Butyrate Prevents Type 1 Diabetes in Biobreeding Diabetes Prone (BBdp) Rats. PAS meeting, 2007.
172. Constantinidis, I.; Flint, J.; Wasserfall, C.; Campbell-Thompson, M.; **Atkinson, M.**; Blackband, S.: MR Imaging of Islets and the Pancreas. American Diabetes Association's 67th Scientific Session, 2007.
173. Zhang B, Tang M, Wasserfall, C, **Atkinson M**, Song S.: Alpha 1 antitrypsin (AAT) inhibits granzyme B activity and NK cell killing. American Diabetes Association, 67th Scientific Sessions, 2007.
174. Campbell-Thompson, M.; Dixon, L.; Chen, M.; Monroe, M.; Wasserfall, C.H.; Mcguigan, J.M.; Crawford, J.M.; **Atkinson, M.A.**: Chronic Pancreatitis Increases Adult Beta Cell Replication. American Diabetes Association's 67th Scientific Session, 2007.
175. Haller MJ, Viener H, Brusko T, Wasserfall C, McGrail K, Staba S, Cogle C, **Atkinson M**, Schatz DA.: Insulin requirements, HbA1c, and stimulated C-peptide following autologous umbilical cord blood transfusion in children with T1D. American Diabetes Association, 67th Scientific Sessions, 2007.
176. Xue S, Loiler S, Lira A, Cruz P, Wasserfall C, Schatz D, Flotte T, **Atkinson M**, Ramiya V.: Reversal of Diabetes in Streptozotocin Induced Diabetic Mice Following Direct Intra-Pancreatic Gene Delivery of Adeno-Associated Virus Vector Encoding Glucagon-Like Peptide-1 (GLP-1). American Diabetes Association, 67th Scientific Sessions, 2007.
177. Viener H, Brusko T, Wasserfall C, McGrail K, Staba S, Cogle C, **Atkinson M**, Schatz DA, Haller MJ.: Changes in regulatory T cells following autologous umbilical cord blood transfusion in children with type 1 diabetes. American Diabetes Association, 67th Scientific Sessions, 2007.
178. Jie HB, Lin H, Lee H, Wilson B, Viener H, Brusko T, Wasserfall C, Clare-Salzler M, **Atkinson, MA.**: The critical roles of IL-2 in iNKT cell mediated tolerance. American Diabetes Association, 67th Scientific Sessions, 2007.
179. Brusko T, Wasserfall C, McGrail K, Huegel A, Moore M, Schatz D, **Atkinson M.**: Regulatory T cells require serum for suppression of effector T cell proliferation and express stable membrane-bound CD25. American Diabetes Association, 67th Scientific Sessions, 2007.
180. Huang, YF.; Parker, M.; Xia, CQ.; Peng, RH.; Wasserfall, C.; Clare-Salzler, M.; **Atkinson, M.**; Womer, K.: Murine anti-thymocyte globulin administration alters dendritic cell profile and function in NOD mice. American Journal of Transplantation 7: 414, 2007.
181. Pileggi, A.; Molano, RD.; Song, S.; Zahr, E.; San Jose, S.; Villate, S.; Wasserfall, C.; Ricordi, C.; **Atkinson, MA.**; Inverardi, L.: Effects of alpha-1 antitrypsin on islet allograft survival in spontaneously diabetic NOD mice. American Diabetes Association's 67th Scientific Session, Diabetes 56: A719-A720, 2007.
182. Song, S.; Pileggi, A.; Molano, RD.; Lu, Y.; Campbell-Thompson, M.; Wasserfall, CC.; Zahr, E.; Jose, SS.; Ricordi, C.; Inverardi, L.; **Atkinson, MA.**: Alpha 1 antitrypsin therapy does not prevent recurrence of autoimmunity in NOD mice. American Diabetes Association 67th Scientific Session, Diabetes 56: A525, 2007.
183. Song, SH.; Molano, RD.; Pileggi, A.; Lu YQ.; Wasserfall, C.; Campbell-Thompson, M.; Zahr, E.; Sanjose, S.; Ricordi, C.; **Atkinson, MA.**; Inverardi, L.: Islet allograft survival under systemic alpha 1 antitrypsin treatment: Comparison of gene therapy versus protein therapy. American Diabetes Association's 67th

184. Molano, RD.; Pileggi, A.; Song, SH.; Zahr, E.; Sanjose, S.; Wasserfall, C.; Ricordi, C.; **Atkinson, MA.**; Inverardi, L.: The role of humoral immunity in alpha 1 antitrypsi-mediated islet allograft survival prolongation. American Diabetes Association's 67th Scientific Session, Diabetes 56: A524, 2007.
185. Stalvey, M.; Brusko, T.; Muller, C.; Wasserfall, C.; Schatz, D.; Flotte, T.; **Atkinson, M.**: Hyperglycemia exacerbates TH2 immune reactivity in a cystic fibrosis related diabetes mouse model. Diabetes 56: A482, 2007.
186. Parker, M.; Wasserfall, C.; Campbell-Thompson, M.; Frances, P.; **Atkinson, M.**: Combination Therapy utilizing murine anti-thymocyte globulin (ATG) and rapamycin for the reversal of overt type 1 diabetes in NOD mice. Diabetes 56: A326, 2007.
187. Lu, YQ.; Zhang, B.; Choi, YK.; Campbell-Thompson, M.; Wasserfall, C.; Brantly, M.; **Atkinson, M.**; Song SH.: Induction of type 1 hypersensitivity in NOD mice subjected to alpha 1-antitrypsin (AAT) protein therapy. American Diabetes Association, 67th Scientific Sessions, Diabetes 56: A924, 2007.
188. Zhang, CY.; Kandeel, F.; Todorov, I.; **Atkinson, M.**; Lin, CL.; Forman, S.; Zeng, DF.: Elimination of insulinitis and augmentation of islet beta cell regeneration via induction of chimerism in overtly diabetic NOD mice. Clinical Immunology 123: S103-S104, 2007.
189. Pearson, T.; King, M.; Shultz, L.; Leif, J.; Greiner, D.; Mordes, J.; Rossini, A.; **Atkinson, M.**; Wasserfall, C.; Trucco, M.; Herold, K.; Botti, R.: Development of latest-generation HU-PBMC-NOD/SCID mice to study human islet allo-reactivity. Clinical Immunology 123: S69, 2007.
190. Tao, B.; Pietropaolo, M.; **Atkinson, M.**; Schatz, D.; Taylor, D.: A matching method for estimating the cost of type 1 diabetes in the U.S. 2nd Biennial Conference of the American Society of Health Economists, 2008. PMID: [PMC2901386]
191. Pileggi, A.; Molano, R.D.; SanJose, S.; Zahr, E.; Molina, J.; An, W.; Worley, J.; Gonzalez-Quintana, J.; **Atkinson, M.A.**; Ricordi, C.; Inverardi, L.: Targeted Bone Marrow Radioablation Enhances Hematopoietic Chimerism and Spontaneous Diabetes Onset in NOD Mice Treated with Anti-CD3 Antibody. American Diabetes Association's 68th Scientific Session, 2008.
192. Gianani, R.; Campbell-Thompson, M.; Wasserfall, C.; Pugliese, A.; Kent, S.; Hering, B.; West, E.; Steck, A.; Bonner-Weir, S.; Eisenbarth, G.; **Atkinson, M.**: Dimorphic Histopathology of Longstanding Childhood Diabetes. American Diabetes Association's 69th Scientific Session, 2009.
193. Ma, H.; Lu, Y.; Li, W.; Wasserfall, C.; Haller, M.; Campbell-Thompson, M.; Brantly, M.; Schatz, D.; **Atkinson, M.**; Song, S.: Prevention and Reversal of Type 1 Diabetes by Alpha 1 Antitrypsin (AAT) Given Intradermally in NOD Mice. American Diabetes Association's 69th Scientific Session, 2009.
194. Ramiya, V.; Wasserfall, C.; Xue, S.; Parker, M.; Haller, M.; Schatz, D.; **Atkinson, M.**: Combination Therapy with IL-2 and Rapamycin Reverses Type 1 Diabetes in Non-Obese Diabetic (NOD) Mice. American Diabetes Association's 69th Scientific Session, 2009.
195. Ize-Ludlow, D.; Luzardo, Y.; Wasserfall, C.; Schatz, D.; **Atkinson, M.**; Mathews, C.: Progressive Erosion of Beta Cell Function Precedes the Onset of Type 1 Diabetes in the NOD Mouse. American Diabetes Association's 69th Scientific Session, 2009.
196. Rowe, P.A.; Campbell-Thompson, M.; Wasserfall, C.H.; Martino, M.F.; Albanese-O'Neil, A.; Schatz, D.; **Atkinson, M.**: Network for Pancreatic Organ Donors with Type 1 Diabetes (nPOD): Progress and Donor Demographics. American Diabetes Association's 69th Scientific Session, 2009.
197. Zhang, B.; Wasserfall, C.; **Atkinson, M.**; Song, S.: Alpha 1-Antitrypsin (AAT) Enhances the Function of Pancreatic Beta-Cells. American Diabetes Association's 69th Scientific Session, 2009.

198. Bierschenk, L.; Alexander, J.; Wasserfall, C.; Haller, M.; Schatz, D.; **Atkinson, M.**: Suboptimal Vitamin D Levels Are Not Limited to Those with Type 1 Diabetes. American Diabetes Association's 69th Scientific Session, 2009.
199. Racine, J.; Zhang, C.; Wang, M.; Todorov, I.; Lin, C.L.; **Atkinson, M.**; Kandeel, F.; Forman, S.; Zeng, D.: Induction of mixed chimerism with MHC-mismatched but not matched BM transplants results in thymic deletion of de novo developed host-type autoreactive T cells in autoimmune NOD mice. 10th Annual Rachmiel Levine Diabetes and Obesity Symposium, 2010.
200. Han, Z.; Garrigan, E.; **Atkinson, M.**; Wasserfall, C.; Clare-Salzler, M.J.; Amick, M.; Litherland, S.A.: Epigenetic Dysfunction in Autoimmune Diabetes: Persistent Monocyte STAT5 Phosphorylation Promotes Epigenetic Dysregulation of GM-CSF-Induced PGS2/COX2 Expression in Type 1 Diabetes. American Diabetes Association's 70th Scientific Session, 2010.
201. Campbell-Thompson, M.; Rowe, P.A.; Wasserfall, C.H.; Pietras, R.; Albanese-O'Neill, A.; Gianani, R.; Schatz, D.; **Atkinson, M.A.**: Histopathology of Type 1 Diabetes in U.S. Organ Donors. American Diabetes Association's 70th Scientific Session, 2010.
202. Michels, A.W.; Ostrov, D.A.; Zhang, L.; Nakayama, M.; **Atkinson, M.A.**; Eisenbarth, G.S.: Identification of Small Molecules That Enhance Anti-Insulin Peptide T Cell Receptor Signaling and IL-10 Secretion. American Diabetes Association's 70th Scientific Session, 2010.
203. Parker, M.; Wasserfall, C.; Xue, S.; Campbell-Thompson, M.; Mathews, C.; Schatz, D.; Haller, M.; **Atkinson, M.**: Granulocyte Colony-Stimulating Factor Enhances Both ATG and Anti-CD3 mAb-Mediated Reversal of Type 1 Diabetes in NOD Mice. American Diabetes Association's 70th Scientific Session, 2010.
204. Myhr, C.; Wasserfall, C.; Haller, M.; Schatz, D.; **Atkinson, M.**: Unique Gene Expression Profiles from Peripheral Blood in Subjects with Type 1 Diabetes. American Diabetes Association's 70th Scientific Session, 2010.
205. Rowe, P.A.; Campbell-Thompson, M.; Wasserfall, C.; Martino, M.F.; Albanese-O'Neill, A.; **Atkinson, M.**; Schatz, D.: Clinical Findings in U.S. Organ Donors with Type 1 Diabetes Mellitus. American Diabetes Association's 70th Scientific Session, 2010.
206. Garrigan, E.; Han, Z.; Seydel, F.; Belkin, N.; Riggs, C.; Amick, M.; CdeBaca, A.; Pilant, T.; Bober, R.; Wasserfall, C.; **Atkinson, M.**; Clare-Salzler, M.J.; Morel, L.; McDuffie, M.; Litherland, S.A.: A Model for Studying the Impact of Nurture on Nature: Development of Diabetes in Multicongenetic Mice with an Epigenetic Gene Expression Dysregulation Defect from the Nonobese Diabetic Mouse (NOD). American Diabetes Association's 70th Scientific Session, 2010.
207. Rowe, P.A.; Wasserfall, C.; Martino, M.F.; Albanese-O'Neill, A.; Schatz, D.; **Atkinson, M.**: Islet Glucagon Staining in Pancreata from Diabetic Organ Donors May Be Inversely Related to In-Vivo β -Cell Insulin Function. American Diabetes Association's 70th Scientific Session, 2010.
208. Blanton, D.; Hong, P.; Alexander, J.J.; Myhr, C.; Han, Z.; Wasserfall, C.; Schatz, D.; **Atkinson, M.**: QRT-PCR and Custom Immune System Phenotyping Arrays for Characterizing Gene Expression in Type 1 Diabetes. American Diabetes Association's 70th Scientific Session, 2010.
209. Yip, L.; Creusot, R.J.; **Atkinson, M.**; Su, L.; Fathman, C. G.: Deaf1 Controls the Translation of Peripheral Tissue Antigens in PLN Stromal Cells by Regulating the Expression of eIF4G3 and Caspase 3. 2010.
210. Myhr, C.; Wasserfall, C.; Haller, M.J.; Schatz, D.A.; **Atkinson, M.**: IL-23/IL-17 Axis Profiling in Type 1 Diabetes. 2010.
211. Xue, S.; Wasserfall, C.; Savinov, A.; Mathews, C.; Haller, M.; Schatz, D.; Burn, P.; Rabinovitch, A.; **Atkinson, M.**: Combination Therapy Effectively Reverses Established Type 1 Diabetes in the NOD Mouse.

2010.

212. Cabrera, R.; Ararat, M.; Cao, M.; Xu, Y.; Wasserfall, C.; Brusko, T.; **Atkinson, M.A.**; Liu, C.; Nelson, D.R.: Sorafenib Modulates Immune Responses in Patients with Hepatocellular Carcinoma. American Association for Cancer Research, 2011.
213. Ararat, M.A.; Fitian, A.I.; Brusko, T.; Xu, Y.; Wasserfall, C.; **Atkinson, M.**; Liu, C.; Allegra, C.J.; Nelson, D.; Cabrera, R.: The Soluble Form of the IL-2 Receptor (sCD25) as a Novel Biomarker for Hepatocellular Carcinoma. American Society for Clinical Oncology, 2011.
214. Rowe, P.; Posgai, A.L.; Campbell-Thompson, M.; Wasserfall, C.; Martino, M.F.; Albanese-O'Neil, A.; Schatz, D.; **Atkinson, M.A.**: Islet Cell Autoantibody Reactivity on Pancreatic Tissue from Donors with Type 1 Diabetes. American Diabetes Association's 71st Scientific Session, 2011.
215. Donelan, E.; Li, Y.; Li, S.W.; Wang, H.; Wasserfall, C.; **Atkinson, M.**; Reeves W.; Winter, W.; Yang, L.J.: Detection of Pancreatic and Duodenal Homeobox 1 (Pdx1) Autoantibodies Using LIPS (Luciferase Immunoprecipitation System) Assay. American Diabetes Association's 71st Scientific Session, 2011.
216. Rowe, P.; Campbell-Thompson, M.; Wasserfall, C.; Fernanda-Martino, M.; Kaddis, J.; Eisenbarth, G.; Gianani, R.; Albanese-O'Neil, A.; **Atkinson, M.**: Correlation of Pancreatic Histopathology in U.S. Organ Donors with Type 1 Diabetes of Longstanding Duration. American Diabetes Association's 71st Scientific Session, 2011.
217. Hulme, M.A.; Wasserfall, C.H.; Brusko, T.M.; Haller, M.J.; Schatz, D.A.; Ostrov, D.A.; **Atkinson, M.A.**: Small Molecule Modification of the IL-2 Receptor: Implications for Therapy in Type 1 Diabetes. American Diabetes Association's 71st Scientific Session, 2011.
218. Myhr, C.; Wasserfall, C.; Schatz, D.; Haller, M.; **Atkinson, M.**: Th1 and Th17 Associated Gene Expression Profiles in Subjects with Type 1 Diabetes. American Diabetes Association's 71st Scientific Session, 2011.
219. Coppieters, K.; Wiberg, A.; Amirian, N.; Kent, S.; Kay, T.W.H.; Campbell, P.D.; **Atkinson, M.A.**; Frisk, G.; Tracy, S.; Hebrok, M.G.: MHC Class I on Pancreatic Islets from Longstanding Diabetes Patients: Persistent Hyperexpression is Restricted to Type 1 Diabetes and Does Not Correlate with Enteroviral Infection, Infiltration or Insulin Depletion. American Diabetes Association's 71st Scientific Session, 2011.
220. Han, Z.; Whitener, R.; **Atkinson, M.A.**; Haller, M.J.; Schatz, D.A.; Bluestone, J.A.; Brusko, T.M.: Generation of Antigen-Specific Regulatory T Cells from Human Umbilical Cord Blood. American Diabetes Association's 71st Scientific Session, 2011.
221. Xue, S.; Wasserfall, C.; Brusko, T.; Mathews, C.; Burn, P.; Schatz, D.; **Atkinson, M.**; Haller, M.: Multi-Drug Combination Therapy Increases the Frequency of Regulatory T- and B-Cells in NOD Mice with Established Disease. American Diabetes Association's 71st Scientific Session, 2011.
222. Xue, S.; Wasserfall, C.; Parker, M.; Mathews, C.; Burn, P.; Rabinovitch, A.; Savinov, A.; Schatz, D.; **Atkinson, M.**; Haller, M.: Multi-Drug Combination Therapy Reverses Diabetes in NOD Mice with Established Disease. American Diabetes Association's 71st Scientific Session, 2011.
223. Brown, C.T.; Giongo, A.; Davis-Richardson, A.G.; Gano, K.A.; Crabb, D.B.; Mukherjee, N.; Casella, G.; Drew, J.C.; Ilonen, J.; Mikael, K.; Hyoty, H.; Veijola, R.; Simell, T.; Simell, O.; Neu, J.; Wasserfall, C.H.; Schatz, D.; **Atkinson, M.A.**; Triplett, E.W.: The Autoimmune Metagenome for Type 1 Diabetes Reveals Differences in the Metabolic Potential of an Aberrant Gut Microbiota. American Diabetes Association's 71st Scientific Session, 2011.
224. Yoon, Y.M.; Wasserfall, C.; Lewis, J.; **Atkinson, M.**; Keselowsky, B.: Development of a Tolerogenic Matrix Containing Autoantigens for the Prevention of Type 1 Diabetes. American Diabetes Association's 71st Scientific Session, 2011.

225. Haller, M.J.; Wasserfall, C.; McGrail, K.; Brusko, T.; Wingard, J.; Slayton, W.B.; **Atkinson, M.A.**; Schatz, D.A.: Pilot Study of Autologous Umbilical Cord Blood (UCB) Transfusion Followed by Docosahexanoic Acid (DHA) and Vitamin D (VitD) Supplementation in Children with Type 1 Diabetes (T1D). American Diabetes Association's 72nd Scientific Session, 2012.
226. Bian, X.; Miersch, S.; Wallstrom, G.; Sibani, S.; Logvinenko, T.; Wasserfall, C.; Schatz, D.; **Atkinson, M.**; Qiu, J.; LaBaer, J.: Autoantibody Biomarkers Discovery of Type 1 Diabetes (T1D) Using Nucleic Acid Programmable Protein Array (NAPPA). HUPO, 2012.
227. Brown CT, Giongo A, Davis-Richardson AG, Gano KA, Crabb DB, Mukherjee N, Casella G, Drew JC, Ilonen J, Knip M, Hyöty H, Veijola R, Simell T, Simell O, Neu J, Wasserfall CH, Schatz DA, **Atkinson MA**, Triplett EW.: The Autoimmune Metagenome for Type 1 Diabetes Reveals Differences in the Metabolic Potential of an Aberrant Gut Microbiota. American Diabetes Association, 71st Scientific Sessions, 2011.
228. Xue S, Wasserfall C, Parker M, Mathews C, Burn P, Rabinovitch A, Savinov A, Schatz D, **Atkinson M**, Haller M.: Multi-Drug Combination Therapy Reverses Diabetes in NOD Mice with Established Disease. American Diabetes Association, 71st Scientific Sessions, 2011.
229. Xue S, Wasserfall C, Brusko T, Mathews C, Haller M, Burn P, **Atkinson M**, Schatz D.: Multi-Drug Combination Therapy Increases the Frequency of Regulatory T- and B-Cells in NOD Mice with Established Disease. American Diabetes Association, 71st Scientific Sessions, 2011.
230. Myhr C, Wasserfall C, Schatz D, Haller M, **Atkinson M.**: Th1 and Th17 Associated Gene Expression Profiles in Subjects with Type 1 Diabetes. American Diabetes Association, 71st Scientific Sessions, 2011.
231. Rowe P, Campbell-Thompson M, Wasserfall C, Martino MF, Kaddis J, Eisenbarth G, Gianani R, Albanese-O'Neil A, **Atkinson M**, Schatz D.: Correlation of Pancreatic Histopathology in U.S. Organ Donors with Type 1 Diabetes of Longstanding Duration. American Diabetes Association, 71st Scientific Sessions, 2011.
232. Hulme MA, Wasserfall CH, Brusko TM, Haller MJ, Schatz DA, Ostrov DA, **Atkinson MA.**: Small Molecule Modification of the IL-2 Receptor: Implications for Therapy in Type 1 Diabetes. American Diabetes Association, 71st Scientific Sessions, 2011.
233. Donelan W, Li Y, Li SW, Wang H, Wasserfall C, **Atkinson M**, Reeves, Winter W, Yang LJ.: Detection of Pancreatic and Duodenal Homeobox 1 (Pdx1) Autoantibodies Using LIPS (Luciferase Immunoprecipitation System) Assay. American Diabetes Association, 71st Scientific Sessions, 2011.
234. Yoon YM, Wasserfall C, Lewis J, **Atkinson M**, Keselowsky B.: Development of a Tolerogenic Matrix Containing Autoantigens for the Prevention of Type 1 Diabetes. American Diabetes Association, 71st Scientific Sessions, 2011.
235. Rowe P, Posgai AL, Campbell-Thompson M, Wasserfall C, Martino MF, Albanese-O'Neil A, Schatz D, **Atkinson M.**: Islet Cell Autoantibody Reactivity on Pancreatic Tissue from Donors with Type 1 Diabetes. American Diabetes Association, 71st Scientific Sessions, 2011.
236. Cabrera, R.; Ararat, M.; Cao, M.; Xu, Y.; Wasserfall, C.; Brusko, T.; **Atkinson, M.A.**; Liu, C.; Nelson, D.R.: Sorafenib Modulates Immune Responses in Patients with Hepatocellular Carcinoma. American Association for Cancer Research, 2011.
237. Ararat, M.A.; Fitian, A.I.; Brusko, T.; Xu, Y.; Wasserfall, C.; **Atkinson, M.**; Liu, C.; Allegra, C.J.; Nelson, D.; Cabrera, R.: The Soluble Form of the IL-2 Receptor (sCD25) as a Novel Biomarker for Hepatocellular Carcinoma. American Society for Clinical Oncology, 2011.
238. Haller, M.J.; Wasserfall, C.; McGrail, K.; Brusko, T.; Wingard, J.; Slayton, W.B.; **Atkinson, M.A.**; Schatz, D.A.: Pilot Study of Autologous Umbilical Cord Blood (UCB) Transfusion Followed by Docosahexanoic Acid

226. Bian, X.; Miersch, S.; Wallstrom, G.; Sibani, S.; Logvinenko, T.; Wasserfall, C.; Schatz, D.; **Atkinson, M.**; Qiu, J.; LaBaer, J.: Autoantibody Biomarkers Discovery of Type 1 Diabetes (T1D) Using Nucleic Acid Programmable Protein Array (NAPPA). HUPO, 2012.
227. Brown CT, Giongo A, Davis-Richardson AG, Gano KA, Crabb DB, Mukherjee N, Casella G, Drew JC, Ilonen J, Knip M, Hyöty H, Veijola R, Simell T, Simell O, Neu J, Wasserfall CH, Schatz DA, **Atkinson MA**, Triplett EW.: The Autoimmune Metagenome for Type 1 Diabetes Reveals Differences in the Metabolic Potential of an Aberrant Gut Microbiota. American Diabetes Association, 71st Scientific Sessions, 2011.
228. Xue S, Wasserfall C, Parker M, Mathews C, Burn P, Rabinovitch A, Savinov A, Schatz D, **Atkinson M**, Haller M.: Multi-Drug Combination Therapy Reverses Diabetes in NOD Mice with Established Disease. American Diabetes Association, 71st Scientific Sessions, 2011.
229. Xue S, Wasserfall C, Brusko T, Mathews C, Haller M, Burn P, **Atkinson M**, Schatz D.: Multi-Drug Combination Therapy Increases the Frequency of Regulatory T- and B-Cells in NOD Mice with Established Disease. American Diabetes Association, 71st Scientific Sessions, 2011.
230. Myhr C, Wasserfall C, Schatz D, Haller M, **Atkinson M.**: Th1 and Th17 Associated Gene Expression Profiles in Subjects with Type 1 Diabetes. American Diabetes Association, 71st Scientific Sessions, 2011.
231. Rowe P, Campbell-Thompson M, Wasserfall C, Martino MF, Kaddis J, Eisenbarth G, Gianani R, Albanese-O'Neil A, **Atkinson M**, Schatz D.: Correlation of Pancreatic Histopathology in U.S. Organ Donors with Type 1 Diabetes of Longstanding Duration. American Diabetes Association, 71st Scientific Sessions, 2011.
232. Hulme MA, Wasserfall CH, Brusko TM, Haller MJ, Schatz DA, Ostrov DA, **Atkinson MA.**: Small Molecule Modification of the IL-2 Receptor: Implications for Therapy in Type 1 Diabetes. American Diabetes Association, 71st Scientific Sessions, 2011.
233. Donelan W, Li Y, Li SW, Wang H, Wasserfall C, **Atkinson M**, Reeves, Winter W, Yang LJ.: Detection of Pancreatic and Duodenal Homeobox 1 (Pdx1) Autoantibodies Using LIPS (Luciferase Immunoprecipitation System) Assay. American Diabetes Association, 71st Scientific Sessions, 2011.
234. Yoon YM, Wasserfall C, Lewis J, **Atkinson M**, Keselowsky B.: Development of a Tolerogenic Matrix Containing Autoantigens for the Prevention of Type 1 Diabetes. American Diabetes Association, 71st Scientific Sessions, 2011.
235. Rowe P, Posgai AL, Campbell-Thompson M, Wasserfall C, Martino MF, Albanese-O'Neil A, Schatz D, **Atkinson M.**: Islet Cell Autoantibody Reactivity on Pancreatic Tissue from Donors with Type 1 Diabetes. American Diabetes Association, 71st Scientific Sessions, 2011.
236. Cabrera, R.; Ararat, M.; Cao, M.; Xu, Y.; Wasserfall, C.; Brusko, T.; **Atkinson, M.A.**; Liu, C.; Nelson, D.R.: Sorafenib Modulates Immune Responses in Patients with Hepatocellular Carcinoma. American Association